<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>053 Pharmacology Ini-Cet 2021 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQs / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">35</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x1947e1=_0xb405;(function(_0x260fb3,_0x5b57e9){const _0x3b50a7=_0xb405,_0x415afe=_0x260fb3();while(!![]){try{const _0x44e33f=parseInt(_0x3b50a7(0x2b3))/0x1*(-parseInt(_0x3b50a7(0x22a))/0x2)+-parseInt(_0x3b50a7(0x239))/0x3+-parseInt(_0x3b50a7(0x293))/0x4*(parseInt(_0x3b50a7(0x45c))/0x5)+parseInt(_0x3b50a7(0x42e))/0x6*(-parseInt(_0x3b50a7(0x2b8))/0x7)+-parseInt(_0x3b50a7(0x1d1))/0x8*(-parseInt(_0x3b50a7(0x1da))/0x9)+-parseInt(_0x3b50a7(0x1d3))/0xa*(-parseInt(_0x3b50a7(0x309))/0xb)+parseInt(_0x3b50a7(0x398))/0xc;if(_0x44e33f===_0x5b57e9)break;else _0x415afe['push'](_0x415afe['shift']());}catch(_0x21b716){_0x415afe['push'](_0x415afe['shift']());}}}(_0x30a8,0xe1852));const _0x5069f4=(function(){let _0x46c93c=!![];return function(_0x4815c6,_0x195a8d){const _0x49ad88=_0x46c93c?function(){const _0x2e26fd=_0xb405;if(_0x195a8d){const _0x53c691=_0x195a8d[_0x2e26fd(0x200)](_0x4815c6,arguments);return _0x195a8d=null,_0x53c691;}}:function(){};return _0x46c93c=![],_0x49ad88;};}()),_0x24cfcb=_0x5069f4(this,function(){const _0x5e3135=_0xb405,_0x57939d={'Rauoq':'(((.+)+)+)+$'};return _0x24cfcb[_0x5e3135(0x29b)]()[_0x5e3135(0x36e)](_0x5e3135(0x306))[_0x5e3135(0x29b)]()[_0x5e3135(0x2c0)](_0x24cfcb)['search'](_0x57939d[_0x5e3135(0x42b)]);});_0x24cfcb();const _0x495c5f=(function(){let _0x53c581=!![];return function(_0x8e6234,_0x5e9c7a){const _0x29f01f=_0x53c581?function(){const _0x3670d7=_0xb405;if(_0x5e9c7a){const _0x4bcdba=_0x5e9c7a[_0x3670d7(0x200)](_0x8e6234,arguments);return _0x5e9c7a=null,_0x4bcdba;}}:function(){};return _0x53c581=![],_0x29f01f;};}()),_0x393828=_0x495c5f(this,function(){const _0x436e19=_0xb405,_0xd1afbf={'QUxrt':function(_0x2eb7ee,_0x422af5){return _0x2eb7ee>_0x422af5;},'tHDdD':function(_0x3f8f16,_0x2f70d3){return _0x3f8f16-_0x2f70d3;},'impdd':_0x436e19(0x310),'QuJsG':'bWMKA','BAAEM':function(_0x50b041,_0x42324e){return _0x50b041(_0x42324e);},'nkucH':function(_0x2c70c7,_0x2d480f){return _0x2c70c7+_0x2d480f;},'IzRYv':function(_0x4a64d3,_0x4efcc6){return _0x4a64d3+_0x4efcc6;},'xEQKL':'{}.constructor(\x22return\x20this\x22)(\x20)','jUCBi':function(_0x2165e2){return _0x2165e2();},'IUfeZ':_0x436e19(0x447),'Mtbnp':_0x436e19(0x25b),'hBWPI':_0x436e19(0x1c7),'EOaue':'error','HkCoE':_0x436e19(0x3bf),'qwYhX':_0x436e19(0x368),'foPtX':_0x436e19(0x3c7),'BENWI':function(_0x1fd4c0,_0x3bc1aa){return _0x1fd4c0<_0x3bc1aa;}},_0x11964d=function(){const _0x5be280=_0x436e19,_0x1ea511={'lQxDq':function(_0x2876dc,_0x476a68){const _0x4b843a=_0xb405;return _0xd1afbf[_0x4b843a(0x283)](_0x2876dc,_0x476a68);},'pgPti':function(_0x26200b){return _0x26200b();},'ltRXG':function(_0x59f132,_0x359257){return _0xd1afbf['tHDdD'](_0x59f132,_0x359257);}};if('gflcM'==='gflcM'){let _0xbea76f;try{_0xd1afbf['impdd']!==_0xd1afbf[_0x5be280(0x2e8)]?_0xbea76f=_0xd1afbf[_0x5be280(0x3c3)](Function,_0xd1afbf['nkucH'](_0xd1afbf[_0x5be280(0x1f1)](_0x5be280(0x42a),_0xd1afbf[_0x5be280(0x354)]),');'))():_0x1ea511[_0x5be280(0x3ff)](_0x28cade,0x0)&&(_0x14f5c8&&(_0x5d8144[_0x1eaca1][_0x5be280(0x2f6)]+=_0x1adf0b['now']()-_0x32e504),_0x817f1c--,_0x1ea511[_0x5be280(0x246)](_0x2f2054));}catch(_0xa5923){_0xbea76f=window;}return _0xbea76f;}else _0x1e2257[_0x1e0cb6][_0x5be280(0x2f6)]+=_0x1ea511[_0x5be280(0x32d)](_0xaf74b6[_0x5be280(0x2a7)](),_0x59169d);},_0x425365=_0xd1afbf[_0x436e19(0x238)](_0x11964d),_0x2ffb62=_0x425365['console']=_0x425365[_0x436e19(0x31c)]||{},_0x2370c3=[_0xd1afbf[_0x436e19(0x243)],_0xd1afbf[_0x436e19(0x39f)],_0xd1afbf[_0x436e19(0x272)],_0xd1afbf[_0x436e19(0x2c7)],_0xd1afbf[_0x436e19(0x2c2)],_0xd1afbf[_0x436e19(0x417)],_0xd1afbf['foPtX']];for(let _0x27b604=0x0;_0xd1afbf[_0x436e19(0x345)](_0x27b604,_0x2370c3[_0x436e19(0x3e3)]);_0x27b604++){const _0x1eb76f=_0x495c5f[_0x436e19(0x2c0)][_0x436e19(0x374)][_0x436e19(0x1dc)](_0x495c5f),_0x1337d5=_0x2370c3[_0x27b604],_0xefa419=_0x2ffb62[_0x1337d5]||_0x1eb76f;_0x1eb76f[_0x436e19(0x235)]=_0x495c5f[_0x436e19(0x1dc)](_0x495c5f),_0x1eb76f[_0x436e19(0x29b)]=_0xefa419['toString']['bind'](_0xefa419),_0x2ffb62[_0x1337d5]=_0x1eb76f;}});_0x393828();let questionsData=[{'text':_0x1947e1(0x452),'choices':[{'id':0x1,'text':_0x1947e1(0x20c)},{'id':0x2,'text':_0x1947e1(0x25e)},{'id':0x3,'text':_0x1947e1(0x1f6)},{'id':0x4,'text':'Disease\x20prevalence\x20is\x20considered'}],'correct_choice_id':0x3,'solution':_0x1947e1(0x325),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2034-year-old\x20man\x20with\x20hypertension\x20is\x20diagnosed\x20with\x20stage\x204\x20chronic\x20kidney\x20disease,\x20with\x20eGFR\x20of\x20<30.\x20His\x20doctor\x20wants\x20to\x20prescribe\x20a\x20thiazide\x20diuretic.\x20Which\x20of\x20the\x20following\x20can\x20be\x20given?','choices':[{'id':0x1,'text':'Chlorothiazide'},{'id':0x2,'text':_0x1947e1(0x270)},{'id':0x3,'text':_0x1947e1(0x2e1)},{'id':0x4,'text':_0x1947e1(0x3dc)}],'correct_choice_id':0x3,'solution':_0x1947e1(0x297),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20patient\x20who\x20was\x20diagnosed\x20with\x20epilepsy\x20was\x20put\x20on\x20retigabine\x20TDS.\x20Now\x20phenytoin\x20is\x20being\x20added.\x20Which\x20of\x20the\x20following\x20changes\x20should\x20be\x20made\x20to\x20retigabine?','choices':[{'id':0x1,'text':_0x1947e1(0x375)},{'id':0x2,'text':'Decrease\x20the\x20dose'},{'id':0x3,'text':_0x1947e1(0x358)},{'id':0x4,'text':_0x1947e1(0x288)}],'correct_choice_id':0x1,'solution':_0x1947e1(0x2d7),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x276),'choices':[{'id':0x1,'text':_0x1947e1(0x312)},{'id':0x2,'text':_0x1947e1(0x362)},{'id':0x3,'text':_0x1947e1(0x23e)},{'id':0x4,'text':_0x1947e1(0x27b)}],'correct_choice_id':0x1,'solution':'<p><strong>Downregulation\x20of\x20CYP2C19</strong>\x20is\x20responsible\x20for\x20the\x20failure\x20of\x20clopidogrel\x20in\x20this\x20patient.</p>\x0a<p>Clopidogrel\x20is\x20a\x20<strong>prodrug</strong>\x20and\x20its\x20metabolic\x20activation\x20occurs\x20in\x20the\x20liver.\x20It\x20is\x20<strong>bioactivated\x20by\x20the\x20CYP2C19</strong>\x20enzyme.\x20If\x20there\x20is\x20downregulation\x20of\x20this\x20enzyme\x20it\x20will\x20cause\x20a\x20decrease\x20in\x20the\x20efficacy\x20of\x20clopidogrel\x20and\x20can\x20lead\x20to\x20thrombotic\x20events\x20like\x20stroke.\x20Drugs\x20that\x20inhibit\x20CYP2C19\x20can\x20also\x20decrease\x20the\x20antiplatelet\x20effect\x20of\x20clopidogrel.\x20<strong>Proton-pump\x20inhibitors</strong>\x20may\x20cause\x20<strong>inhibition\x20of\x20CYP2C19</strong>\x20and\x20when\x20they\x20are\x20given\x20in\x20combination\x20there\x20would\x20be\x20a\x20decrease\x20in\x20the\x20efficacy\x20of\x20clopidogrel.&nbsp;</p>\x0a<p><strong>Therapeutic\x20uses</strong>:\x20Clopidogrel\x20is\x20used\x20to\x20reduce\x20the\x20rate\x20of\x20stroke\x20and\x20myocardial\x20infarction.\x20It\x20also\x20decreases\x20the\x20rate\x20of\x20deaths\x20in\x20patients\x20with\x20recent\x20myocardial\x20infarction\x20or\x20stroke.\x20Other\x20uses\x20are\x20acute\x20coronary\x20syndrome\x20and\x20peripheral\x20arterial\x20disease.</p>\x0a<p><strong>Adverse\x20effects</strong>:\x20Increased\x20<strong>risk\x20of\x20bleeding</strong>\x20especially\x20when\x20given\x20with\x20an\x20anticoagulant\x20or\x20aspirin.\x20Rarely\x20thrombotic\x20thrombocytopenic\x20purpura\x20can\x20occur.</p>\x0a<p><strong>CYP2C19</strong>:\x20Common\x20drugs\x20that\x20are\x20metabolized\x20include\x20omeprazole,\x20phenytoin,\x20diazepam,\x20and\x20propanolol.\x20Inducers\x20of\x20the\x20CYP2C\x20subfamily\x20are\x20rifampicin\x20and\x20carbamazepine.\x20Omeprazole\x20is\x20an\x20inhibitor.</p>\x0a<p>Other\x20options:</p>\x0a<p><strong>CYP2D6</strong>:\x20Drugs\x20metabolized\x20include\x20SSRIs,&nbsp;\x20tricyclic\x20antidepressants,\x20antiarrhythmic\x20drugs,\x20beta-blockers,\x20and\x20opiates.\x20It\x20is\x20<strong>inhibited\x20by\x20quinidine</strong>\x20and\x20it\x20will\x20prevent\x20the\x20formation\x20of\x20morphine\x20from\x20codeine.\x20Hence\x20quinidine\x20decreases\x20the\x20analgesic\x20effect\x20of\x20codeine.</p>\x0a<p><strong>CYP1A1/2</strong>:\x20It\x20metabolizes\x20few\x20drugs\x20like\x20theophylline,\x20paracetamol,\x20caffeine\x20and\x20carbamazepine.\x20It\x20plays\x20an\x20important\x20role\x20in\x20the\x20<strong>activation\x20of\x20procarcinogens.</strong>\x20Inducers\x20are\x20rifampicin,\x20carbamazepine,\x20polycyclic\x20hydrocarbons,\x20charbroiled\x20meat,\x20and\x20cigarette\x20smoke.</p>\x0a<p><strong>CYP2E1</strong>:\x20It\x20is\x20involved\x20in\x20the\x20oxidation\x20of\x20alcohol,\x20halothane,\x20and\x20minor\x20metabolism\x20of\x20other\x20drugs.\x20It\x20is\x20important\x20to\x20note\x20that\x20it\x20is\x20involved\x20in\x20the\x20formation\x20of\x20hepatotoxic<strong>&nbsp;N-acetyl\x20benzoquinone\x20imine</strong>\x20from\x20<strong>paracetamol.</strong>\x20Chronic\x20alcoholism\x20is\x20responsible\x20for\x20the\x20induction\x20of\x20this\x20enzyme.</p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x2da),'choices':[{'id':0x1,'text':_0x1947e1(0x333)},{'id':0x2,'text':_0x1947e1(0x28d)},{'id':0x3,'text':_0x1947e1(0x456)},{'id':0x4,'text':_0x1947e1(0x39d)}],'correct_choice_id':0x1,'solution':'<p><strong>Liraglutide</strong>\x20is\x20used\x20in\x20the\x20long-term\x20management\x20of\x20obesity.</p>\x0a<p>Mechanism\x20of\x20action:</p>\x0a<ul>\x0a<li>Increase\x20glucose-mediated\x20insulin\x20release</li>\x0a<li>Lowers\x20the\x20glucagon\x20levels</li>\x0a<li><strong>Delays\x20gastric\x20emptying</strong></li>\x0a<li><strong>Decreases\x20feeding</strong>\x20by\x20stimulating\x20<strong>GLP-1\x20receptors</strong>\x20in\x20the\x20<strong>arcuate</strong>\x20nucleus\x20of\x20the\x20hypothalamus.</li>\x0a</ul>\x0a<p>It\x20is\x20a\x20GLP-1\x20analog\x20used\x20as\x20a\x20<strong>parenteral\x20hypoglycemic\x20agent</strong>\x20and\x20<strong>anti-obesity\x20drug</strong>.\x20It\x20is\x20administered\x20subcutaneously.\x20It\x20is\x20used\x20as\x20an\x20adjuvant\x20in\x20patients\x20who\x20are\x20not\x20achieving\x20glycemic\x20control\x20with\x20oral\x20agents.\x20It\x20can\x20be\x20also\x20added\x20with\x20basal\x20insulin.</p>\x0a<p>It\x20is\x20found\x20to\x20decrease\x20the\x20risk\x20of\x20cardiovascular\x20death,\x20nonfatal\x20myocardial\x20infarction,\x20and\x20stroke\x20in\x20patients\x20with\x20type\x202\x20diabetes\x20and\x20cardiovascular\x20disease.</p>\x0a<p>Adverse\x20effects:\x20Nausea,\x20vomiting,\x20diarrhea,\x20or\x20constipation.\x20It\x20should\x20not\x20be\x20given\x20in\x20patients\x20with\x20a\x20personal\x20or\x20family\x20history\x20of\x20MEN\x20syndrome\x20or\x20medullary\x20carcinoma\x20of\x20the\x20thyroid.</p>\x0a<p>Other\x20options:</p>\x0a<p><strong>Metformin</strong>:\x20It\x20belongs\x20to\x20the\x20biguanides\x20class\x20of\x20oral\x20hypoglycemic\x20agents.\x20It\x20is\x20used\x20as\x20a\x20first-line\x20agent\x20in\x20the\x20management\x20of\x20type\x202\x20diabetes\x20and\x20it\x20acts\x20by\x20reducing\x20hepatic\x20glucose\x20production.\x20It\x20is\x20also\x20used\x20to\x20treat\x20infertility\x20in\x20PCOD\x20patients.\x20IT\x20is\x20usually\x20not\x20associated\x20with\x20weight\x20gain\x20and\x20in\x20some\x20cases,\x20it\x20may\x20cause\x20mild\x20weight\x20reduction.</p>\x0a<p><strong>Sibutramine</strong>:\x20It\x20has\x20both\x20serotonergic\x20and\x20noradrenergic\x20action.\x20It\x20is\x20also\x20an\x20anorectic\x20agent\x20with\x20a\x20similar\x20mechanism\x20of\x20action\x20to\x20fenfluramine.\x20But\x20due\x20to\x20severe\x20adverse\x20effects,\x20US-FDA\x20has\x20banned\x20its\x20use.</p>\x0a<p><strong>Fenfluramine</strong>:\x20It\x20is\x20a\x20serotonergic\x20anorectic\x20agent.\x20It\x20reduces\x20food-seeking\x20behavior\x20due\x20to\x20increased\x20serotonergic\x20transmission\x20in\x20the\x20hypothalamus.\x20The\x20use\x20of\x20is\x20not\x20recommended\x20now\x20by\x20the\x20US-FDA\x20due\x20to\x20its\x20severe\x20side\x20effects.</p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x2a9),'choices':[{'id':0x1,'text':_0x1947e1(0x2dc)},{'id':0x2,'text':'Ergotism'},{'id':0x3,'text':_0x1947e1(0x23b)},{'id':0x4,'text':_0x1947e1(0x449)}],'correct_choice_id':0x2,'solution':_0x1947e1(0x212),'explanation_video':'','question_images':[_0x1947e1(0x41c)],'explanation_images':[]},{'text':_0x1947e1(0x28c),'choices':[{'id':0x1,'text':_0x1947e1(0x2bc)},{'id':0x2,'text':'Treatment\x20of\x20Lennox\x20Gastaut\x20syndrome'},{'id':0x3,'text':_0x1947e1(0x38f)},{'id':0x4,'text':_0x1947e1(0x334)}],'correct_choice_id':0x2,'solution':_0x1947e1(0x3b0),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x3e2),'choices':[{'id':0x1,'text':_0x1947e1(0x3d5)},{'id':0x2,'text':_0x1947e1(0x37e)},{'id':0x3,'text':'Idarucizumab\x20:\x20Dabigatran'},{'id':0x4,'text':_0x1947e1(0x1d4)}],'correct_choice_id':0x4,'solution':_0x1947e1(0x2c6),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Inhaled\x20Nitric\x20oxide\x20is\x20approved\x20for\x20treatment\x20of','choices':[{'id':0x1,'text':'Labile\x20hypertension'},{'id':0x2,'text':_0x1947e1(0x2eb)},{'id':0x3,'text':_0x1947e1(0x376)},{'id':0x4,'text':_0x1947e1(0x28e)}],'correct_choice_id':0x2,'solution':'<p><strong>Inhaled\x20nitric\x20oxide</strong>\x20(NO)\x20is\x20used\x20in\x20the\x20management\x20of\x20<strong>pulmonary\x20hypertension.</strong></p>\x0a<p>The\x20only<strong>\x20FDA-approved\x20therapeutic\x20indication</strong>\x20of\x20inhaled\x20nitric\x20oxide\x20is\x20in\x20<strong>persistent\x20pulmonary\x20hypertension\x20</strong>of\x20the\x20<strong>newborn</strong>.\x20It\x20has\x20the\x20ability\x20to\x20selectively\x20dilate\x20pulmonary\x20vasculature.\x20Hence\x20it\x20can\x20be\x20used\x20in\x20conditions\x20with\x20increased\x20pulmonary\x20vascular\x20resistance.</p>\x0a<p>It\x20is\x20proposed\x20for\x20the:</p>\x0a<ul>\x0a<li>Long-term\x20management\x20of\x20pulmonary\x20artery\x20hypertension(PAH)\x20and\x20other\x20forms\x20of\x20pulmonary\x20hypertension</li>\x0a<li>Rescue\x20therapy\x20for\x20severely\x20hypoxemic\x20patients\x20with\x20or\x20without\x20pulmonary\x20hypertension</li>\x0a</ul>\x0a<p><strong>Diagnostic\x20indications</strong>:</p>\x0a<ul>\x0a<li>In\x20heart\x20failure\x20patients\x20and\x20infants\x20with\x20congenital\x20heart\x20disease\x20during\x20<strong>cardiac\x20catheterizatio</strong>n\x20to\x20evaluate\x20<strong>pulmonary\x20vasoreactivity.</strong></li>\x0a<li>In\x20determining\x20the<strong>&nbsp;diffusion\x20capacity</strong>\x20across\x20the\x20alveolar-capillary\x20unit.\x20It\x20is\x20considered\x20superior\x20to\x20carbon\x20dioxide\x20in\x20this\x20because\x20it\x20has\x20a\x20greater\x20affinity\x20for\x20hemoglobin\x20and\x20higher\x20water\x20solubility\x20at\x20body\x20temperature.</li>\x0a</ul>\x0a<p><strong>Mechanism\x20of\x20action</strong>:</p>\x0a<p>It\x20activates\x20soluble\x20guanylyl\x20cyclase\x20and\x20produces\x20cGMP,\x20which\x20then\x20activates\x20cGMP-dependent\x20protein\x20kinase.\x20This\x20leads\x20to\x20the\x20activation\x20of\x20multiple\x20regulatory\x20mechanisms\x20that\x20decrease\x20intracellular\x20calcium\x20and\x20cause\x20vasodilation\x20in\x20precapillary\x20resistance\x20arterioles.</p>\x0a<p><strong>Adverse\x20effects</strong>:</p>\x0a<ul>\x0a<li><strong>Methemoglobinemia</strong>\x20at\x20higher\x20concentrations.</li>\x0a<li>It\x20can\x20worsen\x20left\x20ventricular\x20performance\x20in\x20patients\x20with\x20an\x20already\x20impaired\x20left\x20ventricular\x20function.</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x410),'choices':[{'id':0x1,'text':_0x1947e1(0x44c)},{'id':0x2,'text':_0x1947e1(0x43c)},{'id':0x3,'text':_0x1947e1(0x224)},{'id':0x4,'text':_0x1947e1(0x461)}],'correct_choice_id':0x4,'solution':_0x1947e1(0x3dd),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Paradoxical\x20bronchoconstriction\x20seen\x20with\x20ipratropium\x20bromide\x20is\x20due\x20to\x20all\x20except','choices':[{'id':0x1,'text':_0x1947e1(0x287)},{'id':0x2,'text':_0x1947e1(0x377)},{'id':0x3,'text':_0x1947e1(0x416)},{'id':0x4,'text':_0x1947e1(0x469)}],'correct_choice_id':0x1,'solution':_0x1947e1(0x313),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x22e),'choices':[{'id':0x1,'text':_0x1947e1(0x2bf)},{'id':0x2,'text':_0x1947e1(0x2ac)},{'id':0x3,'text':_0x1947e1(0x1f5)},{'id':0x4,'text':_0x1947e1(0x3b4)}],'correct_choice_id':0x1,'solution':_0x1947e1(0x280),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20steps\x20does\x20Vancomycin\x20act\x20on?','choices':[{'id':0x1,'text':'1'},{'id':0x2,'text':'2'},{'id':0x3,'text':'3'},{'id':0x4,'text':'4'}],'correct_choice_id':0x4,'solution':_0x1947e1(0x3bd),'explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/941c257ca30f4a91994ba614ee06e0f8.JPEG'],'explanation_images':[]},{'text':_0x1947e1(0x213),'choices':[{'id':0x1,'text':_0x1947e1(0x339)},{'id':0x2,'text':_0x1947e1(0x335)},{'id':0x3,'text':'Half-life\x20and\x20plasma\x20concentration\x20remains\x20the\x20same'},{'id':0x4,'text':_0x1947e1(0x331)}],'correct_choice_id':0x2,'solution':_0x1947e1(0x37d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x2a6),'choices':[{'id':0x1,'text':_0x1947e1(0x435)},{'id':0x2,'text':_0x1947e1(0x281)},{'id':0x3,'text':'PTSD'},{'id':0x4,'text':_0x1947e1(0x31e)}],'correct_choice_id':0x4,'solution':_0x1947e1(0x3bb),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x285),'choices':[{'id':0x1,'text':_0x1947e1(0x27c)},{'id':0x2,'text':'6.9\x20hours'},{'id':0x3,'text':'13.8\x20hours'},{'id':0x4,'text':_0x1947e1(0x33b)}],'correct_choice_id':0x3,'solution':_0x1947e1(0x35e),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x206),'choices':[{'id':0x1,'text':_0x1947e1(0x328)},{'id':0x2,'text':_0x1947e1(0x216)},{'id':0x3,'text':_0x1947e1(0x317)},{'id':0x4,'text':'120\x20minutes'}],'correct_choice_id':0x4,'solution':_0x1947e1(0x41f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x1d0),'choices':[{'id':0x1,'text':'Safety\x20in\x20pregnancy'},{'id':0x2,'text':_0x1947e1(0x3fc)},{'id':0x3,'text':_0x1947e1(0x44a)},{'id':0x4,'text':_0x1947e1(0x29e)}],'correct_choice_id':0x1,'solution':_0x1947e1(0x269),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Identify\x20the\x20false\x20statement\x20regarding\x20suicidal\x20inhibition.','choices':[{'id':0x1,'text':'The\x20inhibitor\x20can\x20bind\x20with\x20any\x20site\x20resulting\x20in\x20suicidal\x20inhibition'},{'id':0x2,'text':_0x1947e1(0x324)},{'id':0x3,'text':_0x1947e1(0x3f0)},{'id':0x4,'text':'The\x20inhibitor\x20forms\x20a\x20product\x20with\x20the\x20enzyme\x20and\x20the\x20product\x20inhibits\x20it'}],'correct_choice_id':0x1,'solution':_0x1947e1(0x40b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x261),'choices':[{'id':0x1,'text':'2-10\x20mcg/kg/min'},{'id':0x2,'text':'<2\x20mcg/kg/min'},{'id':0x3,'text':_0x1947e1(0x33a)},{'id':0x4,'text':_0x1947e1(0x350)}],'correct_choice_id':0x1,'solution':'<p>The\x20dose\x20at\x20which\x20<strong>dopamine</strong>\x20acts\x20on\x20<strong>-1</strong>\x20receptors\x20is\x20<strong>2-10\x20mcg/kg/min</strong>.</p>\x0a<p>The\x20<strong>systemic\x20effects</strong>\x20of\x20dopamine\x20<strong>vary</strong>\x20with\x20its\x20<strong>concentration</strong>\x20in\x20the\x20body.</p>\x0a<p>When\x20administered\x20at\x20an\x20infusion\x20rate\x20of\x20<strong>2-5\x20mcg/kg/min</strong>,\x20it\x20directly\x20<strong>stimulates\x20</strong>cardiac\x20<strong></strong><strong>\u00a0receptors.\u00a0</strong>This\u00a0enhances\x20myocardial\x20contractility\x20and\x20is\x20useful\x20in\x20the\x20management\x20of\x20cardiogenic\x20shock.</p>\x0a<p>At\x20doses\x20of\x20<strong>5-15\x20mcg/kg/min</strong>\x20and\x20<strong>above</strong>,\x20it\x20stimulates\u00a0<strong>\u00a0adrenergic\x20receptors</strong>.\x20This\x20causes\x20peripheral\x20arterial\x20and\x20venous\x20<strong>vasoconstriction.</strong></p>\x0a<p>At\x20lower\x20doses\x20of\x20<strong>&lt;2\x20mcg/kg/min</strong>,\x20it\x20directly\x20stimulates\x20both\x20<strong>D1</strong>\x20and\x20<strong>D2\x20receptors</strong>.\x20The\x20D1\x20receptors\x20in\x20renal\x20and\x20mesenteric\x20blood\x20vessels\x20are\x20the\x20most\x20sensitive:\x20i.v.\x20infusion\x20of\x20low\x20dose\x20of\x20DA\x20dilates\x20these\x20vessels\x20subsequently,\x20causing\x20increased\x20renal\x20blood\x20flow\x20and\x20increased\x20urine\x20output.</p>\x0a<p>The\x20clinical\x20indications\x20of\x20dopamine\x20include\x20cardiogenic\x20and\x20vasodilatory\x20<strong>shock</strong>,\x20<strong>congestive\x20cardiac\x20failure</strong>\x20and\x20symptomatic\x20<strong>bradycardia</strong>\x20unresponsive\x20to\x20atropine\x20or\x20pacing.</p>\x0a<p>The\x20major\x20side\x20effects\x20are:\u00a0</p>\x0a<ul>\x0a<li>Severe\x20hypertension\x20(especially\x20when\x20taken\x20with\x20nonselective\x20-blockers)</li>\x0a<li>Ventricular\x20arrhythmias</li>\x0a<li>Cardiac\x20ischemia</li>\x0a<li>Tissue\x20ischemia/gangrene\x20(high\x20doses/extravasation\x20into\x20tissues)</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x2b2),'choices':[{'id':0x1,'text':_0x1947e1(0x2a2)},{'id':0x2,'text':'Inhibits\x20negative\x20feedback\x20on\x20GnRH'},{'id':0x3,'text':_0x1947e1(0x3e1)},{'id':0x4,'text':'Can\x20be\x20used\x20with\x20gonadotropin'}],'correct_choice_id':0x1,'solution':'<p>The\x20incorrect\x20statement\x20regarding\x20clomiphene\x20citrate\x20is\x20that\x20it\x20causes\x20monofollicular\x20development;\x20rather,\x20it\x20causes\x20multi\x20follicular\x20development.</p>\x0a<p>Clomiphene\x20is\x20an\x20unequal\x20mixture\x20of\x20two\x20isomers,\x20enclomiphene\x20and\x20zuclomiphene.\x20<strong>Zuclomiphene</strong>&nbsp;is\x20a\x20non-steroidal\x20compound\x20closely\x20<strong>resembling</strong>\x20an\x20<strong>estrogen</strong>,\x20<strong>blocks</strong>\x20the\x20<strong>negative</strong>\x20<strong>i</strong><strong>nhibitory\x20feedback</strong>&nbsp;of\x20<strong>estrogens</strong>\x20on\x20the\x20<strong>hypothalamus</strong>,\x20causing\x20a\x20surge\x20of\x20gonadotropins\x20(FSH,\x20LH),\x20which\x20leads\x20to\x20ovulation.\x20The\x20<strong>continued\x20flow\x20of\x20FSH</strong>\x20encourages\x20<strong>multiple\x20follicular\x20development</strong>\x20which\x20is\x20relatively\x20common.</p>\x0a<p>Being\x20an\x20anti-estrogen,\x20it\x20causes\x20<strong>thickening\x20</strong>of<strong>\x20cervical\x20mucus</strong>\x20and\x20<strong>thinning</strong>\x20of\x20the\x20<strong>endometrium</strong>.&nbsp;</p>\x0a<p><strong>Clomiphene\x20citrate\x20</strong>(CC)<strong>&nbsp;</strong>is\x20used\x20for&nbsp;the\x20treatment\x20of\x20absent\x20or\x20irregular\x20ovulation\x20due\x20to\x20hypothalamic-pituitary\x20dysfunction\x20associated\x20with\x20normal\x20levels\x20of\x20endogenous\x20estradiol;\x20the\x20patient\x20must\x20be\x20treated\x20repeatedly\x20until\x20pregnancy\x20is\x20achieved\x20since\x20the\x20normal\x20cyclic\x20ovulatory\x20function\x20does\x20not\x20usually\x20resume.\x20Clomiphene\x20citrate\x20has\x20no\x20effect\x20on\x20patients\x20with\x20ovarian\x20or\x20pituitary\x20failure.\x20Ovulation\x20induction\x20with\x20clomiphene\x20citrate\x20and\x20a\x20gonadotropin\x20like\x20FSH\x20increases\x20the\x20likelihood\x20of\x20multiple\x20concurrent\x20ovulations.</p>\x0a<p>Side\x20effects\x20of\x20CC\x20include\x20hot\x20flushes\x20and\x20some\x20nausea.\x20However,\x20it\x20is\x20usually\x20very\x20well\x20tolerated.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x223),'choices':[{'id':0x1,'text':_0x1947e1(0x39b)},{'id':0x2,'text':'RNA-dependent\x20RNA\x20polymerase\x20inhibition'},{'id':0x3,'text':'Fusion\x20inhibition'},{'id':0x4,'text':_0x1947e1(0x3da)}],'correct_choice_id':0x2,'solution':'<p>The\x20mechanism\x20of\x20action\x20of<strong>&nbsp;remdesivir\x20</strong>is\x20inhibition\x20of\x20the\x20enzyme\x20<strong>RNA-dependent\x20RNA\x20polymerase</strong>.</p>\x0a<p>Remdesivir\x20is\x20an\x20<strong>adenosine\x20nucleotide\x20prodrug.</strong>&nbsp;It\x20distributes\x20into\x20cells\x20where\x20it\x20is\x20metabolized\x20to\x20form\x20<strong>remdesivir\x20triphosphate</strong>\x20(<strong>RDV-TP</strong>).\x20It\x20binds\x20to\x20the\x20viral\x20RNA-dependent\x20RNA\x20polymerase\x20and\x20inhibits\x20viral\x20replication\x20by\x20prematurely\x20terminating\x20RNA\x20transcription.&nbsp;</p>\x0a<p>Remdesivir\x20(under\x20Emergency\x20Use\x20Authorization)\x20is\x20used\x20in\x20the\x20treatment\x20of\x20COVID-19.\x20It\x20may\x20be\x20considered\x20in\x20patients&nbsp;with\x20<strong>moderate\x20to\x20severe\x20disease,</strong>\x20requiring\x20supplemental\x20<strong>oxygen</strong>,<strong>&nbsp;</strong><strong>within\x2010\x20days</strong>\x20of\x20onset\x20of\x20the\x20illness.</p>\x0a<p><strong>Dose</strong>:\x20200\x20mg\x20IV\x20on\x20day\x201\x20followed\x20by\x20100\x20mg\x20IV\x20daily\x20for\x204\x20days\x20(total\x205\x20days).</p>\x0a<p>The\x20following\x20are&nbsp;<strong>contraindications&nbsp;</strong>to\x20the\x20use\x20of\x20remdesivir:</p>\x0a<ul>\x0a<li><strong>Renal</strong>\x20or\x20<strong>hepatic</strong>\x20dysfunction\x20(eGFR\x20&lt;30\x20ml/min/m<sup>2</sup>;\x20AST/ALT\x20&gt;5\x20times\x20upper\x20limit\x20of\x20normal)\x20(Not\x20an\x20absolute\x20contraindication)</li>\x0a<li><strong>Pregnant</strong>\x20or\x20<strong>lactating</strong>\x20females</li>\x0a<li>Patients\x20&lt;12\x20years\x20of\x20age</li>\x0a<li>Patients\x20who\x20are\x20not\x20on\x20oxygen\x20support\x20or\x20in-home\x20settings&nbsp;</li>\x0a</ul>\x0a<p>Remdesivir\x20can\x20cause\x20gastrointestinal\x20symptoms,\x20elevated\x20transaminase\x20levels,\x20increased\x20prothrombin\x20time,\x20and\x20hypersensitivity\x20reactions.\x20Hence,\x20<strong>liver\x20function\x20tests</strong>\x20and\x20<strong>prothrombin\x20time</strong>\x20should\x20be\x20obtained\x20before\x20and\x20during\x20treatment\x20with\x20remdesivir.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A-\x20<strong>RNA-dependent\x20DNA\x20Polymerase</strong>\x20/\x20<strong>reverse\x20transcriptase</strong>\x20<strong>inhibitors</strong>\x20prevent\x20the\x20conversion\x20of\x20viral\x20RNA\x20into\x20proviral\x20DNA.\x20They\x20help\x20to\x20prevent\x20infection\x20of\x20susceptible\x20cells\x20but\x20do\x20not\x20eradicate\x20the\x20virus\x20from\x20cells\x20that\x20are\x20integrated\x20with\x20proviral\x20DNA.\x20Examples:\x20<strong>zidovudine</strong>,\x20<strong>lamivudine</strong>,\x20<strong>stavudine</strong>,\x20<strong>tenofovir</strong>,&nbsp;<strong>didanosine</strong>,<strong>\x20zalcitabine,</strong>&nbsp;and<strong>\x20emtricitabine</strong>.\x20These\x20are\x20drugs\x20used\x20to\x20manage\x20<strong>HIV\x20infection</strong>.</p>\x0a<p>Options\x20C\x20and\x20D-&nbsp;<strong>Entry/fusion\x20inhibitors</strong>&nbsp;include\x20enfuvirtide\x20and\x20maraviroc.\x20<strong>Enfuvirtide</strong>\x20inhibits\x20the\x20fusion\x20of\x20viral\x20and\x20cell\x20membranes\x20mediated\x20by\x20gp41\x20and\x20CD4\x20interactions.\x20<strong>Maraviroc</strong>\x20is\x20a\x20chemokine\x20receptor\x20antagonist\x20and\x20binds\x20to\x20host\x20cell\x20CCR5\x20receptor\x20to\x20block\x20binding\x20of\x20viral\x20gp120.\x20They\x20are\x20also\x20used\x20to\x20manage\x20<strong>HIV\x20infection</strong>.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Administration\x20of\x20which\x20of\x20the\x20following\x20drugs\x20would\x20increase\x20the\x20bioavailability\x20of\x20saquinavir?','choices':[{'id':0x1,'text':'Ritonavir'},{'id':0x2,'text':_0x1947e1(0x207)},{'id':0x3,'text':_0x1947e1(0x26f)},{'id':0x4,'text':_0x1947e1(0x441)}],'correct_choice_id':0x1,'solution':_0x1947e1(0x20b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x3e9),'choices':[{'id':0x1,'text':_0x1947e1(0x442)},{'id':0x2,'text':_0x1947e1(0x1cf)},{'id':0x3,'text':_0x1947e1(0x347)},{'id':0x4,'text':_0x1947e1(0x393)}],'correct_choice_id':0x2,'solution':_0x1947e1(0x29d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x25c),'choices':[{'id':0x1,'text':'Inhibition\x20of\x20calcineurin'},{'id':0x2,'text':'AMP\x20kinase\x20stimulation'},{'id':0x3,'text':_0x1947e1(0x421)},{'id':0x4,'text':'Dihydro-orotate\x20dehydrogenase\x20inhibition'}],'correct_choice_id':0x1,'solution':'<p>The\x20mechanism\x20of\x20action\x20of\x20cyclosporine\x20is\x20inhibition\x20of\x20calcineurin\x20activity.</p>\x0a<p>Calcineurin\x20is\x20a\x20calcium/calmodulin-dependent\x20phosphatase\x20required\x20for\x20the\x20induction\x20of\x20T\x20cell\x20lymphokine\x20production\x20and\x20proliferation.&nbsp;<strong>Cyclosporine</strong>\x20is\x20an\x20immunomodulatory\x20drug\x20that&nbsp;<strong>inhibits\x20calcineurin\x20activity</strong>\x20by<strong>&nbsp;</strong>forming\x20a\x20complex\x20with\x20<strong>cyclophilin</strong>,\x20a\x20cytoplasmic-receptor\x20protein\x20present\x20in\x20target\x20cells,\x20to\x20form\x20a\x20<strong>cyclosporine-cyclophilin\x20complex</strong>.\x20This\x20drug-receptor\x20complex\x20specifically\x20and\x20competitively\x20binds\x20to\x20and\x20<strong>inhibits\x20calcineurin</strong>,\x20a\x20calcium\x20and\x20calmodulin-dependent\x20phosphatase.\x20This\x20in\x20turn,\x20inhibits\x20the\x20translocation\x20of\x20a\x20family\x20of\x20transcription\x20factors\x20(NF-AT),\x20leading\x20to\x20reduced\x20transcriptional\x20activation\x20of\x20cytokine\x20genes\x20for\x20interleukin\x20(IL)-2,\x20tumour\x20necrosis\x20factor\x20(TNF)-alpha,\x20IL-3,\x20IL-4,\x20CD40L,\x20granulocyte-macrophage\x20colony-stimulating\x20factor,\x20and\x20interferon-gamma.\x20Ultimately,\x20the\x20proliferation\x20of\x20T\x20lymphocytes\x20is\x20reduced,\x20resulting\x20in\x20<strong>immunomodulation.</strong></p>\x0a<p>Its\x20uses\x20are\x20:</p>\x0a<ul>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20solid\x20organ\x20transplantation,\x20to\x20treat\x20organ\x20rejection\x20in\x20kidney,\x20liver,\x20and\x20heart\x20allogeneic\x20transplants.</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20patients\x20with\x20rheumatoid\x20arthritis,\x20when\x20the\x20disease\x20has\x20not\x20adequately\x20responded\x20to\x20methotrexate.</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>It\x20is\x20approved\x20to\x20treat\x20amyotrophic\x20lateral\x20sclerosis\x20(ALS\x20or\x20Lou\x20Gehrig\x20disease)\x20and\x20its\x20variants.</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20nephrotic\x20syndrome,\x20to\x20treat\x20focal\x20segmental\x20glomerulosclerosis\x20not\x20responding\x20to\x20corticosteroids.</li>\x0a</ul>\x0a<p>Adverse\x20effects\x20of\x20cyclosporine\x20include\x20a\x20<strong>decrease</strong>\x20in\x20glomerular\x20filtration\x20rate\x20(<strong>GFR</strong>)&nbsp;and\x20<strong>metabolic\x20disturbances</strong>\x20like\x20hypomagnesemia,\x20hyperkalemia,\x20dyslipidemia,\x20gynecomastia,\x20hypertrichosis;\x20<strong>neurotoxicity</strong>\x20in\x20the\x20form\x20of\x20convulsions.&nbsp;There\x20is\x20an\x20increased\x20risk\x20of\x20developing\x20skin\x20and\x20lymphoproliferative\x20malignancies\x20in\x20cyclosporine-treated\x20psoriasis\x20patients.</p>\x0a<p>Other\x20options:<br\x20/><br\x20/>Option\x20B:&nbsp;<strong>AMP\x20kinase</strong>\x20is\x20<strong>stimulated</strong>\x20by\x20<strong>metformin,</strong>\x20a\x20first-line\x20orally\x20administered\x20drug\x20in\x20the\x20management\x20of\x20type-2\x20diabetes\x20mellitus.</p>\x0a<p>Option\x20C:&nbsp;<strong>IMP\x20dehydrogenase</strong>\x20is\x20<strong>inhibited</strong>\x20reversibly\x20by\x20the\x20drug\x20<strong>mycophenolate\x20mofetil</strong>,\x20which\x20is\x20indicated\x20in\x20the\x20prophylaxis\x20of\x20transplant\x20rejection.</p>\x0a<p>Option\x20D:&nbsp;<strong>Dihydro-orotate\x20dehydrogenase</strong>\x20is\x20<strong>inhibited</strong>\x20by\x20<strong>leflunomide,</strong>\x20a\x20pyrimidine\x20synthesis\x20inhibitor\x20indicated\x20for\x20the\x20management\x20of\x20rheumatoid\x20arthritis\x20in\x20adults.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x2d6),'choices':[{'id':0x1,'text':_0x1947e1(0x43b)},{'id':0x2,'text':_0x1947e1(0x217)},{'id':0x3,'text':_0x1947e1(0x28b)},{'id':0x4,'text':_0x1947e1(0x249)}],'correct_choice_id':0x1,'solution':_0x1947e1(0x3d9),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x1e9),'choices':[{'id':0x1,'text':_0x1947e1(0x409)},{'id':0x2,'text':_0x1947e1(0x298)},{'id':0x3,'text':'Cotrimoxazole\x20is\x20the\x20drug\x20of\x20choice,\x20but\x20patient\x20is\x20allergic\x20to\x20sulfa\x20drugs'},{'id':0x4,'text':_0x1947e1(0x2ca)}],'correct_choice_id':0x4,'solution':_0x1947e1(0x2a1),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x2ab),'choices':[{'id':0x1,'text':_0x1947e1(0x2c9)},{'id':0x2,'text':_0x1947e1(0x250)},{'id':0x3,'text':_0x1947e1(0x270)},{'id':0x4,'text':_0x1947e1(0x41b)}],'correct_choice_id':0x2,'solution':_0x1947e1(0x2fb),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x1f2),'choices':[{'id':0x1,'text':_0x1947e1(0x3a1)},{'id':0x2,'text':'Buspirone\x20SR'},{'id':0x3,'text':_0x1947e1(0x273)},{'id':0x4,'text':_0x1947e1(0x348)}],'correct_choice_id':0x1,'solution':'<p><strong>Varenicline</strong>\x20is\x20the\x20most\x20effective\x20drug\x20in\x20smoking\x20cessation.</p>\x0a<p><strong>Nicotine</strong>\x20is\x20the\x20principal\x20constituent\x20of\x20tobacco\x20responsible\x20for\x20its\x20addictive\x20behaviour.\x20One\x20of\x20the\x20newest\x20agents\x20introduced\x20to\x20aid\x20in\x20smoking\x20cessation\x20is\x20<strong>varenicline</strong>.</p>\x0a<p>Varenicline\x20works\x20by\x20blocking\x20the\x20effects\x20of\x20nicotine\x20on\x20the\x20brain.\x20It\x20<strong>blocks</strong>\x20&alpha;-4,\x20&beta;-2\x20<strong>nicotinic\x20acetylcholine\x20receptor</strong>\x20subtypes\x20and\x20varenicline\x20<strong>inhibits\x20dopaminergic\x20activation</strong>\x20produced\x20by\x20smoking\x20through\x20their\x20<strong>partial\x20agonism</strong>,\x20and\x20decreases\x20the\x20craving\x20and\x20withdrawal\x20syndrome\x20that\x20occurs\x20with\x20cessation\x20attempts.\x20It\x20prevents\x20nicotine\x20stimulation\x20of\x20the\x20mesolimbic\x20dopamine\x20system\x20associated\x20with\x20nicotine\x20addiction,\x20thus\x20helping\x20to\x20occlude\x20the\x20\x22rewarding\x22\x20effect\x20of\x20smoking.</p>\x0a<p>Varenicline\x20is\x20prescribed\x20only\x20to\x20patients\x2018\x20years\x20or\x20older.\x20Varenicline\x20is\x20taken\x20orally\x20and\x20the\x20dose\x20taken\x20is\x200.5\x20mg\x20once\x20daily\x20on\x20days\x201\x20to\x203,\x20increased\x20to\x200.5\x20mg\x20twice\x20daily\x20on\x20days\x204\x20through\x207\x20and\x201\x20mg\x20twice\x20daily\x20after\x20day\x208\x20for\x2011\x20weeks.\x20Therapy\x20should\x20start\x20one\x20week\x20before\x20the\x20target\x20quit\x20date.\x20It\x20can\x20be\x20continued\x20for\x20another\x2012\x20weeks\x20(1\x20mg\x20BD)\x20to\x20maintain\x20abstinence.</p>\x0a<p>The\x20adverse\x20effects\x20include\x20nausea,\x20which\x20can\x20be\x20mitigated\x20by\x20starting\x20at\x20lower\x20doses\x20and\x20gradually\x20increasing\x20the\x20dose.\x20Other\x20symptoms\x20include\x20disturbed\x20sleep,\x20sleepwalking,\x20agitation,\x20drowsiness,\x20and\x20constipation\x20and&nbsp;may\x20also\x20increase\x20the\x20risk\x20of\x20pancreatitis.\x20Varenicline\x20has\x20also\x20been\x20implicated\x20in\x20specific\x20skin\x20syndromes\x20such\x20as\x20<strong>Stevens-Johnson&nbsp;syndrome</strong>,\x20erythema\x20multiforme,\x20and\x20photosensitivity.\x20Varenicline\x20can\x20cause\x20renal\x20failure\x20and\x20kidney\x20stones,\x20thus\x20renal\x20function\x20must\x20be\x20monitored.</p>\x0a<p>The\x20FDA\x20has\x20issued\x20a\x20warning\x20about\x20<strong>mood</strong>\x20and\x20<strong>behavioral\x20changes</strong>\x20associated\x20with\x20its\x20use,\x20and\x20there\x20is\x20some\x20evidence\x20of\x20<strong>increased\x20cardiovascular\x20risk.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Buspirone\x20</strong>sustained\x20release&nbsp;is\x20a\x20<strong>partial\x20agonist</strong>\x20at<strong>\x205HT</strong>\x20receptors\x20but\x20affinity\x20for\x20D<sub>2</sub>\x20receptors\x20may\x20also\x20be\x20present.\x20Its\x20effects\x20are\x20slow\x20onset,\x20over\x20a\x20couple\x20of\x20weeks\x20and\x20is\x20used\x20in\x20the\x20management\x20of\x20generalised\x20anxiety\x20states.</p>\x0a<p>Option\x20C:\x20<strong>Nicotine</strong>\x20gum\x20has\x20nicotine\x20which\x20is\x20an\x20<strong>agonist</strong>\x20at\x20<strong>N<sub>n</sub>\x20</strong>type\x20nicotinic\x20cholinergic\x20receptors\x20and\x20is\x20also\x20advised\x20for\x20smoking\x20cessation\x20along\x20with\x20psychotherapy.\x20However,\x20varenicline\x20was\x20more\x20effective\x20when\x20compared\x20with\x20singleproduct\x20nicotine\x20replacement\x20therapy\x20(NRT)\x20and\x20was\x20similarly\x20effective\x20compared\x20with\x20combination\x20NRT.</p>\x0a<p>Option\x20D:\x20<strong>Rimonabant</strong>\x20is\x20an\x20<strong>inverse\x20agonist</strong>\x20at\x20cannabinoid\x20receptor\x20CB<sub>1&nbsp;</sub>which\x20decreases\x20neurotransmitter\x20release\x20at\x20GABAergic\x20and\x20glutamatergic\x20synapses;\x20its\x20usage\x20for\x20smoking\x20cessation\x20and\x20treat\x20obesity\x20was\x20stopped\x20after\x20serious\x20side\x20effects\x20notably\x20<strong>severe\x20depression</strong>\x20and\x20<strong>increased\x20risk</strong>\x20of\x20<strong>suicide.</strong>\x20However,\x20it\x20continues\x20to\x20be\x20used\x20off-label\x20for\x20smoking\x20cessation.&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x231),'choices':[{'id':0x1,'text':_0x1947e1(0x2ce)},{'id':0x2,'text':_0x1947e1(0x38c)},{'id':0x3,'text':_0x1947e1(0x3b7)},{'id':0x4,'text':_0x1947e1(0x34c)}],'correct_choice_id':0x2,'solution':'<p>The\x20cephalosporin\x20antibiotic\x20most\x20likely\x20to\x20have\x20caused<strong>\x20hemarthrosis</strong>\x20in\x20this\x20patient\x20on\x20warfarin\x20therapy\x20is\x20<strong>cefoperazone</strong>.</p>\x0a<p>Cephalosporins\x20containing\x20a&nbsp;methylthiotetrazole\x20(NMTT)\x20group\x20can\x20<strong>prolong</strong>\x20the\x20<strong>prothrombin\x20time.\x20</strong>This&nbsp;results\x20in\x20<strong>clinically\x20significant\x20bleeding</strong>\x20in\x20patients\x20<strong>already</strong>\x20on\x20<strong>anticoagulant\x20therapy</strong>\x20or\x20having\x20<strong>vitamin\x20K\x20deficiency</strong>.&nbsp;</p>\x0a<p>This\x20is\x20because\x20NMTT\x20cephalosporins\x20<strong>inhibit</strong>\x20the\x20enzyme\x20<strong>vitamin\x20K\x20epoxide\x20reductase</strong>\x20in\x20the\x20liver,\x20which\x20is\x20the\x20key\x20enzyme\x20for\x20<strong>vitamin\x20K-dependent\x20carboxylation</strong>,\x20a\x20posttranslational\x20modification\x20that\x20is\x20essential\x20for\x20the\x20biological\x20functions\x20of\x20coagulation\x20factors.&nbsp;<br\x20/>NMTT\x20group\x20containing\x20cephalosporins\x20include\x20latamoxef,\x20cefmenoxime,<strong>\x20cefoperazone,\x20cefotetan,\x20cefamandole</strong>.</p>\x0a<p>Vitamin\x20K\x20epoxide\x20reductase\x20is\x20also\x20the\x20target\x20of\x20<strong>anticoagulants</strong>\x20like\x20<strong>warfarin.\x20</strong>Oral\x20administration\x20of\x20vitamin\x20K\x20can\x20prevent\x20this\x20problem.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x2ee),'choices':[{'id':0x1,'text':_0x1947e1(0x336)},{'id':0x2,'text':_0x1947e1(0x262)},{'id':0x3,'text':'Asenapine'},{'id':0x4,'text':_0x1947e1(0x412)}],'correct_choice_id':0x2,'solution':_0x1947e1(0x405),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x236),'choices':[{'id':0x1,'text':_0x1947e1(0x301)},{'id':0x2,'text':'Amlodipine'},{'id':0x3,'text':_0x1947e1(0x3ee)},{'id':0x4,'text':_0x1947e1(0x330)}],'correct_choice_id':0x1,'solution':_0x1947e1(0x240),'explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/37758943b0974770b61e968d337fcac4.JPEG'],'explanation_images':[]},{'text':_0x1947e1(0x2f2),'choices':[{'id':0x1,'text':'Ambroxol'},{'id':0x2,'text':'Diphenoxylate'},{'id':0x3,'text':_0x1947e1(0x3e8)},{'id':0x4,'text':'Levorphanol'}],'correct_choice_id':0x3,'solution':_0x1947e1(0x2e9),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x1947e1(0x277),'choices':[{'id':0x1,'text':_0x1947e1(0x230)},{'id':0x2,'text':_0x1947e1(0x26e)},{'id':0x3,'text':_0x1947e1(0x2a5)},{'id':0x4,'text':_0x1947e1(0x21e)}],'correct_choice_id':0x2,'solution':'<p>The\x20<strong>anti-epileptic\x20drugs</strong>\x20which\x20can\x20also\x20be\x20used\x20for\x20<strong>neuropathic\x20pain</strong>\x20are\x20<strong>1</strong>,\x20<strong>2</strong>,\x20and\x20<strong>4</strong>&nbsp;which\x20are\x20pregabalin,\x20carbamazepine\x20and\x20gabapentin\x20respectively.</p>\x0a<p><strong>Pregabalin</strong>\x20is\x20an\x20anti-epileptic\x20drug\x20that\x20acts\x20by\x20binding\x20to\x20&alpha;2&delta;,\x20a\x20protein\x20that\x20is\x20a\x20subunit\x20of\x20voltage-gated\x20calcium\x20channels\x20and\x20causes\x20a\x20decrease\x20in\x20glutamate\x20release\x20at\x20excitatory\x20synapses.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20neuropathic\x20pain\x20associated\x20with\x20<strong>diabetic\x20peripheral\x20neuropathy</strong>,\x20<strong>spinal\x20cord\x20injury</strong>\x20or\x20<strong>postherpetic\x20neuralgia</strong>.</p>\x0a<p><strong>Gabapentin</strong>\x20is\x20an\x20anti-epileptic\x20drug\x20that,&nbsp;like\x20pregabalin,\x20acts\x20by\x20binding\x20to\x20&alpha;2&delta;\x20protein.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20neuropathic\x20pain\x20due\x20to\x20<strong>postherpetic\x20neuralgia</strong>\x20in\x20adults.</p>\x0a<p>The\x20binding\x20of\x20gabapentin\x20and\x20pregabalin,\x20also\x20called\x20\x22gabapentinoids\x22\x20due\x20to\x20their\x20structural\x20similarity\x20to\x20GABA,\x20to&nbsp;<strong>calcium\x20channel\x20subunit\x20a2&delta;&nbsp;</strong>protein,\x20is&nbsp;considered\x20to\x20mediate\x20the\x20anti-convulsant\x20effects\x20of\x20gabapentin\x20and\x20pregabalin.\x20They\x20are\x20used\x20in\x20focal\x20onset\x20seizures\x20with\x20or\x20without\x20progression\x20to\x20bilateral\x20tonic-clonic\x20seizures\x20when\x20used\x20in\x20addition\x20to\x20other\x20anti-epileptic\x20drugs.</p>\x0a<p><strong>Carbamazepine</strong>\x20is\x20an\x20iminostilbine\x20derivative.\x20It\x20blocks&nbsp;<strong>voltage-activated</strong>\x20<strong>sodium\x20channels,&nbsp;</strong>slowing\x20their\x20rate\x20of\x20recovery&nbsp;and\x20limiting\x20the\x20repetitive\x20firing\x20of\x20action\x20potentials.&nbsp;It\x20is\x20used\x20in\x20the\x20treatment\x20of:</p>\x0a<ul>\x0a<li>Generalized,\x20focal-to-bilateral\x20and\x20idiopathic\x20<strong>tonic-clonic\x20seizures</strong></li>\x0a<li><strong>Focal\x20seizures</strong></li>\x0a<li>Neuropathic\x20pain\x20associated\x20with\x20<strong>trigeminal</strong>\x20and\x20<strong>glossopharyngeal\x20neuralgias</strong>.</li>\x0a</ul>\x0a<p><strong>Lamotrigine</strong>\x20is\x20an\x20anti-folate\x20agent\x20whose\x20mechanism\x20of\x20action\x20is\x20similar\x20to\x20that\x20of\x20carbamazepine\x20i.e.\x20it\x20<strong>delays</strong>\x20the\x20recovery\x20from\x20inactivation\x20of\x20recombinant\x20<strong>sodium\x20channels.\x20</strong>It\x20also&nbsp;<strong>inhibits</strong>\x20the\x20<strong>release</strong>\x20of\x20<strong>glutamate</strong>\x20by\x20acting\x20directly\x20on\x20the\x20sodium\x20channels.\x20Therefore,\x20when\x20used\x20concurrently\x20with\x20carbamazepine,\x20is\x20associated\x20with\x20toxicity\x20in\x20some\x20patients\x20due\x20to\x20increase\x20in\x2010,11-\x20epoxide\x20of\x20carbamazepine.\x20It\x20is\x20useful\x20in\x20the\x20management\x20of:</p>\x0a<ul>\x0a<li>Focal\x20and\x20secondarily\x20generalized\x20<strong>tonic-clonic\x20seizures</strong>\x20in\x20adults</li>\x0a<li><strong>Lennox-Gastaut\x20syndrome\x20</strong>-&nbsp;a\x20childhood\x20disorder\x20characterized\x20by\x20multiple\x20type\x20seizures,\x20mental\x20retardation,\x20and\x20refractoriness\x20to\x20anti-seizure\x20medication.</li>\x0a</ul>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20breast\x20cancer\x20patient\x20post-chemotherapy\x20developed\x20a\x20low-grade\x20fever\x20with\x20anemia\x20and\x20leukocytopenia\x20(<4000/cm3;\x20DNC:\x2030).\x20Which\x20of\x20the\x20following\x20antibiotics\x20will\x20not\x20be\x20used\x20in\x20the\x20empirical\x20management\x20of\x20this\x20patient?','choices':[{'id':0x1,'text':_0x1947e1(0x460)},{'id':0x2,'text':_0x1947e1(0x3f8)},{'id':0x3,'text':_0x1947e1(0x366)},{'id':0x4,'text':_0x1947e1(0x1ef)}],'correct_choice_id':0x3,'solution':_0x1947e1(0x279),'explanation_video':'','question_images':[],'explanation_images':[]}],quizName=_0x1947e1(0x41d),hierarchy=[_0x1947e1(0x3ab),'PYQs','Pharmacology'];if(window['location'][_0x1947e1(0x332)][_0x1947e1(0x445)](_0x1947e1(0x34d))){const customData=JSON[_0x1947e1(0x3a4)](localStorage[_0x1947e1(0x3e4)](_0x1947e1(0x403)));if(customData){const jqiWGf=_0x1947e1(0x443)[_0x1947e1(0x2de)]('|');let IINFCc=0x0;while(!![]){switch(jqiWGf[IINFCc++]){case'0':document[_0x1947e1(0x20d)](_0x1947e1(0x40e))['textContent']=hierarchy[_0x1947e1(0x22d)]('\x20>\x20');continue;case'1':quizName=customData[_0x1947e1(0x2e2)];continue;case'2':hierarchy=customData[_0x1947e1(0x44e)];continue;case'3':questionsData=customData[_0x1947e1(0x343)];continue;case'4':document['getElementById']('totalQuestions')[_0x1947e1(0x255)]=questionsData[_0x1947e1(0x3e3)];continue;case'5':document[_0x1947e1(0x344)]=quizName+'\x20-\x20Brain\x20And\x20Scalpel';continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x1947e1(0x1c6),timer=null,timeRemaining=0x0,questionStartTime=Date['now'](),quizStartTime=Date[_0x1947e1(0x2a7)](),isQuizCompleted=![],questionStates=new Array(questionsData['length'])[_0x1947e1(0x26c)](null)[_0x1947e1(0x32b)](()=>({'status':_0x1947e1(0x369),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0x1947e1(0x3e3)]};const urlParams=new URLSearchParams(window[_0x1947e1(0x420)][_0x1947e1(0x36e)]);currentQuestionIndex=Math[_0x1947e1(0x3db)](parseInt(urlParams[_0x1947e1(0x320)](_0x1947e1(0x2fe)))||0x0,questionsData[_0x1947e1(0x3e3)]-0x1);function goBack(){const _0x28be28=_0x1947e1,_0x5bb818={'RIvRW':function(_0x3097e3,_0x1446f3){return _0x3097e3(_0x1446f3);},'tMFvx':function(_0x99ef4a,_0x4f1bd3){return _0x99ef4a+_0x4f1bd3;},'pycCZ':'return\x20(function()\x20','hettL':_0x28be28(0x1d5),'ZeDdv':_0x28be28(0x2b9),'yhMPR':function(_0x50d532,_0x5f1d23){return _0x50d532===_0x5f1d23;}};(isQuizCompleted||confirm(_0x5bb818['ZeDdv']))&&(_0x5bb818[_0x28be28(0x30c)](_0x28be28(0x1e1),'tIyqb')?_0x1b38ed=SFYMKE[_0x28be28(0x1f9)](_0x56df2a,SFYMKE[_0x28be28(0x3e5)](SFYMKE['pycCZ'],SFYMKE[_0x28be28(0x286)])+');')():window['history'][_0x28be28(0x295)]());}function selectMode(_0x139db5){const _0x48dfa7=_0x1947e1;currentMode=_0x139db5,document[_0x48dfa7(0x20d)](_0x48dfa7(0x42d))[_0x48dfa7(0x1d6)]['display']=_0x48dfa7(0x446),initializeQuiz();}function initializeQuiz(){const _0x545984=_0x1947e1,_0x4144f3={'vHEtT':_0x545984(0x407),'jiGdx':_0x545984(0x391),'nSscp':'testModeReviewLegend','muNGv':function(_0x1779b2,_0x2f6e92){return _0x1779b2===_0x2f6e92;},'mgCcg':_0x545984(0x2fc),'nFVuY':function(_0x250ae0,_0x373f36){return _0x250ae0===_0x373f36;},'kzNbu':_0x545984(0x446),'yLplQ':_0x545984(0x257),'wHSoB':'studyModeLegend','lTosx':_0x545984(0x254),'VfdrU':_0x545984(0x259),'HyekX':_0x545984(0x2df),'MVgrm':function(_0x23e6a4,_0x3b5389){return _0x23e6a4===_0x3b5389;},'MKtJQ':'timed_study','JkaYv':function(_0xa691c9,_0x57b441){return _0xa691c9===_0x57b441;},'dePRg':'timed_exam','IoDEo':'timerContainer','jYGDJ':function(_0x111c59){return _0x111c59();},'KtTgz':function(_0x12b9c5){return _0x12b9c5();}};quizStartTime=Date['now']();const _0x1cca53=document[_0x545984(0x20d)](_0x4144f3['vHEtT']),_0x5c286d=document[_0x545984(0x20d)](_0x4144f3[_0x545984(0x397)]),_0x5f0f71=document[_0x545984(0x20d)](_0x4144f3['nSscp']),_0x1fce8c=_0x4144f3[_0x545984(0x27f)](currentMode,_0x4144f3[_0x545984(0x3cc)])||_0x4144f3[_0x545984(0x23c)](currentMode,_0x545984(0x2c8));document['getElementById'](_0x545984(0x459))['style'][_0x545984(0x3cb)]=_0x1fce8c?_0x4144f3[_0x545984(0x454)]:_0x4144f3[_0x545984(0x3aa)],document[_0x545984(0x20d)](_0x4144f3[_0x545984(0x3ed)])[_0x545984(0x1d6)][_0x545984(0x3cb)]=_0x1fce8c?_0x545984(0x446):_0x4144f3[_0x545984(0x3aa)],document[_0x545984(0x20d)](_0x4144f3[_0x545984(0x1e4)])[_0x545984(0x1d6)]['display']=_0x1fce8c?_0x4144f3[_0x545984(0x3aa)]:_0x4144f3['kzNbu'],document[_0x545984(0x20d)](_0x4144f3[_0x545984(0x204)])[_0x545984(0x1d6)][_0x545984(0x3cb)]=_0x1fce8c?_0x4144f3['yLplQ']:_0x4144f3[_0x545984(0x454)],_0x1cca53[_0x545984(0x1d6)][_0x545984(0x3cb)]=_0x1fce8c?_0x4144f3[_0x545984(0x454)]:_0x4144f3[_0x545984(0x253)],_0x5c286d[_0x545984(0x1d6)][_0x545984(0x3cb)]=_0x1fce8c?_0x4144f3[_0x545984(0x253)]:_0x4144f3[_0x545984(0x454)],_0x5f0f71['style'][_0x545984(0x3cb)]=_0x1fce8c?_0x4144f3[_0x545984(0x253)]:_0x4144f3[_0x545984(0x454)],(_0x4144f3[_0x545984(0x35d)](currentMode,_0x4144f3['MKtJQ'])||_0x4144f3[_0x545984(0x430)](currentMode,_0x4144f3[_0x545984(0x24e)]))&&document['getElementById'](_0x4144f3[_0x545984(0x3b9)])[_0x545984(0x3c4)][_0x545984(0x2f0)](_0x545984(0x32a)),_0x4144f3[_0x545984(0x242)](loadBookmarkedQuestions),_0x4144f3[_0x545984(0x28f)](generateQuestionNav),_0x4144f3[_0x545984(0x242)](updateStats),_0x4144f3[_0x545984(0x28f)](displayQuestion);}function generateQuestionNav(){const _0x268fb2=_0x1947e1,_0x32bf8e={'LikDx':'questionNav','RLIfA':function(_0x48b81e,_0x3985a4){return _0x48b81e<_0x3985a4;},'nQsCH':function(_0x394bd5,_0x516b6e){return _0x394bd5!==_0x516b6e;},'PZbPo':_0x268fb2(0x2d1),'AMHhN':'button','ossbc':_0x268fb2(0x2a0),'ehsOo':function(_0x379eee){return _0x379eee();}},_0x31613=document['getElementById'](_0x32bf8e[_0x268fb2(0x3a9)]);_0x31613[_0x268fb2(0x2c1)]='';for(let _0x3cabe8=0x0;_0x32bf8e[_0x268fb2(0x2b4)](_0x3cabe8,questionsData['length']);_0x3cabe8++){if(_0x32bf8e[_0x268fb2(0x428)](_0x32bf8e[_0x268fb2(0x1e7)],_0x32bf8e[_0x268fb2(0x1e7)])){if(_0x2930f8){const _0x5399a4=_0x5b4cfa[_0x268fb2(0x200)](_0x3db8bf,arguments);return _0x57cd0a=null,_0x5399a4;}}else{const _0x282993=document[_0x268fb2(0x1e0)](_0x32bf8e[_0x268fb2(0x35f)]);_0x282993[_0x268fb2(0x255)]=_0x3cabe8+0x1,_0x282993[_0x268fb2(0x3eb)]=_0x32bf8e['ossbc'],_0x282993['onclick']=()=>jumpToQuestion(_0x3cabe8),_0x282993['id']=_0x268fb2(0x423)+_0x3cabe8,_0x31613[_0x268fb2(0x2cb)](_0x282993);}}_0x32bf8e[_0x268fb2(0x371)](updateQuestionNav);}function updateQuestionNav(){const _0xb449fd=_0x1947e1,_0x39a3d4={'psaYw':_0xb449fd(0x43e),'LRCSD':function(_0x583e34,_0x5d3717){return _0x583e34(_0x5d3717);},'wHitT':function(_0x44b524,_0x3171af){return _0x44b524<_0x3171af;},'zIRLJ':function(_0x4674ca,_0x5a544f){return _0x4674ca===_0x5a544f;},'zmynb':'ScRjf','GEXNq':_0xb449fd(0x389),'TTSlv':function(_0x52d644,_0x4d6901){return _0x52d644===_0x4d6901;},'vxObL':_0xb449fd(0x3f7),'fWqsa':_0xb449fd(0x1e2),'lPxle':function(_0x238133,_0x502afc){return _0x238133===_0x502afc;},'bxGaD':_0xb449fd(0x1c6),'jAYkw':function(_0x10f445,_0xcd4a21){return _0x10f445===_0xcd4a21;},'pKZeG':_0xb449fd(0x2e0),'BObht':function(_0xdd14c,_0x3477f7){return _0xdd14c===_0x3477f7;},'mHRKJ':_0xb449fd(0x434),'YvISS':_0xb449fd(0x3a8),'INsAc':_0xb449fd(0x318),'URaaN':function(_0x29b1ab,_0x30b597){return _0x29b1ab!==_0x30b597;},'lVplc':_0xb449fd(0x237)};for(let _0x7305ca=0x0;_0x39a3d4[_0xb449fd(0x3c6)](_0x7305ca,questionsData[_0xb449fd(0x3e3)]);_0x7305ca++){if(_0x39a3d4[_0xb449fd(0x43f)](_0x39a3d4[_0xb449fd(0x24b)],_0x39a3d4['GEXNq'])){const _0x564043=_0x496b46(_0x3cc66b['getAttribute'](_0x39a3d4['psaYw']));_0x39a3d4[_0xb449fd(0x35a)](_0x1c08e9,_0x564043);}else{const _0x1ea032=document[_0xb449fd(0x20d)]('navBtn_'+_0x7305ca),_0x351209=questionStates[_0x7305ca];let _0x402b0d='';if(_0x39a3d4[_0xb449fd(0x3a7)](_0x7305ca,currentQuestionIndex))_0x402b0d=_0xb449fd(0x41e);else{if(_0x351209[_0xb449fd(0x3df)])_0x402b0d=_0x39a3d4[_0xb449fd(0x2ad)];else{if(_0x351209['markedForReview'])_0x402b0d=_0x39a3d4['fWqsa'];else{if(_0x39a3d4['lPxle'](currentMode,_0x39a3d4[_0xb449fd(0x453)])||currentMode===_0xb449fd(0x2e5)){if(_0x39a3d4['jAYkw'](_0x351209[_0xb449fd(0x43d)],_0x39a3d4['pKZeG']))_0x402b0d=_0xb449fd(0x2a3);else{if(_0x39a3d4['BObht'](_0x351209['status'],_0x39a3d4[_0xb449fd(0x274)]))_0x402b0d=_0x39a3d4[_0xb449fd(0x39c)];else _0x402b0d=_0x39a3d4[_0xb449fd(0x34a)];}}else{if(_0x39a3d4[_0xb449fd(0x1d7)](_0x351209[_0xb449fd(0x44f)],null))_0x402b0d=_0x39a3d4[_0xb449fd(0x31a)];else _0x402b0d=_0x39a3d4[_0xb449fd(0x34a)];}}}}_0x1ea032[_0xb449fd(0x3eb)]=_0xb449fd(0x353)+_0x402b0d;}}}function jumpToQuestion(_0x2666f5){const _0x3c30c6=_0x1947e1,_0x313ac3={'EoghP':_0x3c30c6(0x34d),'pRCOj':function(_0x143041,_0x41b9a6){return _0x143041>=_0x41b9a6;},'JzAAF':function(_0x289b10,_0x44e421){return _0x289b10<_0x44e421;},'SwvxE':function(_0x512a05,_0x131591){return _0x512a05!==_0x131591;},'ZZgdT':'iCGxs','DwpEw':_0x3c30c6(0x275),'yHjhw':function(_0x292f27,_0x73dd4a){return _0x292f27-_0x73dd4a;},'edkfa':function(_0x277535){return _0x277535();}};_0x313ac3[_0x3c30c6(0x2f9)](_0x2666f5,0x0)&&_0x313ac3[_0x3c30c6(0x2d0)](_0x2666f5,questionsData[_0x3c30c6(0x3e3)])&&(questionStartTime&&(_0x313ac3[_0x3c30c6(0x40c)](_0x313ac3[_0x3c30c6(0x466)],_0x313ac3['DwpEw'])?questionStates[currentQuestionIndex]['timeSpent']+=_0x313ac3[_0x3c30c6(0x37b)](Date['now'](),questionStartTime):(_0x2b998e['location'][_0x3c30c6(0x332)][_0x3c30c6(0x445)](_0x313ac3[_0x3c30c6(0x44b)])&&_0x6e53ab['removeItem']('customQuizData'),_0x18eaf8[_0x3c30c6(0x386)]())),currentQuestionIndex=_0x2666f5,_0x313ac3[_0x3c30c6(0x225)](displayQuestion));}function updateStats(){const _0x1d732b=_0x1947e1,_0x5e81c1={'gSugN':_0x1d732b(0x2e0),'SDfit':function(_0x44264e,_0x4e2a94){return _0x44264e===_0x4e2a94;},'HmGIW':_0x1d732b(0x1c6),'UcEnH':_0x1d732b(0x2e5),'uxxaC':'BxvZk','QWZyy':_0x1d732b(0x23a),'dPoqj':'correctCount','UpTGd':'incorrectCount','EATbI':_0x1d732b(0x24f),'iyLQu':function(_0x10a7e4,_0x4016cc){return _0x10a7e4>_0x4016cc;},'lxGdp':_0x1d732b(0x2cf),'dwVJs':function(_0x3be83c,_0x83d03e){return _0x3be83c+_0x83d03e;},'zDkWv':function(_0x3f2888,_0x3fcfa4){return _0x3f2888/_0x3fcfa4;},'oIHsf':function(_0x3a912e,_0x260318){return _0x3a912e/_0x260318;},'WEYHg':function(_0x16b5f7,_0xdd517e){return _0x16b5f7%_0xdd517e;},'gbaCQ':_0x1d732b(0x2f6),'yKNsu':function(_0x23b5ff,_0x4d580d){return _0x23b5ff+_0x4d580d;}};if(_0x5e81c1[_0x1d732b(0x3c9)](currentMode,_0x5e81c1['HmGIW'])||_0x5e81c1[_0x1d732b(0x3c9)](currentMode,_0x5e81c1[_0x1d732b(0x436)])){if(_0x5e81c1['SDfit'](_0x5e81c1[_0x1d732b(0x413)],_0x5e81c1['QWZyy']))_0x4e92f1++,_0x1050fc[_0x1d732b(0x43d)]=_0x5e81c1[_0x1d732b(0x284)];else{document['getElementById'](_0x5e81c1[_0x1d732b(0x3d7)])[_0x1d732b(0x255)]=stats[_0x1d732b(0x2d2)],document[_0x1d732b(0x20d)](_0x5e81c1['UpTGd'])[_0x1d732b(0x255)]=stats['incorrectAnswers'],document[_0x1d732b(0x20d)](_0x5e81c1[_0x1d732b(0x382)])[_0x1d732b(0x255)]=stats['totalAttempted'];const _0x41bb6f=_0x5e81c1[_0x1d732b(0x42f)](stats[_0x1d732b(0x24f)],0x0)?Math[_0x1d732b(0x2ed)](stats['correctAnswers']/stats[_0x1d732b(0x24f)]*0x64):0x0;document[_0x1d732b(0x20d)](_0x5e81c1[_0x1d732b(0x468)])[_0x1d732b(0x255)]=_0x5e81c1[_0x1d732b(0x1f8)](_0x41bb6f,'%'),stats[_0x1d732b(0x29f)]=questionStates[_0x1d732b(0x33f)]((_0x779a0b,_0x32744e)=>_0x779a0b+_0x32744e[_0x1d732b(0x2f6)],0x0);const _0x5c56ec=Math[_0x1d732b(0x3fb)](_0x5e81c1[_0x1d732b(0x3f5)](stats['totalTime'],0x3e8)),_0x33c369=Math[_0x1d732b(0x3fb)](_0x5e81c1['oIHsf'](_0x5c56ec,0x3c)),_0x369722=_0x5e81c1[_0x1d732b(0x316)](_0x5c56ec,0x3c);document[_0x1d732b(0x20d)](_0x5e81c1[_0x1d732b(0x2cc)])[_0x1d732b(0x255)]=_0x5e81c1[_0x1d732b(0x3d6)](_0x33c369,':')+_0x369722[_0x1d732b(0x29b)]()['padStart'](0x2,'0');}}}function setupVideo(_0x3561f8,_0x8c0256){const _0x48bb98=_0x1947e1,_0x4b9262={'oyAst':function(_0x51eda6){return _0x51eda6();},'wRCFb':function(_0x336bd9,_0x261d24){return _0x336bd9===_0x261d24;},'bwdOM':_0x48bb98(0x432),'loijE':_0x48bb98(0x401),'vMfpv':function(_0xb2d0b4,_0x21c48c){return _0xb2d0b4!==_0x21c48c;},'KcrOl':'CPjTO'};if(Hls[_0x48bb98(0x1ee)]()){if(_0x4b9262[_0x48bb98(0x439)](_0x4b9262[_0x48bb98(0x388)],_0x4b9262[_0x48bb98(0x3e6)]))_0x4b9262[_0x48bb98(0x30b)](_0x12287d);else{const _0x2f0abb=new Hls();_0x2f0abb[_0x48bb98(0x352)](_0x8c0256),_0x2f0abb[_0x48bb98(0x45d)](_0x3561f8);}}else _0x3561f8[_0x48bb98(0x392)](_0x48bb98(0x203))&&(_0x4b9262[_0x48bb98(0x2ff)](_0x4b9262['KcrOl'],_0x48bb98(0x2d5))?_0x3561f8[_0x48bb98(0x451)]=_0x8c0256:_0x123e64());}function _0xb405(_0x2edee4,_0x660d69){const _0x567d5b=_0x30a8();return _0xb405=function(_0x393828,_0x495c5f){_0x393828=_0x393828-0x1c5;let _0x43e912=_0x567d5b[_0x393828];return _0x43e912;},_0xb405(_0x2edee4,_0x660d69);}function displayQuestion(){const _0x291df4=_0x1947e1,_0x1d888c={'DbpfX':function(_0x3361bb,_0x428eae){return _0x3361bb===_0x428eae;},'QAZaT':_0x291df4(0x369),'bFSph':_0x291df4(0x2e0),'VvrxG':function(_0x1d75f4){return _0x1d75f4();},'xwOze':function(_0x4ae282,_0x30fb93){return _0x4ae282(_0x30fb93);},'ssXDd':function(_0x188531,_0x394b2e){return _0x188531===_0x394b2e;},'HKbnJ':_0x291df4(0x1f7),'wagVD':_0x291df4(0x296),'QnykV':'Option\x20','Xroso':function(_0x58d7bd,_0xa1cef1){return _0x58d7bd+_0xa1cef1;},'KrXCO':_0x291df4(0x337),'ettkp':function(_0x547ba4,_0x1d80d6){return _0x547ba4(_0x1d80d6);},'zKWMP':'w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','mLrZC':function(_0x1ec285,_0x42f629){return _0x1ec285===_0x42f629;},'UxcJW':_0x291df4(0x30e),'jlJzl':'No\x20questions\x20available\x20for\x20this\x20quiz.','fZIer':function(_0x2bd8cb,_0x1e968b){return _0x2bd8cb*_0x1e968b;},'LKkWJ':_0x291df4(0x383),'pfRsR':'currentQuestion','vSdnJ':_0x291df4(0x29c),'kDMhq':function(_0x4930f9,_0x8acb05){return _0x4930f9===_0x8acb05;},'ZNaNL':'solutionContainer','HkeGw':_0x291df4(0x32a),'ycvdk':function(_0x13bc4c,_0x41a5bd){return _0x13bc4c!==_0x41a5bd;},'yubyz':'lFBYn','zHJXc':_0x291df4(0x27d),'PbYfL':'optionsContainer','PzVHL':_0x291df4(0x380),'xwtXK':_0x291df4(0x364),'AyHvr':function(_0x1b5566){return _0x1b5566();},'cgDAS':function(_0x9b684e,_0x4cf066){return _0x9b684e===_0x4cf066;},'WdRsX':_0x291df4(0x2e5),'dKxET':_0x291df4(0x2c8),'rufst':function(_0x2a2db5,_0x416130){return _0x2a2db5===_0x416130;},'PFblo':_0x291df4(0x3de),'oXVjd':_0x291df4(0x3c2),'fDEOI':function(_0x37a22a){return _0x37a22a();}};if(!questionsData||_0x1d888c['mLrZC'](questionsData[_0x291df4(0x3e3)],0x0)){document[_0x291df4(0x20d)](_0x1d888c[_0x291df4(0x21f)])[_0x291df4(0x2c1)]=_0x1d888c[_0x291df4(0x264)];return;};const _0x39c2d7=questionsData[currentQuestionIndex];questionStartTime=Date[_0x291df4(0x2a7)](),selectedOption=questionStates[currentQuestionIndex][_0x291df4(0x44f)];const _0x21b20c=_0x1d888c['fZIer']((currentQuestionIndex+0x1)/questionsData['length'],0x64);document[_0x291df4(0x20d)](_0x1d888c[_0x291df4(0x3ba)])[_0x291df4(0x1d6)][_0x291df4(0x3fe)]=_0x1d888c['Xroso'](_0x21b20c,'%'),document[_0x291df4(0x20d)](_0x1d888c[_0x291df4(0x363)])[_0x291df4(0x255)]=currentQuestionIndex+0x1,_0x1d888c[_0x291df4(0x299)](updateQuestionNav),document[_0x291df4(0x20d)](_0x1d888c[_0x291df4(0x367)])[_0x291df4(0x3b2)]=_0x1d888c[_0x291df4(0x3f9)](currentQuestionIndex,0x0),document['getElementById'](_0x1d888c[_0x291df4(0x31f)])['classList'][_0x291df4(0x372)](_0x1d888c[_0x291df4(0x36d)]),document[_0x291df4(0x20d)](_0x291df4(0x30e))['innerHTML']=_0x39c2d7[_0x291df4(0x24d)]||_0x291df4(0x329);let _0x3a6437='';if(_0x39c2d7[_0x291df4(0x351)])_0x3a6437+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22'+_0x39c2d7[_0x291df4(0x351)]+_0x291df4(0x411);if(_0x39c2d7[_0x291df4(0x294)])_0x3a6437+=_0x291df4(0x38b)+_0x39c2d7[_0x291df4(0x294)]+_0x291df4(0x2b5);if(_0x39c2d7['question_images']){if(_0x1d888c[_0x291df4(0x27e)]('lFBYn',_0x1d888c['yubyz'])){const _0x3c9e22=_0x1433e7[_0x5e47f2],_0x539031=_0x3c9e22[_0x291df4(0x37a)];if(_0x1d888c[_0x291df4(0x2be)](_0x23a53c,null))return;const _0x155299=_0x3c9e22[_0x291df4(0x370)][_0x24c25d],_0x2396ec=_0x1d888c['DbpfX'](_0x155299['id'],_0x539031);if(_0x1d888c['DbpfX'](_0x449d16[_0x56786e][_0x291df4(0x43d)],_0x1d888c[_0x291df4(0x271)])){_0xb7ed3f[_0x291df4(0x24f)]++,_0xb9713b[_0x291df4(0x2c5)]--;if(_0x2396ec)_0x209688[_0x291df4(0x2d2)]++;else _0x2bd248[_0x291df4(0x3ef)]++;}_0x1a4e78[_0x4e8d70][_0x291df4(0x43d)]=_0x2396ec?_0x1d888c[_0x291df4(0x23f)]:'incorrect',_0x1d888c[_0x291df4(0x299)](_0x548ab9),_0x1d888c[_0x291df4(0x20e)](_0x566045,_0x2396ec),_0x1d888c[_0x291df4(0x299)](_0x200cb8);}else _0x39c2d7[_0x291df4(0x1d9)]['forEach'](_0x15639a=>{const _0xc2f8f3=_0x291df4;if(_0x15639a)_0x3a6437+=_0xc2f8f3(0x304)+_0x15639a+'\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>';});}document[_0x291df4(0x20d)](_0x1d888c[_0x291df4(0x3fa)])[_0x291df4(0x2c1)]=_0x3a6437;const _0x482393=document[_0x291df4(0x20d)](_0x1d888c[_0x291df4(0x209)]);_0x482393[_0x291df4(0x2c1)]='',_0x482393[_0x291df4(0x3c4)][_0x291df4(0x2f0)](_0x1d888c[_0x291df4(0x210)]);_0x39c2d7[_0x291df4(0x370)]&&Array[_0x291df4(0x32c)](_0x39c2d7[_0x291df4(0x370)])&&(_0x39c2d7[_0x291df4(0x370)][_0x291df4(0x34e)]((_0x1326c0,_0x2fb765)=>{const _0x4b820c=_0x291df4,_0x268c49=String[_0x4b820c(0x3cd)](0x41+_0x2fb765),_0x26cc26=_0x1d888c[_0x4b820c(0x45e)](selectedOption,_0x2fb765),_0x3d6703=document[_0x4b820c(0x1e0)](_0x1d888c[_0x4b820c(0x27a)]);_0x3d6703[_0x4b820c(0x2c1)]=_0x4b820c(0x268)+(_0x26cc26?_0x1d888c['wagVD']:'')+_0x4b820c(0x3b8)+_0x2fb765+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0x268c49+_0x4b820c(0x307)+(_0x1326c0[_0x4b820c(0x24d)]||_0x1d888c[_0x4b820c(0x464)]+_0x1d888c['Xroso'](_0x2fb765,0x1))+_0x4b820c(0x208),_0x482393[_0x4b820c(0x2cb)](_0x3d6703);}),_0x482393[_0x291df4(0x415)](_0x1d888c['xwtXK'],function(_0x15bbbf){const _0x15dd38=_0x291df4,_0x4fb4f2=_0x15bbbf['target']['closest'](_0x1d888c[_0x15dd38(0x22c)]);if(_0x4fb4f2){const _0x1d9726=_0x1d888c[_0x15dd38(0x399)](parseInt,_0x4fb4f2[_0x15dd38(0x3a0)]('data-option-index'));selectOption(_0x1d9726);}}));_0x1d888c[_0x291df4(0x299)](updateBookmarkButton),_0x1d888c[_0x291df4(0x426)](updateMarkReviewButton);if((_0x1d888c[_0x291df4(0x1ff)](currentMode,_0x1d888c[_0x291df4(0x418)])||currentMode===_0x1d888c[_0x291df4(0x2a4)])&&!isQuizCompleted){if(_0x1d888c[_0x291df4(0x24c)](_0x1d888c['PFblo'],_0x1d888c[_0x291df4(0x1de)])){const _0x1e2964=_0x5441b7[_0x291df4(0x1e0)](_0x291df4(0x241));_0x1e2964[_0x291df4(0x255)]=_0x1d888c[_0x291df4(0x1f4)](_0x29e7ae,0x1),_0x1e2964['className']=_0x1d888c[_0x291df4(0x32e)],_0x1e2964[_0x291df4(0x3a2)]=()=>_0x547206(_0x508f7b),_0x1e2964['id']=_0x291df4(0x423)+_0x2f6ac2,_0x39041f[_0x291df4(0x2cb)](_0x1e2964);}else _0x1d888c[_0x291df4(0x406)](startTimer);}}function selectOption(_0x2c6bf0){const _0xaedd2b=_0x1947e1,_0x368bf2={'WUaEX':function(_0x5196a1,_0x36a569){return _0x5196a1===_0x36a569;},'NVjyt':'optionsContainer','PUWFo':_0xaedd2b(0x337),'oNiDl':_0xaedd2b(0x1c6),'gYypG':_0xaedd2b(0x2e5),'xdnfU':function(_0x575630,_0x59bd64){return _0x575630===_0x59bd64;},'OGwfA':'tpYQQ','hrfhS':_0xaedd2b(0x45b),'WrWUY':'answered','ietDk':function(_0x2a933e){return _0x2a933e();}},_0x20d51b=document['getElementById'](_0x368bf2['NVjyt']);if(_0x20d51b[_0xaedd2b(0x3c4)]['contains']('answered'))return;questionStartTime&&(questionStates[currentQuestionIndex][_0xaedd2b(0x2f6)]+=Date['now']()-questionStartTime,questionStartTime=Date[_0xaedd2b(0x2a7)]());selectedOption=_0x2c6bf0,questionStates[currentQuestionIndex][_0xaedd2b(0x44f)]=_0x2c6bf0,document[_0xaedd2b(0x3a6)](_0x368bf2[_0xaedd2b(0x258)])[_0xaedd2b(0x34e)]((_0x390784,_0x599f23)=>{const _0x49b4a7=_0xaedd2b;_0x390784[_0x49b4a7(0x3c4)][_0x49b4a7(0x3d8)]('selected',_0x368bf2['WUaEX'](_0x599f23,_0x2c6bf0));});if(_0x368bf2[_0xaedd2b(0x1cb)](currentMode,_0x368bf2['oNiDl'])||_0x368bf2[_0xaedd2b(0x1cb)](currentMode,_0x368bf2[_0xaedd2b(0x463)]))setTimeout(processAnswer,0x12c);else{if(_0x368bf2[_0xaedd2b(0x3d2)](questionStates[currentQuestionIndex]['status'],'not_attempted')){if(_0x368bf2[_0xaedd2b(0x1dd)]!==_0x368bf2['hrfhS'])questionStates[currentQuestionIndex][_0xaedd2b(0x43d)]=_0x368bf2[_0xaedd2b(0x46a)],stats[_0xaedd2b(0x24f)]++,stats[_0xaedd2b(0x2c5)]--;else{const _0x27a397=_0xc4059a['apply'](_0x30a02f,arguments);return _0x20e91d=null,_0x27a397;}}_0x368bf2['ietDk'](updateQuestionNav);}}function processAnswer(){const _0x10a8ed=_0x1947e1,_0x4002c9={'EJWDP':function(_0x507ee2,_0x2c75a5){return _0x507ee2===_0x2c75a5;},'GBHfP':function(_0x2da5fb,_0x296818){return _0x2da5fb===_0x296818;},'IGjUm':_0x10a8ed(0x369),'BeRIr':function(_0x4281d2){return _0x4281d2();},'qFMrD':function(_0x4b6dfc,_0x33b254){return _0x4b6dfc(_0x33b254);}},_0x146792=questionsData[currentQuestionIndex],_0x2d58a0=_0x146792[_0x10a8ed(0x37a)];if(_0x4002c9[_0x10a8ed(0x43a)](selectedOption,null))return;const _0xac3604=_0x146792[_0x10a8ed(0x370)][selectedOption],_0x5effd1=_0xac3604['id']===_0x2d58a0;if(_0x4002c9[_0x10a8ed(0x3d1)](questionStates[currentQuestionIndex][_0x10a8ed(0x43d)],_0x4002c9[_0x10a8ed(0x361)])){stats['totalAttempted']++,stats[_0x10a8ed(0x2c5)]--;if(_0x5effd1)stats[_0x10a8ed(0x2d2)]++;else stats[_0x10a8ed(0x3ef)]++;}questionStates[currentQuestionIndex]['status']=_0x5effd1?_0x10a8ed(0x2e0):_0x10a8ed(0x434),_0x4002c9[_0x10a8ed(0x226)](updateStats),_0x4002c9[_0x10a8ed(0x3ca)](showInlineFeedback,_0x5effd1),updateQuestionNav();}function showInlineFeedback(_0x4a7d14){const _0x4f8699=_0x1947e1,_0xdb7fea={'IFRKT':_0x4f8699(0x296),'NGlKg':function(_0x463431,_0x4ce6e4){return _0x463431===_0x4ce6e4;},'eXdUE':_0x4f8699(0x2e0),'jWhlG':function(_0x1838ed,_0x1bb55c){return _0x1838ed===_0x1bb55c;},'nVjzw':_0x4f8699(0x434),'gwuwQ':function(_0x3eebcb,_0x47bc64){return _0x3eebcb!==_0x47bc64;},'PFVwm':_0x4f8699(0x1c6),'MaOmx':_0x4f8699(0x2e5),'poxek':_0x4f8699(0x337),'UsuHE':_0x4f8699(0x380)};if(_0xdb7fea[_0x4f8699(0x408)](currentMode,_0xdb7fea[_0x4f8699(0x2e4)])&&_0xdb7fea[_0x4f8699(0x408)](currentMode,_0xdb7fea[_0x4f8699(0x1db)]))return;const _0x453f80=document[_0x4f8699(0x20d)](_0x4f8699(0x1fc)),_0x5285fc=_0x453f80[_0x4f8699(0x3a6)](_0xdb7fea[_0x4f8699(0x1ca)]),_0xddd2c6=questionsData[currentQuestionIndex],_0x183155=_0xddd2c6[_0x4f8699(0x37a)];let _0x4835e4=_0xddd2c6[_0x4f8699(0x370)]['findIndex'](_0xb39d16=>_0xb39d16['id']===_0x183155);_0x453f80['classList']['add'](_0xdb7fea[_0x4f8699(0x247)]),_0x5285fc[_0x4f8699(0x34e)]((_0x3ba4a8,_0x24f6ef)=>{const _0x253df5=_0x4f8699;_0x3ba4a8[_0x253df5(0x3c4)][_0x253df5(0x2f0)](_0xdb7fea[_0x253df5(0x305)]);if(_0xdb7fea['NGlKg'](_0x24f6ef,_0x4835e4))_0x3ba4a8['classList'][_0x253df5(0x372)](_0xdb7fea[_0x253df5(0x229)]);else{if(_0xdb7fea[_0x253df5(0x2d3)](_0x24f6ef,selectedOption)&&!_0x4a7d14)_0x3ba4a8['classList'][_0x253df5(0x372)](_0xdb7fea['nVjzw']);}}),setTimeout(showSolution,0x5dc);}function showSolution(){const _0x50eb1a=_0x1947e1,_0x57a209={'Nibyq':function(_0x3e4f56,_0x15c6d4){return _0x3e4f56-_0x15c6d4;},'cUmvB':'selected','rkdXo':_0x50eb1a(0x2e0),'QSmea':_0x50eb1a(0x42d),'TNWqH':function(_0x4bff52,_0x58c1a6){return _0x4bff52!==_0x58c1a6;},'VqQXN':_0x50eb1a(0x3f1),'KexsF':_0x50eb1a(0x1c6),'HWZTG':_0x50eb1a(0x2e5),'eHcJF':_0x50eb1a(0x38e),'SUFza':'No\x20solution\x20provided','IhFWa':'explanationVideoPlayer','vWiLw':_0x50eb1a(0x32a),'vRYMG':_0x50eb1a(0x319),'MPcXY':'amkRF','ExyxV':_0x50eb1a(0x2b6),'ATGQL':function(_0x33d9d3,_0x1e43b9){return _0x33d9d3!==_0x1e43b9;},'AFgqk':_0x50eb1a(0x218),'duers':_0x50eb1a(0x1f3),'ZbCay':function(_0x1a6697,_0x280fa2){return _0x1a6697===_0x280fa2;},'bYmRF':_0x50eb1a(0x2f4),'jFWqF':_0x50eb1a(0x346)};if(currentMode!==_0x57a209[_0x50eb1a(0x359)]&&currentMode!==_0x57a209[_0x50eb1a(0x3ac)])return;const _0x2dd832=questionsData[currentQuestionIndex];document[_0x50eb1a(0x20d)](_0x57a209[_0x50eb1a(0x400)])[_0x50eb1a(0x2c1)]=_0x2dd832['solution']||_0x57a209[_0x50eb1a(0x205)];const _0x40b6a7=document[_0x50eb1a(0x20d)](_0x50eb1a(0x450)),_0x58e36a=document[_0x50eb1a(0x20d)](_0x57a209[_0x50eb1a(0x221)]),_0x33d5dc=_0x2dd832['explanation_video'];if(_0x33d5dc){_0x40b6a7[_0x50eb1a(0x3c4)]['remove'](_0x57a209[_0x50eb1a(0x3b5)]);if(_0x33d5dc['includes'](_0x57a209[_0x50eb1a(0x424)]))setupVideo(_0x58e36a,_0x33d5dc);else _0x58e36a[_0x50eb1a(0x451)]=_0x33d5dc;}else _0x57a209[_0x50eb1a(0x2f8)](_0x57a209[_0x50eb1a(0x3ec)],_0x50eb1a(0x2d4))?_0x40b6a7['classList'][_0x50eb1a(0x372)](_0x57a209[_0x50eb1a(0x3b5)]):(_0x4c190b[_0xa8212e][_0x50eb1a(0x2f6)]+=_0x57a209[_0x50eb1a(0x33e)](_0x3457e6[_0x50eb1a(0x2a7)](),_0x52fc76),_0x3f1204=_0x3c468e[_0x50eb1a(0x2a7)]());const _0x3ceab4=document[_0x50eb1a(0x20d)](_0x57a209[_0x50eb1a(0x23d)]);_0x3ceab4[_0x50eb1a(0x2c1)]='';_0x2dd832[_0x50eb1a(0x462)]&&(_0x3ceab4[_0x50eb1a(0x2c1)]+=_0x50eb1a(0x3c5)+_0x2dd832['explanation_audio_eng']+_0x50eb1a(0x411));if(_0x2dd832['explanation_audio_hin']){if(_0x57a209[_0x50eb1a(0x455)](_0x57a209[_0x50eb1a(0x438)],'BXYvP'))_0x3ceab4[_0x50eb1a(0x2c1)]+=_0x50eb1a(0x422)+_0x2dd832['explanation_audio_hin']+_0x50eb1a(0x411);else{_0x35b7a3[_0x50eb1a(0x3c4)]['remove'](_0x57a209['cUmvB']);if(_0x36ff1a===_0x5071b6)_0x34d29d['classList']['add'](_0x57a209[_0x50eb1a(0x3d3)]);else{if(_0x5a785e===_0x267982&&!_0x29e106)_0x13cd1f['classList']['add'](_0x50eb1a(0x434));}}}const _0x20141a=document[_0x50eb1a(0x20d)](_0x57a209[_0x50eb1a(0x414)]);_0x20141a['innerHTML']='',_0x2dd832[_0x50eb1a(0x349)]&&(_0x57a209[_0x50eb1a(0x3fd)](_0x57a209[_0x50eb1a(0x36c)],_0x57a209['bYmRF'])?_0x2dd832[_0x50eb1a(0x349)][_0x50eb1a(0x34e)](_0x35ff73=>{const _0x5ec40d=_0x50eb1a,_0x200297={'XEYmF':_0x57a209['QSmea']};if(_0x57a209['TNWqH'](_0x57a209[_0x5ec40d(0x33d)],'VOAEY'))_0x443bc1[_0x5ec40d(0x20d)](_0x200297[_0x5ec40d(0x1ec)])[_0x5ec40d(0x1d6)][_0x5ec40d(0x3cb)]=_0x5ec40d(0x2df);else{if(_0x35ff73)_0x20141a[_0x5ec40d(0x2c1)]+='<div\x20class=\x22mt-4\x22><img\x20src=\x22'+_0x35ff73+_0x5ec40d(0x2db);}}):(_0x1ba53e||_0x4ef61d(_0x50eb1a(0x2b9)))&&_0x476da7[_0x50eb1a(0x2f5)]['back']()),document[_0x50eb1a(0x20d)](_0x57a209[_0x50eb1a(0x256)])['classList'][_0x50eb1a(0x2f0)](_0x50eb1a(0x32a));}function submitQuiz(){const _0x48d368=_0x1947e1,_0x3435d9={'mCZCS':function(_0x125315,_0xb38ced){return _0x125315!==_0xb38ced;},'WuDvp':function(_0x4b76a8,_0x3013d5){return _0x4b76a8===_0x3013d5;},'OqZKg':'nwdTI','IKTwJ':_0x48d368(0x233),'srgYf':_0x48d368(0x2e0),'bBPOF':function(_0x26df4d,_0x111825){return _0x26df4d(_0x111825);},'oCJnw':function(_0x95492a,_0x544bf5){return _0x95492a(_0x544bf5);},'NlezA':_0x48d368(0x211),'UIyZn':function(_0x49f1c7,_0x4c9ec3){return _0x49f1c7-_0x4c9ec3;},'SUXbm':function(_0x3e3125,_0x26c5db){return _0x3e3125+_0x26c5db;},'aExqe':'quizPerformanceData','BXuRO':function(_0x2e0029,_0x1411f0,_0x23f069,_0xc246f2,_0x5402b3){return _0x2e0029(_0x1411f0,_0x23f069,_0xc246f2,_0x5402b3);}};if(timer)_0x3435d9[_0x48d368(0x234)](clearInterval,timer);if(!_0x3435d9['oCJnw'](confirm,_0x3435d9['NlezA']))return;isQuizCompleted=!![];let _0xafa7f9=0x0,_0x14068e=0x0;const _0x5b5984=_0x3435d9[_0x48d368(0x1df)](Date[_0x48d368(0x2a7)](),quizStartTime);questionsData[_0x48d368(0x34e)]((_0x50753e,_0x483b41)=>{const _0x17e2ec=_0x48d368,_0x2fdb86=questionStates[_0x483b41];_0x3435d9[_0x17e2ec(0x21a)](_0x2fdb86[_0x17e2ec(0x44f)],null)&&(_0x3435d9[_0x17e2ec(0x201)](_0x50753e[_0x17e2ec(0x370)][_0x2fdb86['selectedAnswer']]['id'],_0x50753e['correct_choice_id'])?_0x3435d9[_0x17e2ec(0x21a)](_0x3435d9[_0x17e2ec(0x30f)],_0x3435d9[_0x17e2ec(0x3a5)])?(_0xafa7f9++,_0x2fdb86[_0x17e2ec(0x43d)]=_0x3435d9[_0x17e2ec(0x45f)]):_0x25ce99[_0x17e2ec(0x451)]=_0x83397b:(_0x14068e++,_0x2fdb86['status']=_0x17e2ec(0x434)));});const _0x2192bb=JSON[_0x48d368(0x3a4)](localStorage[_0x48d368(0x3e4)](_0x48d368(0x360)))||[];_0x2192bb[_0x48d368(0x356)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x48d368(0x2a7)](),'totalTime':_0x5b5984,'stats':{'correct':_0xafa7f9,'incorrect':_0x14068e,'notAttempted':_0x3435d9['UIyZn'](questionsData['length'],_0x3435d9[_0x48d368(0x396)](_0xafa7f9,_0x14068e))}}),localStorage[_0x48d368(0x2b1)](_0x3435d9['aExqe'],JSON[_0x48d368(0x267)](_0x2192bb)),_0x3435d9['BXuRO'](showPerformanceAnalysis,_0xafa7f9,_0x14068e,questionsData['length']-(_0xafa7f9+_0x14068e),_0x5b5984);}function showPerformanceAnalysis(_0x123df8,_0xb3c178,_0x1fac89,_0x1f2685){const _0x5bd37f=_0x1947e1,_0x32aba2={'zlIjh':_0x5bd37f(0x21b),'fYJks':function(_0x154b41,_0x44404a){return _0x154b41+_0x44404a;},'HiuUc':function(_0x50264d,_0x449baa){return _0x50264d*_0x449baa;},'XrAbU':function(_0x563c2c,_0x5adfe6){return _0x563c2c*_0x5adfe6;},'hRccV':function(_0x1b86fc,_0x4b5b9c){return _0x1b86fc*_0x4b5b9c;},'FQptA':'scoreCircle','seEIc':function(_0x15d12f,_0x44a423){return _0x15d12f-_0x44a423;},'IFsmK':function(_0x1ab10e,_0x11aa24){return _0x1ab10e*_0x11aa24;},'UIXgG':function(_0x26e91a,_0x14ce77){return _0x26e91a/_0x14ce77;},'uUhus':_0x5bd37f(0x384),'wIVBE':function(_0x35b904,_0x5686d4){return _0x35b904%_0x5686d4;},'tpcFY':_0x5bd37f(0x381),'CtPsq':function(_0x4cfb44,_0x8ac1b1){return _0x4cfb44/_0x8ac1b1;},'gKFSv':function(_0x21ef8c,_0x2b170f){return _0x21ef8c/_0x2b170f;},'pxcqa':function(_0x59672c,_0x50f078){return _0x59672c%_0x50f078;},'TTLKU':_0x5bd37f(0x32a)},_0x298e8b=document[_0x5bd37f(0x20d)](_0x32aba2['zlIjh']),_0x3a1ed2=_0x32aba2[_0x5bd37f(0x378)](_0x123df8,_0xb3c178)>0x0?Math['round'](_0x32aba2[_0x5bd37f(0x278)](_0x123df8/_0x32aba2[_0x5bd37f(0x378)](_0x123df8,_0xb3c178),0x64)):0x0,_0x2743c0=_0x32aba2[_0x5bd37f(0x228)](_0x32aba2[_0x5bd37f(0x315)](0x2,Math['PI']),0x41),_0x369ce6=document[_0x5bd37f(0x20d)](_0x32aba2[_0x5bd37f(0x2e6)]);_0x369ce6[_0x5bd37f(0x1d6)]['strokeDasharray']=_0x2743c0+'\x20'+_0x2743c0,_0x369ce6[_0x5bd37f(0x1d6)][_0x5bd37f(0x1e3)]=_0x32aba2[_0x5bd37f(0x425)](_0x2743c0,_0x32aba2[_0x5bd37f(0x2ec)](_0x32aba2[_0x5bd37f(0x429)](_0x3a1ed2,0x64),_0x2743c0)),document['getElementById']('accuracyScore')['textContent']=_0x3a1ed2+'%',document[_0x5bd37f(0x20d)](_0x5bd37f(0x282))['textContent']=questionsData[_0x5bd37f(0x3e3)],document[_0x5bd37f(0x20d)](_0x32aba2[_0x5bd37f(0x385)])[_0x5bd37f(0x255)]=_0x123df8,document['getElementById']('incorrectResult')[_0x5bd37f(0x255)]=_0xb3c178,document['getElementById']('notAttemptedResult')[_0x5bd37f(0x255)]=_0x1fac89;const _0x47416b=Math[_0x5bd37f(0x3fb)](_0x32aba2[_0x5bd37f(0x429)](_0x1f2685,0xea60)),_0x24b0e6=Math[_0x5bd37f(0x3fb)](_0x32aba2[_0x5bd37f(0x3e7)](_0x1f2685,0xea60)/0x3e8);document[_0x5bd37f(0x20d)](_0x32aba2[_0x5bd37f(0x1e8)])[_0x5bd37f(0x255)]=_0x47416b+':'+_0x24b0e6[_0x5bd37f(0x29b)]()[_0x5bd37f(0x1d2)](0x2,'0');const _0x259335=_0x32aba2[_0x5bd37f(0x429)](_0x1f2685,questionsData[_0x5bd37f(0x3e3)]),_0x63d540=Math[_0x5bd37f(0x3fb)](_0x32aba2['CtPsq'](_0x259335,0xea60)),_0x2d5f24=Math[_0x5bd37f(0x3fb)](_0x32aba2[_0x5bd37f(0x444)](_0x32aba2[_0x5bd37f(0x39e)](_0x259335,0xea60),0x3e8));document[_0x5bd37f(0x20d)]('avgTimeResult')['textContent']=_0x63d540+':'+_0x2d5f24[_0x5bd37f(0x29b)]()[_0x5bd37f(0x1d2)](0x2,'0'),_0x298e8b[_0x5bd37f(0x3c4)]['remove'](_0x32aba2[_0x5bd37f(0x42c)]);}function closePerformanceModal(){const _0x174611=_0x1947e1,_0x410a26={'EtlJm':'performanceModal'};document[_0x174611(0x20d)](_0x410a26[_0x174611(0x22f)])[_0x174611(0x3c4)][_0x174611(0x372)]('hidden');}function reviewQuestions(){const _0x1d8458=_0x1947e1,_0x2dd696={'Tgvny':'nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','UtMhb':function(_0x12af8a){return _0x12af8a();},'PSiHH':function(_0x119bc4,_0x33fd8d){return _0x119bc4===_0x33fd8d;},'UeCDz':'pokfB','uDEuh':function(_0x2e9086,_0x2475d3){return _0x2e9086===_0x2475d3;},'WZCwp':'border-green-500','oFbUw':_0x1d8458(0x33c),'OCUlQ':function(_0x2fa878,_0x1198c5){return _0x2fa878+_0x1198c5;},'Tkpee':_0x1d8458(0x3d4),'pwUBc':function(_0x2c497a,_0x3a33ee){return _0x2c497a!==_0x3a33ee;},'SeBMs':function(_0x497bd3,_0x43c6aa){return _0x497bd3===_0x43c6aa;},'jzjAN':_0x1d8458(0x434),'WzgZo':_0x1d8458(0x323),'TmuPY':'div','uiQZv':_0x1d8458(0x2e0),'TXpID':_0x1d8458(0x3bc),'pSPTM':function(_0x30b27d,_0x50bc14){return _0x30b27d===_0x50bc14;},'KKRbh':_0x1d8458(0x437),'zXmDR':_0x1d8458(0x252),'KYtjq':_0x1d8458(0x266),'rVPFj':_0x1d8458(0x2f1)};document['getElementById'](_0x2dd696['rVPFj'])['classList'][_0x1d8458(0x2f0)](_0x1d8458(0x32a));const _0x20e2f9=document[_0x1d8458(0x20d)](_0x1d8458(0x2ea));_0x20e2f9[_0x1d8458(0x2c1)]='',questionsData[_0x1d8458(0x34e)]((_0x4d40b3,_0x1f61c5)=>{const _0x498747=_0x1d8458,_0x33e758=questionStates[_0x1f61c5],_0x45e4e4=_0x4d40b3[_0x498747(0x37a)];let _0x531d95=_0x2dd696['Tkpee'],_0x3f3662=_0x498747(0x36f);if(_0x2dd696[_0x498747(0x3b1)](_0x33e758[_0x498747(0x44f)],null)){const _0x1b1544=_0x4d40b3[_0x498747(0x370)][_0x33e758[_0x498747(0x44f)]];if(_0x1b1544['id']===_0x45e4e4){if(_0x2dd696['SeBMs']('zaQdk',_0x498747(0x1ce))){if(_0xcb05d5[_0x498747(0x44f)]!==null)_0x3ea21e='nav-btn-answered';else _0x63042d=_0x2dd696[_0x498747(0x3ad)];}else _0x531d95=_0x498747(0x2e0),_0x3f3662=_0x498747(0x251);}else _0x531d95=_0x2dd696[_0x498747(0x35c)],_0x3f3662=_0x2dd696[_0x498747(0x34f)];}const _0xef53c9=document[_0x498747(0x1e0)](_0x2dd696[_0x498747(0x244)]);_0xef53c9[_0x498747(0x3eb)]=_0x498747(0x465)+_0x531d95;let _0x3f288f=(_0x4d40b3[_0x498747(0x370)]||[])[_0x498747(0x32b)]((_0x4e17b6,_0x104a24)=>{const _0x5ed0e5=_0x498747,_0x4a55ad={'JeOaO':function(_0x2d597b){const _0x5ea18e=_0xb405;return _0x2dd696[_0x5ea18e(0x22b)](_0x2d597b);}};if(_0x2dd696[_0x5ed0e5(0x1ed)](_0x2dd696['UeCDz'],'PLnfZ'))_0x4a55ad[_0x5ed0e5(0x373)](_0x59c5e5);else{const _0x3b7a4a=_0x33e758['selectedAnswer']===_0x104a24,_0x1770e0=_0x2dd696['uDEuh'](_0x4e17b6['id'],_0x45e4e4);let _0x359d11='border-gray-600';if(_0x1770e0)_0x359d11=_0x2dd696[_0x5ed0e5(0x3c1)];else{if(_0x3b7a4a)_0x359d11=_0x2dd696[_0x5ed0e5(0x2c3)];}return _0x5ed0e5(0x431)+_0x359d11+_0x5ed0e5(0x2e3)+String[_0x5ed0e5(0x3cd)](_0x2dd696[_0x5ed0e5(0x290)](0x41,_0x104a24))+_0x5ed0e5(0x387)+_0x4e17b6[_0x5ed0e5(0x24d)]+_0x5ed0e5(0x327);}})[_0x498747(0x22d)]('');const _0x2bb312=_0x4d40b3['explanation_video']?'<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-'+_0x1f61c5+_0x498747(0x2ba)+_0x4d40b3[_0x498747(0x2b0)]+_0x498747(0x31b):'';let _0x5c9d76='';if(_0x4d40b3[_0x498747(0x462)])_0x5c9d76+=_0x498747(0x41a)+_0x4d40b3[_0x498747(0x462)]+_0x498747(0x411);if(_0x4d40b3[_0x498747(0x2f7)])_0x5c9d76+=_0x498747(0x3d0)+_0x4d40b3['explanation_audio_hin']+_0x498747(0x411);let _0x4a33b7=(_0x4d40b3['explanation_images']||[])[_0x498747(0x32b)](_0x21e6e8=>_0x21e6e8?'<div\x20class=\x22mt-4\x22><img\x20src=\x22'+_0x21e6e8+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>':'')[_0x498747(0x22d)]('');_0xef53c9[_0x498747(0x2c1)]=_0x498747(0x1d8)+(_0x1f61c5+0x1)+_0x498747(0x3af)+(_0x531d95===_0x2dd696[_0x498747(0x365)]?_0x2dd696[_0x498747(0x321)]:_0x2dd696['pSPTM'](_0x531d95,_0x2dd696[_0x498747(0x35c)])?_0x2dd696['KKRbh']:_0x2dd696[_0x498747(0x3c8)])+_0x498747(0x2bd)+_0x3f3662+_0x498747(0x36b)+_0x4d40b3[_0x498747(0x24d)]+_0x498747(0x322)+_0x3f288f+_0x498747(0x404)+(_0x4d40b3[_0x498747(0x26d)]||_0x2dd696['KYtjq'])+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x2bb312+_0x498747(0x433)+_0x5c9d76+_0x498747(0x433)+_0x4a33b7+_0x498747(0x32f),_0x20e2f9[_0x498747(0x2cb)](_0xef53c9);}),_0x2dd696['UtMhb'](initializeReviewVideos);}function initializeReviewVideos(){const _0x617e73=_0x1947e1,_0x67dc3d={'dYwDf':_0x617e73(0x319),'tbcSp':function(_0x1f8795,_0x14e893,_0x200134){return _0x1f8795(_0x14e893,_0x200134);}};document[_0x617e73(0x3a6)](_0x617e73(0x227))[_0x617e73(0x34e)](_0x3a04a3=>{const _0x2a011c=_0x617e73,_0x4b1e5e=_0x3a04a3[_0x2a011c(0x248)]['src'];if(_0x4b1e5e&&_0x4b1e5e[_0x2a011c(0x3c0)](_0x67dc3d['dYwDf']))_0x67dc3d['tbcSp'](setupVideo,_0x3a04a3,_0x4b1e5e);else _0x4b1e5e&&(_0x3a04a3['src']=_0x4b1e5e);});}function retakeQuiz(){const _0xc19133=_0x1947e1,_0x4248c9={'lrkqS':function(_0x132802,_0x28703c){return _0x132802(_0x28703c);},'OlTGS':_0xc19133(0x402),'hniEI':function(_0x4f4d39,_0x101eda){return _0x4f4d39===_0x101eda;},'euWfM':'IQAnG','vJTBp':_0xc19133(0x34d),'MCzAC':_0xc19133(0x403)};if(_0x4248c9[_0xc19133(0x390)](confirm,_0x4248c9['OlTGS'])){if(_0x4248c9[_0xc19133(0x25d)](_0x4248c9[_0xc19133(0x260)],_0x4248c9[_0xc19133(0x260)]))window[_0xc19133(0x420)][_0xc19133(0x332)][_0xc19133(0x445)](_0x4248c9[_0xc19133(0x202)])&&localStorage[_0xc19133(0x25a)](_0x4248c9[_0xc19133(0x342)]),location[_0xc19133(0x386)]();else{if(_0x96784a)_0x277a13[_0xc19133(0x2c1)]+=_0xc19133(0x25f)+_0x10f6f3+_0xc19133(0x2db);}}}function loadBookmarkedQuestions(){const _0x539aa3=_0x1947e1,_0x4708d1={'NYKEs':function(_0x9dc7d,_0x4cb219){return _0x9dc7d===_0x4cb219;},'SfmBA':_0x539aa3(0x2af),'zlhYF':function(_0x2966ce,_0x3514e9){return _0x2966ce<_0x3514e9;},'sAmxh':_0x539aa3(0x2bb)},_0x32de7b=JSON['parse'](localStorage['getItem'](_0x4708d1[_0x539aa3(0x341)]))||[];_0x32de7b[_0x539aa3(0x34e)](_0x579e85=>{const _0x47b5ae=_0x539aa3;_0x579e85[_0x47b5ae(0x303)]['includes'](quizName['toLowerCase']()[_0x47b5ae(0x1cc)](/ /g,'-'))&&(_0x4708d1[_0x47b5ae(0x1cd)]('HGGsB',_0x4708d1['SfmBA'])?_0x1578c4=_0x5632b3:_0x4708d1[_0x47b5ae(0x1c8)](_0x579e85[_0x47b5ae(0x2ef)],questionsData[_0x47b5ae(0x3e3)])&&(questionStates[_0x579e85[_0x47b5ae(0x2ef)]]['bookmarked']=!![]));});}function toggleBookmark(){const _0x57b7b8=_0x1947e1,_0x1cbd80={'Wqymn':_0x57b7b8(0x39a),'VgqSs':function(_0x2e37dd){return _0x2e37dd();},'GQUtO':_0x57b7b8(0x2bb),'LTKQL':function(_0x33f1b8,_0x1933e3){return _0x33f1b8===_0x1933e3;},'bPZGf':'arEeH'},_0x2e06dd=!questionStates[currentQuestionIndex][_0x57b7b8(0x3df)];questionStates[currentQuestionIndex][_0x57b7b8(0x3df)]=_0x2e06dd;let _0x5691fd=JSON[_0x57b7b8(0x3a4)](localStorage[_0x57b7b8(0x3e4)](_0x1cbd80[_0x57b7b8(0x1eb)]))||[];if(_0x2e06dd){const _0x34f780={'quizName':quizName,'quizFile':window['location']['pathname'][_0x57b7b8(0x2de)]('/')['pop'](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x57b7b8(0x2a7)]()};_0x5691fd[_0x57b7b8(0x356)](_0x34f780);}else _0x1cbd80[_0x57b7b8(0x3f3)](_0x1cbd80[_0x57b7b8(0x1fd)],_0x1cbd80[_0x57b7b8(0x1fd)])?_0x5691fd=_0x5691fd[_0x57b7b8(0x222)](_0x35536a=>!(_0x35536a['quizFile'][_0x57b7b8(0x3c0)](quizName[_0x57b7b8(0x419)]()[_0x57b7b8(0x1cc)](/ /g,'-'))&&_0x35536a[_0x57b7b8(0x2ef)]===currentQuestionIndex)):_0x554023(_0x1cbd80[_0x57b7b8(0x40d)])&&_0x1cbd80[_0x57b7b8(0x214)](_0x42653b);localStorage[_0x57b7b8(0x2b1)](_0x1cbd80[_0x57b7b8(0x1eb)],JSON[_0x57b7b8(0x267)](_0x5691fd)),updateBookmarkButton(),updateQuestionNav();}function updateBookmarkButton(){const _0x36be2a=_0x1947e1,_0x13fefb={'CqueU':_0x36be2a(0x407),'GluHk':_0x36be2a(0x263),'INttS':_0x36be2a(0x3cf),'QHuTF':_0x36be2a(0x30d),'JsWDP':_0x36be2a(0x314)},_0x59cfe7=document[_0x36be2a(0x20d)](_0x13fefb[_0x36be2a(0x37c)]),_0x2135f4=document[_0x36be2a(0x20d)](_0x13fefb['GluHk']),_0x504de9=questionStates[currentQuestionIndex][_0x36be2a(0x3df)];_0x59cfe7[_0x36be2a(0x3eb)]=_0x504de9?_0x36be2a(0x2c4):_0x13fefb[_0x36be2a(0x338)],_0x2135f4['textContent']=_0x504de9?_0x13fefb[_0x36be2a(0x1e5)]:_0x13fefb['JsWDP'];}function _0x30a8(){const _0x1753eb=['\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>','solutionAudio','timeDisplay','9579402ATHguO','Are\x20you\x20sure\x20you\x20want\x20to\x20leave\x20the\x20quiz?\x20Your\x20progress\x20will\x20be\x20lost.','\x22\x20data-src=\x22','bookmarkedQuestions','Treatment\x20of\x20migrane','-600\x20text-white\x22>','DbpfX','Gonorrhea','constructor','innerHTML','HkCoE','oFbUw','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','notAttempted','<p><strong>Ciraparantag</strong>\x20is\x20a\x20reversal\x20agent\x20for\x20all\x20<strong>direct\x20anticoagulants</strong>\x20and\x20is\x20<strong>not\x20useful</strong>\x20with\x20<strong>fondaparinux</strong>\x20which\x20is\x20an\x20<strong>indirect\x20factor\x20Xa\x20inhibitor.</strong></p>\x0a<p>Ciraparantag,\x20andexanet\x20alfa,\x20and\x20idarucizumab\x20are\x20all\x20reversal\x20agents\x20of\x20direct\x20anticoagulants.</p>\x0a<p><strong>Ciraparantag</strong>:\x20It\x20is\x20considered\x20as\x20a\x20potential\x20<strong>reversal\x20agent\x20against\x20all\x20direct\x20anticoagulants</strong>\x20including\x20dabigatran,\x20rivaroxaban,\x20edoxaban,\x20apixaban,\x20LMWH,\x20and\x20heparin.\x20This\x20drug\x20is\x20in\x20the\x20early\x20stages\x20of\x20development.</p>\x0a<p><strong>Andexanet\x20alfa</strong>:\x20It\x20is\x20a\x20recombinant\x20analog\x20of\x20factor\x20Xa\x20and\x20is\x20proposed\x20for<strong>\x20reversal\x20of\x20oral\x20factor\x20Xa\x20inhibitors</strong>\x20like\x20rivaroxaban,\x20edoxaban,\x20and\x20apixaban.\x20It\x20rapidly\x20reverses\x20the\x20action\x20of\x20these\x20drugs\x20and\x20restores\x20thrombin\x20generation.</p>\x0a<p><strong>Idarucizumab</strong>:\x20It\x20is\x20a\x20licensed\x20monoclonal\x20antibody\x20that\x20specifically\x20acts\x20as\x20a\x20<strong>reversal\x20agent\x20for\x20dabigatran</strong>.\x20It\x20has\x20a\x20350\x20times\x20higher\x20affinity\x20for\x20dabigatran\x20than\x20thrombin.\x20Hence\x20it\x20forms\x20a\x20complex\x20with\x20dabigatran\x20and\x20is\x20excreted\x20by\x20the\x20kidneys.</p>\x0a<p>If\x20a\x20patient\x20on\x20direct\x20oral\x20anticoagulants\x20like\x20dabigatran,\x20rivaroxaban,\x20edoxaban,\x20and\x20apixaban\x20presents\x20with\x20life-threatening\x20bleeds\x20and\x20the\x20reversal\x20agents\x20are\x20not\x20available\x20then\x20other\x20options\x20are\x20the\x20administration\x20of\x20<strong>prothrombin\x20complex\x20concentrate,\x20activated&nbsp;prothrombin\x20complex\x20concentrate,\x20or\x20recombinant\x20factor\x20VII-A.\x20</strong>Hemodialysis\x20is\x20useful\x20in\x20severe\x20bleeding\x20due\x20to\x20dabigatran.&nbsp;</p>\x0a<p>Other\x20reversal\x20agents\x20for\x20anticoagulants:</p>\x0a<ul>\x0a<li><strong>Protamine\x20sulphate</strong>\x20-\x20Heparin</li>\x0a<li>Vitamin\x20K\x20-\x20Warfarin</li>\x0a</ul>\x0a<p>Note:</p>\x0a<p>Andexanet\x20alfa\x20has\x20received\x20US-FDA\x20approval\x20in\x20May\x202018\x20as\x20a\x20reversal\x20agent\x20for\x20rivaroxaban\x20and\x20apixaban.</p>\x0a<p>&nbsp;</p>','EOaue','timed_exam','Triamterene','Hemophilus\x20produces\x20beta\x20lactamase,\x20hence\x20resistant\x20to\x20ampicillin','appendChild','gbaCQ','contains','Cefixime','accuracy','JzAAF','hebxC','correctAnswers','jWhlG','YrPHP','pevMp','Anionic\x20and\x20weakly\x20acidic\x20drugs\x20bind\x20to\x20which\x20of\x20the\x20following?','<p>The\x20dose\x20of\x20retigabine\x20<strong>should\x20be\x20increased</strong>\x20when\x20phenytoin\x20is\x20added\x20because\x20<strong>phenytoin\x20can\x20decrease\x20the\x20plasma\x20concentration\x20of\x20retigabine</strong>\x20when\x20given\x20together.</p>\x0a<p>Retigabine\x20is\x20also\x20known\x20as\x20<strong>ezogabine</strong>.\x20Metabolism\x20of\x20the\x20drug\x20occurs\x20by\x20glucuronidation\x20and\x20acetylation.\x20Its\x20half-life\x20is\x20about\x207-11\x20hours\x20and\x20hence\x20requires\x20thrice-daily\x20dosing.\x20When\x20it\x20is\x20administered\x20with\x20<strong>phenytoin\x20or\x20carbamazepine</strong>&nbsp;there\x20may\x20be\x20a\x20<strong>reduction\x20in\x20the\x20plasma\x20concentration</strong>\x20of\x20the\x20drug.\x20So\x20the\x20dose\x20of\x20retigabine\x20should\x20be\x20increased\x20when\x20given\x20along\x20with\x20these\x20drugs.</p>\x0a<p>It\x20is\x20a\x20<strong>potassium(K+)\x20channel\x20opener</strong>\x20that\x20enhancer\x20transmembrane\x20potassium\x20currents\x20mediated\x20by\x20the<strong>\x20KNCQ</strong>\x20family\x20of\x20ion\x20channels.\x20It\x20was\x20approved\x20as\x20an\x20adjunctive\x20agent\x20for\x20focal\x20onset\x20seizures\x20of\x20patients\x20above\x2018\x20years.\x20But\x20because\x20of\x20its\x20adverse\x20effects\x20like\x20<strong>retinal\x20abnormalities</strong>\x20and\x20<strong>blue\x20pigmentation</strong>,\x20the\x20production\x20of\x20the\x20drug\x20was\x20discontinued\x20by\x20the\x20manufacturer.</p>\x0a<p>Other\x20drug\x20interactions\x20of\x20phenytoin:</p>\x0a<p>It\x20is\x20an\x20<strong>inducer</strong>\x20of\x20the\x20enzymes\x20<strong>CYP2C8/9,\x20CYP3A4/5</strong>,\x20and\x20other\x20CYPs.\x20It\x20is\x20also\x20an\x20<strong>inhibitor\x20of\x20CYP2C9/19.</strong>&nbsp;</p>\x0a<ul>\x0a<li>Phenobarbitone\x20can\x20inhibit\x20the\x20metabolism\x20of\x20phenytoin.\x20But\x20the\x20overall\x20interaction\x20is\x20unpredictable\x20as\x20both\x20the\x20drug\x20enhance\x20each\x20other\x27s\x20degradation\x20by\x20enzyme\x20induction.</li>\x0a<li>Phenytoin\x20and\x20carbamazepine\x20induce\x20each\x20other\x27s\x20metabolism.</li>\x0a<li><strong>Valproate\x20increases</strong>\x20the\x20level\x20of\x20<strong>unbound\x20phenytoin</strong>\x20by\x20displacing\x20the\x20protein-bound\x20form\x20and\x20decreasing\x20its\x20metabolism.</li>\x0a<li>Phenytoin\x20i<strong>ncreases\x20the\x20metabolism</strong>\x20of\x20steroids,\x20<strong>oral\x20contraceptives</strong>,\x20doxycycline,\x20theophylline,\x20etc\x20by\x20enzyme\x20induction.</li>\x0a<li>It\x20produces\x20competitive\x20<strong>inhibition\x20of\x20warfarin\x20metabolism</strong>.\x20(Increased\x20risk\x20of\x20bleeding\x20when\x20given\x20together)</li>\x0a<li>Drugs\x20like\x20chloramphenicol,\x20warfarin,\x20isoniazid,\x20and\x20cimetidine\x20can\x20inhibit\x20the\x20metabolism\x20of\x20phenytoin\x20and\x20cause\x20its\x20toxicity.</li>\x0a<li>Sucralfate\x20decreases\x20the\x20absorption\x20of\x20phenytoin\x20by\x20binding\x20to\x20it\x20in\x20the\x20gastrointestinal\x20tract.</li>\x0a</ul>','yRptw','EPbTA','Which\x20of\x20the\x20following\x20can\x20be\x20given\x20for\x20long\x20term\x20management\x20of\x20obesity?','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','Atherosclerosis','MASxm','split','flex','correct','Metolazone','name','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','PFVwm','timed_study','FQptA','zcJOY','QuJsG','<p><strong>Levopropoxyphene</strong>\x20is\x20a\x20centrally\x20acting\x20opioid\x20antitussive.</p>\x0a<p>Levopropoxyphene\x20is\x20an\x20<strong>opioid\x20derivative</strong>\u00a0that\x20is\x20a\x20strong\x20and\x20partial\x20\x20receptor\x20agonist\x20that\x20helps\x20to\x20<strong>reduce</strong>\x20the\x20<strong>cough\x20reflex</strong>\x20and\x20therefore,\x20is\x20used\x20in\x20the\x20management\x20of\x20acute\x20debilitating\x20cough.\x20The\x20usual\x20antitussive\x20dose\x20is\x2050100\x20mg\x20every\x204\x20hours.\x20It\x20has\x20no\x20analgesic\x20activity.\x20However,\x20it\x20is\x20known\x20to\x20cause\x20some\x20sedation.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Ambroxol</strong>\x20is\x20derived\x20from\x20bromhexine.\x20It\x20is\x20a\x20<strong>mucoactive\x20agent</strong>\x20that\x20helps\x20alter\x20the\x20viscoelastic\x20properties\x20of\x20mucus\x20and\x20increase\x20mucociliary\x20clearance,\x20thereby\x20providing\x20relief\x20in\x20productive\x20cough.\x20It\x20is\x20commonly\x20available\x20as\x20intramuscular\x20or\x20intravenous,\x20lozenges,\x20syrups,\x20or\x20tablets.</p>\x0a<p>Option\x20B:\x20<strong>Diphenoxylate</strong>\x20is\x20an\x20<strong>opioid\x20agonist</strong>\x20that\x20is\x20structurally\x20similar\x20to\x20meperidine.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20acute,\x20chronic,\x20and\x20traveler\x27s\x20diarrhea.\x20Upon\x20administration,\x20it\x20undergoes\x20de-esterification\x20to\x20difenoxin,\x20which\x20is\x20its\x20active\x20metabolite.\x20Its\x20side\x20effects\x20include\x20constipation,\x20toxic\x20megacolon,\x20paralytic\x20ileus\x20and\x20can\x20give\x20rise\x20to\x20CNS\x20depression\x20in\x20children.</p>\x0a<p>Option\x20D:\x20<strong>Levorphanol</strong>\x20is\x20a\x20<strong>synthetic\x20opioid</strong>\x20that\x20is\x20also\x20a\x205HT/Norepinephrine\x20reuptake\x20inhibitor\x20and\x20an\x20NMDA\x20receptor\x20antagonist\x20which\x20is\x20chiefly\x20used\x20in\x20the\x20management\x20of\x20<strong>moderate</strong>\x20to\x20<strong>severe\x20pain</strong>\x20and\x20has\x20a\x20relatively\x20rapid\x20onset\x20of\x20action.\x20Its\x20side\x20effects\x20include\x20delirium\x20and\x20hallucinations.</p>','reviewQuestionsContainer','Pulmonary\x20hypertension','IFsmK','round','Which\x20of\x20the\x20following\x20is\x20a\x20novel\x20anti-depressant?','questionIndex','remove','questionReviewSection','Which\x20of\x20the\x20following\x20is\x20a\x20centrally\x20acting\x20opioid\x20antitussive?','okQRo','POELR','history','timeSpent','explanation_audio_hin','TNWqH','pRCOj','zArOp','<p><span\x20class=\x22notion-enable-hover\x22\x20data-token-index=\x220\x22\x20data-reactroot=\x22\x22>The\x20preferred\x20diuretic\x20for\x20this\x20patient\x20with\x20cirrhosis\x20presenting\x20with\x20abdominal\x20distension\x20and\x20lower\x20limb\x20swelling\x20is\x20<strong>eplerenone</strong>.</span></p>\x0a<p>Eplerenone\x20is\x20a\x20<strong>mineralocorticoid\x20receptor/aldosterone\x20antagonist</strong>.\x20High\x20doses\x20of\x20mineralocorticoid\x20receptor/aldosterone\x20antagonists&nbsp;decrease\x20total\x20body\x20sodium&nbsp;in\x20cirrhotic\x20patients\x20with\x20ascites&nbsp;by&nbsp;natriuresis.&nbsp;</p>\x0a<p>Patients\x20with\x20liver\x20cirrhosis\x20have\x20a\x20decreased\x20effective\x20arterial\x20blood\x20volume\x20because\x20of\x20splanchnic\x20vasodilatation.\x20This\x20stimulates\x20the\x20renin-angiotensin-aldosterone\x20system\x20and\x20results\x20in\x20hyperaldosteronism.\x20This\x20causes\x20increased\x20sodium\x20and\x20water\x20retention\x20and\x20leads\x20to\x20the\x20development\x20of\x20ascites.\x20This\x20also&nbsp;contributes\x20to\x20resistance\x20to\x20loop\x20diuretics.&nbsp;</p>\x0a<p>Normally<strong>,\x20aldosterone</strong>\x20(<strong>AL</strong>)\x20enters\x20the\x20cells\x20of\x20the\x20<strong>late\x20distal\x20tubule</strong>\x20and\x20<strong>collecting\x20ducts</strong>\x20by\x20diffusion\x20and\x20binds\x20to\x20a\x20specific\x20<strong>mineralocorticoid\x20receptor</strong>\x20(<strong>MR</strong>)\x20in\x20the\x20cytoplasm.\x20This\x20AL-MR\x20complex\x20mediates\x20Na<sup>+</sup>\x20reabsorption,\x20which\x20drives\x20the\x20secretion\x20of\x20K<sup>+</sup>\x20and\x20H<sup>+</sup>into\x20the\x20tubules.</p>\x0a<p>Eplerenone\x20<strong>competitively\x20blocks</strong>&nbsp;this<strong>\x20MR</strong>,\x20preventing\x20it\x20from\x20binding\x20with\x20aldosterone.\x20The\x20net\x20effect\x20is&nbsp;<strong>sodium\x20diuresis</strong>\x20and\x20<strong>potassium\x20retention</strong>.\x20It\x20is\x20a\x20potassium-sparing\x20diuretic.\x20Other\x20mineralocorticoid\x20receptor\x20antagonists\x20include&nbsp;<strong>spironolactone</strong>,\x20<strong>canrenone</strong>,\x20<strong>potassium\x20canrenoate</strong>.</p>\x0a<p>Some\x20clinical\x20uses\x20of\x20MR\x20antagonists\x20are\x20-&nbsp;</p>\x0a<ul>\x0a<li>Hypertension\x20due\x20to\x20primary\x20hyperaldosteronism&nbsp;</li>\x0a<li>Edema\x20associated\x20with\x20liver\x20cirrhosis,\x20congestive\x20cardiac\x20failure,\x20chronic\x20kidney\x20disease</li>\x0a<li>They\x20may\x20reduce\x20mortality\x20in\x20patients\x20with\x20myocardial\x20infarction</li>\x0a</ul>\x0a<p><strong>Hyperkalemia</strong>\x20is\x20the\x20major\x20side\x20effect\x20of\x20MR\x20antagonists,\x20the\x20risk\x20being\x20greater\x20in\x20patients\x20with\x20<strong>renal\x20disease</strong>\x20or\x20those\x20already\x20<strong>taking\x20ACE\x20inhibitors</strong>.\x20Other\x20important\x20side\x20effects\x20are\x20<strong>gynecomastia</strong>\x20and\x20<strong>decreased\x20libido</strong>\x20due\x20to\x20the&nbsp;<strong>anti-androgenic\x20effect</strong>\x20of\x20spironolactone\x20but\x20eplerenone\x20does\x20not\x20cause\x20gynecomastia\x20and\x20decreased\x20libido.</p>\x0a<p>Other\x20options\x20:&nbsp;</p>\x0a<p>Option\x20A-&nbsp;<strong>Triamterene</strong>&nbsp;directly\x20<strong>inhibits</strong>\x20renal\x20<strong>epithelial</strong>\x20<strong>sodium\x20channels\x20</strong>(ENaC)\x20in\x20the\x20<strong>late\x20distal\x20tubule</strong>\x20and\x20<strong>collecting\x20duct.</strong>&nbsp;It\x20is\x20a\x20potassium-sparing\x20diuretic\x20and\x20is\x20generally\x20used\x20along\x20with\x20other\x20diuretics\x20in\x20the\x20treatment\x20of\x20hypertension\x20and\x20edema.\x20Triamterene\x20is\x20metabolized\x20in\x20the\x20liver,\x20hence\x20triamterene\x20toxicity\x20may\x20be\x20enhanced\x20in\x20patients\x20with\x20hepatic\x20disease.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20<strong>Liddle\x20syndrome.</strong></p>\x0a<p>Option\x20C-&nbsp;<strong>Chlorthalidone\x20</strong>is\x20a\x20thiazide-like\x20diuretic.\x20It<span\x20style=\x22font-weight:\x20400;\x22><span\x20style=\x22font-weight:\x20400;\x22>&nbsp;<strong>inhibits\x20Na<sup>+</sup>-Cl<sup>-</sup>\x20symporter</strong>&nbsp;in\x20the&nbsp;<strong>early\x20distal\x20tubule</strong>\x20and\x20increases\x20the\x20excretion\x20of\x20sodium\x20and\x20chloride.&nbsp;</span></span>Thiazide\x20diuretics\x20may\x20be\x20used\x20for\x20the\x20treatment\x20of\x20hypertension,\x20heart\x20failure,\x20nephrolithiasis\x20due\x20to\x20idiopathic\x20hypercalciuria,\x20and\x20nephrogenic\x20diabetes\x20insipidus.</p>\x0a<p>Option\x20D-<strong>\x20Furosemide</strong>\x20is\x20a\x20<strong>loop\x20diuretic</strong>.\x20It\x20acts\x20by\x20<strong>inhibiting</strong>\x20the\x20<strong>Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup></strong>\x20symporter\x20in\x20the\x20<strong>thick\x20ascending\x20limb</strong>\x20of\x20the&nbsp;<strong>loop</strong>\x20<strong>of\x20Henle</strong>\x20resulting\x20in\x20increased\x20excretion\x20of\x20sodium\x20and\x20chloride.\x20It\x20also\x20has\x20mild\x20carbonic\x20anhydrase\x20inhibitory\x20activity\x20and\x20also\x20increases\x20urinary\x20excretion\x20of\x20bicarbonate\x20and\x20phosphate.\x20Cirrhotic\x20patients\x20are\x20often\x20resistant\x20to\x20loop\x20diuretics\x20due\x20to&nbsp;<strong>decreased\x20secretion</strong>\x20of\x20the\x20drug\x20into\x20<strong>tubular\x20fluid</strong>\x20and\x20high\x20aldosterone\x20levels.\x20Furosemide\x20may\x20be\x20given\x20along\x20with\x20eplerenone,\x20but\x20the\x20best\x20answer\x20here\x20is\x20eplerenone\x20since\x20<strong>aldosterone\x20antagonists</strong>\x20are\x20the\x20<strong>main\x20therapy</strong>\x20for\x20cirrhotic\x20edema.</p>','test','PwzVa','startAt','vMfpv','YIlRm','Amiodarone','lTBzd','quizFile','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','IFRKT','(((.+)+)+)+$','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','dBCiz','44krDzWl','RlNUd','oyAst','yhMPR','Bookmarked','questionText','OqZKg','gTFok','bHVfC','Downregulation\x20of\x20CYP2C19','<p>Paradoxical\x20bronchoconstriction\x20with\x20ipratropium\x20bromide\x20is\x20seen\x20with\x20a\x20<strong>hypotonic\x20nebulizer\x20solution</strong>\x20and\x20not\x20hypertonic\x20saline.</p>\x0a<p>Paradoxical\x20bronchoconstriction\x20with\x20ipratropium\x20bromide\x20is\x20seen\x20especially\x20when\x20<strong>given\x20by\x20a\x20nebulizer</strong>\x20and\x20may\x20be\x20due\x20to\x20the\x20following\x20factors:</p>\x0a<ul>\x0a<li><strong>Hypotonic</strong>\x20nebulizer\x20solution</li>\x0a<li>Antibacterial\x20additives\x20like\x20<strong>benzalkonium\x20chloride</strong>\x20and\x20<strong>EDTA</strong></li>\x0a<li>It\x20may\x20be\x20also\x20due\x20to\x20<strong>prejunctional\x20M2\x20receptor\x20blockade</strong>\x20on\x20the\x20cholinergic\x20nerves\x20present\x20in\x20the\x20airway.\x20These\x20prejunctional\x20M2\x20receptors\x20normally\x20inhibit\x20acetylcholine\x20release\x20into\x20the\x20synapse.\x20So\x20their\x20blockade\x20can\x20cause\x20increased\x20Ach\x20release\x20and\x20bronchoconstriction.</li>\x0a</ul>\x0a<p>Paradoxical\x20bronchoconstriction\x20is\x20<strong>not\x20reported\x20with\x20tiotropium\x20bromide</strong>\x20or\x20any\x20other\x20long-acting\x20muscarinic\x20antagonists.\x20Tiotropium\x20is\x20<strong>selective</strong>\x20for<strong>\x20M3</strong>\x20and\x20<strong>M1</strong>\x20receptors\x20and\x20therefore\x20less\x20likely\x20to\x20produce\x20prejunctional\x20M2\x20receptor\x20blockade.</p>\x0a<p>Other\x20adverse\x20effects\x20of\x20inhaled\x20muscarinic\x20antagonists:</p>\x0a<ul>\x0a<li>A\x20bitter\x20taste\x20is\x20seen\x20with\x20ipratropium</li>\x0a<li>Nebulization\x20with\x20ipratropium\x20bromide\x20may\x20<strong>precipitate\x20glaucoma</strong>\x20in\x20elderly\x20patients.\x20This\x20is\x20due\x20to\x20the\x20direct\x20effect\x20of\x20the\x20drug\x20on\x20the\x20eyes\x20and\x20can\x20be\x20easily\x20prevented\x20by\x20using\x20a\x20mouthpiece\x20instead\x20of\x20a\x20facemask.</li>\x0a<li>Long-acting\x20agents\x20can\x20cause\x20dryness\x20of\x20the\x20mouth.&nbsp;</li>\x0a<li>In\x20elderly\x20patients,\x20<strong>urinary\x20retention</strong>\x20may\x20be\x20seen\x20occasionally.</li>\x0a</ul>','Bookmark','hRccV','WEYHg','90\x20minutes','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','.m3u8','lVplc','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','console','WHPPn','Bipolar\x20disorder','ZNaNL','get','TXpID','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','Incorrect','The\x20binding\x20of\x20the\x20enzyme\x20to\x20the\x20substrate\x20analogue\x20is\x20irreversible','<p><strong>Fixed\x20drug\x20combinations\x20</strong>are<strong>\x20not\x20preferred</strong>\x20over\x20single\x20drugs\x20while\x20selecting\x20essential\x20drugs.</p>\x0a<p>Criteria\x20for\x20selection\x20of\x20essential\x20medicines\x20as\x20per\x20WHO:</p>\x0a<ul>\x0a<li>There\x20should\x20be\x20<strong>adequate\x20data</strong>\x20on\x20the\x20<strong>safety\x20and\x20efficacy</strong>\x20of\x20the\x20drug.</li>\x0a<li>The\x20drug\x20should\x20be\x20available\x20in\x20a\x20form\x20where\x20its\x20quality\x20including\x20bioavailability\x20and\x20stability\x20on\x20storage\x20is\x20assured.</li>\x0a<li>The\x20choice\x20of\x20the\x20drug\x20depends\x20on\x20the\x20<strong>pattern\x20of\x20prevalent\x20disease</strong>s,\x20financial\x20resources,\x20availability\x20of\x20trained\x20personnel\x20and\x20facilities,\x20genetic,\x20demographic,\x20and\x20environmental\x20factors.</li>\x0a<li>The\x20<strong>cost-benefit\x20ratio</strong>\x20is\x20an\x20important\x20factor.</li>\x0a<li>Pharmacokinetic\x20properties\x20of\x20the\x20drug\x20and\x20the\x20local\x20manufacture\x20and\x20storage\x20facilities\x20are\x20also\x20considered.</li>\x0a<li>Essential\x20drugs\x20<strong>should\x20preferably\x20be\x20single\x20compounds.</strong></li>\x0a<li>Fixed\x20combinations\x20are\x20used\x20only\x20when\x20the\x20dosage\x20of\x20each\x20component\x20meets\x20the\x20requirement\x20of\x20the\x20population\x20in\x20which\x20it\x20is\x20used.\x20It\x20should\x20also\x20have\x20the\x20advantage\x20in\x20safety,\x20therapeutic\x20effect,\x20adherence,\x20and\x20prevention\x20of\x20drug\x20resistance\x20when\x20compared\x20to\x20single\x20compounds.</li>\x0a<li>The\x20selection\x20of\x20essential\x20drugs\x20is\x20a\x20continuous\x20process\x20and\x20changes\x20are\x20to\x20be\x20made\x20with\x20developments\x20in\x20public\x20health\x20and\x20the\x20availability\x20of\x20better\x20drugs.</li>\x0a<li>The\x20selection\x20should\x20be\x20based\x20on\x20rationally\x20developed\x20treatment\x20guidelines.</li>\x0a</ul>\x0a<p>Note:</p>\x0a<p>In\x201977\x20WHO\x20brought\x20the\x20first\x20\x22Model\x20List\x20of\x20Essential\x20Drugs\x22.\x20India\x20made\x20its\x20\x22National\x20Essential\x20Drug\x20List\x22\x20in\x201996\x20and\x20revised\x20the\x20list\x20in\x202011\x20and\x20renamed\x20it\x20as\x20\x22<strong>National\x20List\x20of\x20Essential\x20Medicines</strong>\x22.\x20The\x20latest\x20edition\x20of\x20WHO\x20Model\x20List\x20of\x20Essential\x20Drugs\x20is\x20the\x2021st\x20edition\x20published\x20in\x202019.</p>','DkkXo','</span></div>','30\x20minutes','No\x20question\x20text\x20available','hidden','map','isArray','ltRXG','zKWMP','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','Verapamil','Half\x20life\x20and\x20plasma\x20concentration\x20doubles','pathname','Liraglutide','Treatment\x20of\x20dementia','Half-life\x20remains\x20the\x20same\x20and\x20plasma\x20concentration\x20doubles','Lurasidone','.option-button','INttS','Half-life\x20doubles\x20and\x20plasma\x20concentration\x20remains\x20the\x20same','10-20\x20mcg/kg/min','9.8\x20hours','border-red-500','VqQXN','Nibyq','reduce','yJGYl','sAmxh','MCzAC','questions','title','BENWI','solutionContainer','Drug\x20A\x20increases\x20the\x20metabolism\x20of\x20Drug\x20B','Rimonabant','explanation_images','INsAc','qrhdn','Ceftazidime','custom_quiz.html','forEach','WzgZo','>20\x20mcg/kg/min','question_audio','loadSource','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','xEQKL','qZwyb','push','preventDefault','Stop\x20the\x20drug','KexsF','LRCSD','ZmyPB','jzjAN','MVgrm','<p>The\x20<strong>half-life</strong>\x20of\x20the\x20given\x20drug\x20is\x20<strong>13.8\x20hours</strong>.</p>\x0a<p>The\x20half-life\x20of\x20a\x20drug\x20or&nbsp;<strong>t<sub>1/2</sub></strong>\x20is\x20the\x20time\x20taken\x20for\x20the\x20<strong>plasma\x20concentration</strong>\x20to\x20be\x20<strong>reduced\x20by\x2050%</strong>.\x20The\x20<strong>elimination\x20rate\x20constant</strong>\x20or<strong>&nbsp;k\x20value</strong>\x20of\x20a\x20drug\x20reflects\x20the\x20<strong>fraction\x20of\x20drug\x20removed</strong>\x20from\x20the\x20body\x20compartment\x20per\x20unit\x20of\x20time.</p>\x0a<p\x20style=\x22text-align:\x20left;\x22>The\x20half-life\x20of\x20a\x20drug\x20and\x20its\x20elimination\x20rate\x20constant\x20are\x20inversely\x20proportional\x20to\x20each\x20other.\x20They\x20are\x20represented\x20by\x20the\x20equation:&nbsp;</p>\x0a<p\x20style=\x22text-align:\x20left;\x22><strong>k\x20t<sub>1/2</sub>&nbsp;=&nbsp;\x200.693</strong></p>\x0a<p\x20style=\x22text-align:\x20left;\x22>Therefore,\x20<strong>t<sub>1/2</sub>\x20=\x200.693/\x20k</strong></p>\x0a<p>The\x20given\x20value\x20for\x20elimination\x20rate\x20constant\x20<strong>\x20is\x200.05</strong>,\x20therefore\x20the\x20half-life\x20of\x20the\x20given\x20drug\x20would\x20be:</p>\x0a<p>&nbsp;<strong>0.693/\x200.05\x20=\x2013.8</strong></p>\x0a<p>Therefore,\x20the\x20half-life\x20of\x20the\x20drug\x20would\x20be\x2013.8\x20hours.</p>','AMHhN','quizPerformanceData','IGjUm','Downregulation\x20of\x20CYP2D6','pfRsR','click','uiQZv','Linezolid','vSdnJ','table','not_attempted','bJKpN','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','bYmRF','HkeGw','search','Not\x20Attempted','choices','ehsOo','add','JeOaO','prototype','Increase\x20the\x20dose','Treatment\x20of\x20resistant\x20migraine','EDTA','fYJks','wnhYs','correct_choice_id','yHjhw','CqueU','<p>In\x20this\x20case,\x20the\x20<strong>half-life\x20remains\x20the\x20same,\x20and\x20the\x20plasma\x20concentration\x20doubles.</strong></p>\x0a<p><strong>Half-life\x20is\x20constant</strong>\x20in\x20drugs\x20following\x20<strong>first-order\x20kinetic</strong>s\x20irrespective\x20of\x20the\x20dose\x20as\x20a\x20constant\x20fraction\x20of\x20the\x20drug\x20is\x20eliminated\x20per\x20unit\x20time.</p>\x0a<p>The\x20plasma\x20concentration\x20of\x20the\x20drug\x20increases\x20when\x20the\x20dose\x20given\x20is\x20increased.\x20In\x20this\x20case,\x20as\x20the\x20drug\x20dose\x20is\x20doubled\x20plasma\x20concentration\x20is\x20also\x20doubled.</p>','Andexanet\x20alfa:\x20Rivaroxaban','mLDpS','answered','totalTimeResult','EATbI','progressBar','correctResult','uUhus','reload','</span><span>','bwdOM','nsHXv','oImKV','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','Cefoperazone','key','solutionText','Prophylaxis\x20of\x20ADHD','lrkqS','markReviewBtn','canPlayType','Drug\x20A\x20increases\x20renal\x20elimination\x20of\x20Drug\x20B','TQZyc','FxHww','SUXbm','jiGdx','59259888ZCLAbs','ettkp','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','RNA-dependent\x20DNA\x20polymerase\x20inhibition','YvISS','Fenfluramine','pxcqa','Mtbnp','getAttribute','Varenicline','onclick','iHWWR','parse','IKTwJ','querySelectorAll','TTSlv','nav-btn-incorrect','LikDx','yLplQ','Marrow','HWZTG','Tgvny','GpxrW','</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-','<p>Topiramate\x20is\x20used\x20in\x20the\x20treatment\x20of\x20Lennox-Gastuat\x20syndrome.</p>\x0a<p>Uses\x20of\x20topiramate:</p>\x0a<ul>\x0a<li>In\x20newly\x20diagnosed\x20focal\x20and\x20primary\x20generalized\x20epilepsy\x20in\x20adults\x20and\x20children&nbsp;</li>\x0a<li>As\x20monotherapy\x20for\x20refractory\x20focal\x20epilepsy\x20and\x20generalized\x20tonic-clonic\x20seizures</li>\x0a<li>Treatment\x20of&nbsp;\x20tonic-clonic\x20seizures\x20in\x20patients\x20with\x20<strong>Lennox-Gastuat\x20syndrome</strong></li>\x0a<li>It\x20is\x20also\x20used\x20in\x20the\x20<strong>prophylaxis\x20of\x20migraine(not\x20for\x20treatment)</strong></li>\x0a<li>It\x20can\x20be\x20given\x20as\x20monotherapy\x20for\x20children\x20of\x2010\x20years\x20or\x20more.\x20But\x20if\x20used\x20as\x20adjunctive\x20therapy\x20it\x20can\x20be\x20used\x20in\x20children\x20as\x20young\x20as\x202\x20years.</li>\x0a</ul>\x0a<p>Mechanism\x20of\x20action:\x20It\x20reduces\x20<strong>voltage-gated\x20sodium\x20currents</strong>\x20in\x20the\x20<strong>cerebellar\x20granule\x20cell</strong>s.\x20It\x20also\x20activates\x20a\x20hyperpolarizing\x20potassium\x20current,\x20enhances\x20GABAA\x20receptor\x20currents,\x20and\x20limits\x20the\x20activation\x20of\x20the\x20AMPA-kainate\x20subtype\x20of\x20glutamate\x20receptors.\x20It\x20also\x20produces\x20weak\x20inhibition\x20of\x20the\x20carbonic\x20anhydrase\x20enzyme.</p>\x0a<p>Pharmacokinetics:\x20Only\x2010-20%\x20is\x20bound\x20to\x20plasma\x20proteins\x20and\x20the\x20drug\x20is\x20largely\x20excreted\x20unchanged\x20in\x20the\x20urine.\x20Half-life\x20is\x20about\x201\x20day.\x20Topiramate\x20is\x20found\x20to\x20<strong>decrease</strong>\x20the\x20<strong>plasma\x20concentrations\x20of\x20oral\x20contraceptives</strong>,\x20hence\x20a\x20higher\x20dose\x20of\x20OCPs\x20should\x20be\x20given\x20along\x20with\x20topiramate.</p>\x0a<p>Adverse\x20effects:</p>\x0a<ul>\x0a<li>Somnolence,\x20weight\x20loss,\x20fatigue,\x20and\x20nervousness\x20are\x20commonly\x20seen</li>\x0a<li>It\x20can\x20precipitate\x20<strong>renal\x20calculi</strong>.\x20It\x20may\x20be\x20due\x20to\x20the\x20weak\x20carbonic\x20anhydrase\x20inhibition.</li>\x0a<li>Cognitive\x20impairment</li>\x0a</ul>','pwUBc','disabled','Mark\x20for\x20Review','Malaria','vWiLw','UKrtI','Ceftobiprole','\x22\x20data-option-index=\x22','IoDEo','LKkWJ','<p>Risperidone\x20is\x20<strong>FDA</strong>\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>bipolar\x20affective\x20disorders</strong>.</p>\x0a<p>Uses\x20of\x20risperidone:</p>\x0a<ul>\x0a<li>Long-term\x20management\x20of\x20<strong>psychosis</strong>\x20and\x20<strong>schizophrenia.</strong></li>\x0a<li>Maintenance\x20therapy\x20in\x20mania\x20<strong>bipolar\x20disorders.</strong></li>\x0a<li>Management\x20of\x20irritability\x20associated\x20with\x20<strong>autism</strong>.</li>\x0a</ul>\x0a<p>Off-label\x20uses\x20of\x20risperidone:</p>\x0a<ul>\x0a<li>Management\x20of&nbsp;<strong>psychotic\x20symptoms</strong>&nbsp;in&nbsp;<strong>delirium</strong>\x20and\x20<strong>dementia</strong>.</li>\x0a<li><strong>Obsessive-compulsive\x20disorders.</strong></li>\x0a<li><strong>Post-traumatic\x20stress\x20disorders.</strong></li>\x0a</ul>\x0a<p>Risperidone\x20is\x20an\x20<strong>atypical\x20antipsychotic</strong>\x20that\x20shows\x20both\x20D2\x20and\x205\x20HT2\x20receptor\x20blockade.\x20It\x20also\x20has\x20an\x20affinity\x20for\x20alpha\x201,\x20alpha\x202,\x20and\x20H1\x20receptors.\x20It\x20produces\x20a\x20more\x20potent\x20D2\x20blockade\x20than\x20clozapine.\x20<strong>Hyperprolactinemia</strong>\x20is\x20an\x20important\x20adverse\x20effect.\x20It\x20is\x20also\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20stroke\x20in\x20elderly\x20patients.\x20At\x20low\x20doses,\x20extrapyramidal\x20side\x20effects\x20are\x20less.</p>','green','<p>Vancomycin\x20acts\x20on\x20<strong>step\x204</strong>&nbsp;in\x20the\x20given\x20image.</p>\x0a<p>Mechanism\x20of\x20action\x20of\x20vancomycin:\x20It\x20is\x20a\x20<strong>cell\x20wall\x20synthesis\x20inhibitor</strong>.\x20It\x20binds\x20to\x20the\x20<strong>D-Ala-D-Ala\x20terminus</strong>\x20of\x20the\x20newly\x20formed\x20peptidoglycan\x20pentapeptide\x20and\x20<strong>inhibits\x20the&nbsp;transglycosylase</strong>\x20enzyme.\x20This\x20would\x20<strong>prevent\x20further\x20elongation</strong>\x20of\x20<strong>the\x20peptidoglycan</strong>\x20and\x20its\x20cross-linking.</p>\x0a<p>Vancomycin\x20is\x20a\x20bactericidal\x20agent\x20for\x20<strong>gram-positive</strong>\x20organisms.\x20It\x20is\x20also\x20active\x20against\x20many\x20gram-positive\x20anaerobes\x20like\x20<strong>Clostridium\x20difficile</strong>.&nbsp;Resistance\x20against\x20vancomycin\x20in\x20enterococci\x20is\x20due\x20to\x20the\x20alternation\x20in\x20its\x20binding\x20site\x20where\x20D-Ala\x20is\x20replaced\x20by\x20D-Lactate.</p>\x0a<p><strong>Clinical\x20uses:</strong></p>\x0a<ul>\x0a<li>Parenteral\x20vancomycin\x20is\x20given\x20for\x20bloodstream\x20infections\x20and\x20<strong>endocarditis\x20caused\x20by\x20MRSA</strong>.</li>\x0a<li>Vancomycin\x20plus\x20gentamicin\x20is\x20given\x20as\x20an\x20alternative\x20regimen\x20for\x20enterococcal\x20endocarditis\x20with\x20penicillin\x20allergy.</li>\x0a<li>In\x20combination\x20with\x20other\x20agents\x20for\x20suspected\x20meningitis\x20or\x20<strong>meningitis\x20due\x20to\x20penicillin-resistant\x20pneumococcus</strong>.</li>\x0a<li><strong>Oral\x20vancomycin</strong>\x20is\x20given\x20for\x20<strong>Clostridium\x20difficile\x20colitis.</strong></li>\x0a</ul>\x0a<p>Adverse\x20effects:</p>\x0a<ul>\x0a<li>Injection\x20site\x20phlebitis</li>\x0a<li>Nephrotoxicity</li>\x0a<li><strong>\x22Redman\x22\x20syndrome</strong>\x20due\x20to\x20histamine\x20release\x20following\x20infusion</li>\x0a</ul>\x0a<p>Other\x20options:</p>\x0a<p><strong>Fosfomycin</strong>\x20inhibits\x20<strong>step\x201</strong>\x20in\x20the\x20image.\x20It\x20acts\x20at\x20a\x20very\x20early\x20stage\x20in\x20cell\x20wall\x20synthesis\x20and\x20inhibits\x20the\x20cytoplasmic\x20enzyme<strong>&nbsp;enol\x20pyruvate\x20transferase</strong>.\x20This\x20would\x20block\x20the&nbsp;addition\x20of\x20phosphoenolpyruvate\x20to\x20UDP-N-acetylglucosamine.\x20This\x20<strong>prevents\x20the\x20formation\x20of&nbsp;UDP-N-acetylmuramic\x20acid</strong>\x20which\x20is\x20the\x20precursor&nbsp;N-acetylmuramic\x20acid.\x20N-acetylmuramic\x20acid\x20is\x20a\x20component\x20of\x20the\x20bacterial\x20cell\x20wall\x20and\x20hence\x20cell\x20wall\x20synthesis\x20is\x20inhibited.</p>\x0a<p><strong>Cycloserine</strong>\x20inhibits\x20<strong>step\x202</strong>\x20in\x20the\x20image.\x20It\x20is\x20a\x20structural\x20analog\x20of\x20D-alanine\x20and\x20inhibits\x20the\x20enzymes\x20<strong>alanine\x20racemase</strong>\x20that&nbsp;converts\x20L-alanine\x20to\x20D-alanine\x20and\x20<strong>d-alanyl-d-alanine\x20ligase</strong>.\x20This\x20would\x20thereby\x20inhibit\x20the\x20incorporation\x20of\x20D-alanine\x20into\x20the\x20peptidoglycan\x20pentapeptide.\x20It\x20is\x20mainly\x20used\x20in\x20the\x20management\x20of\x20tuberculosis\x20where\x20there\x20is\x20resistance\x20to\x20the\x20first-line\x20agents.</p>\x0a<p><strong>Bacitracin</strong>\x20inhibits\x20<strong>step\x203</strong>\x20in\x20the\x20image.\x20It\x20is\x20a\x20cell\x20wall\x20synthesis\x20inhibitor\x20that\x20interferes\x20with&nbsp;<strong>dephosphorylation</strong>\x20in\x20the\x20cycling\x20of\x20the\x20<strong>lipid\x20carrier</strong>\x20which\x20transfers&nbsp;peptidoglycan\x20subunits\x20to\x20the\x20growing\x20cell\x20wall.\x20It\x20is\x20only\x20given\x20for\x20topical\x20application\x20because\x20of\x20its\x20severe\x20nephrotoxicity\x20when\x20given\x20systemically.</p>\x0a<p>Note:</p>\x0a<p><strong>Beta-lactam</strong>\x20antibiotics\x20prevent\x20cross-linking\x20by\x20inhibiting\x20the<strong>\x20transpeptidases</strong>.\x20(Last\x20step\x20in\x20the\x20images)</p>','LJlui','exception','includes','WZCwp','BalzZ','BAAEM','classList','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','wHitT','trace','zXmDR','SDfit','qFMrD','display','mgCcg','fromCharCode','jwpeh','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','GBHfP','xdnfU','rkdXo','not-attempted','Andexanet\x20alfa:\x20Edoxaban','yKNsu','dPoqj','toggle','<p><strong>Anionic</strong>\x20and\x20<strong>weakly\x20acidic</strong>\x20drugs\x20bind\x20to\x20<strong>albumin</strong>.</p>\x0a<p>After\x20being\x20distributed\x20in\x20the\x20circulating\x20blood,\x20drugs\x20bind\x20to\x20<strong>serum\x20proteins</strong>\x20to\x20varying\x20degrees.\x20Among\x20serum\x20proteins,<strong>&nbsp;albumin</strong>&nbsp;and\x20<strong>alpha-1\x20acid\x20glycoprotein</strong>&nbsp;play\x20important\x20roles\x20in\x20protein\x20binding\x20for\x20many\x20drugs,\x20which\x20affects\x20their\x20distribution\x20in\x20the\x20body.</p>\x0a<p><strong>Albumin</strong>\x20is\x20a\x20major\x20carrier\x20of\x20and\x20binds\x20to\x20<strong>acidic\x20drugs</strong>\x20like\x20phenytoin,\x20NSAIDs.&nbsp;Whereas,&nbsp;<strong>&alpha;-1\x20acid\x20glycoprotein</strong>&nbsp;binds\x20<strong>basic\x20drugs</strong>\x20like&nbsp;lignocaine,disopyramide,\x20quinidine\x20and\x20propranolol.</p>\x0a<p>Importance\x20of\x20plasma\x20protein\x20binding:</p>\x0a<p>Conditions\x20resulting\x20in\x20<strong>acute\x20phase\x20reaction</strong>\x20response&nbsp;leading\x20to\x20<strong>elevated</strong>\x20levels\x20of\x20alpha-1\x20acid\x20glycoprotein\x20like\x20Crohn&rsquo;s\x20disease,\x20myocardial\x20infarction,\x20arthritis,\x20cancer,\x20etc.&nbsp;<strong>enhance</strong>&nbsp;binding\x20of\x20basic\x20drugs.\x20Conditions\x20causing&nbsp;<strong>hypoalbuminemia</strong>\x20result\x20in\x20decreased\x20binding\x20sites\x20for\x20acidic\x20drugs.&nbsp;</p>\x0a<p>When\x20a\x20drug\x20is\x20bound\x20to\x20the\x20plasma\x20proteins,\x20it\x20is\x20kept\x20in\x20the\x20blood,\x20while\x20the\x20unbound\x20(free)\x20drug&nbsp;can\x20produce\x20a\x20therapeutic\x20effect,\x20be\x20metabolized,\x20or\x20excreted.&nbsp;In\x20the\x20majority\x20of\x20the\x20drugs,\x20this\x20does\x20not\x20have\x20a\x20significant\x20effect,\x20but\x20in\x20drugs\x20with\x20a\x20<strong>narrow\x20therapeutic\x20index</strong>\x20like\x20<strong>warfarin</strong>,\x20it\x20is\x20clinically\x20relevant\x20as\x20excessive\x20free\x20warfarin\x20can\x20produce\x20toxicity.</p>\x0a<p>Many\x20<strong>drugs\x20displace\x20other\x20drugs</strong>\x20from\x20their\x20protein\x20binding\x20sites.\x20This\x20may\x20cause\x20an\x20increase\x20in\x20the\x20pharmacological\x20effect\x20of\x20the\x20<strong>displaced</strong>\x20drug.&nbsp;</p>\x0a<p>A\x20drug\x20bound\x20to\x20a\x20plasma\x20protein\x20cannot\x20cross\x20membranes\x20and\x20this\x20bound\x20fraction\x20of\x20a\x20drug\x20is\x20also\x20not\x20available\x20for\x20metabolism\x20or\x20glomerular\x20filtration\x20which\x20can\x20make\x20the\x20drug\x20<strong>long-acting.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B-&nbsp;<strong>Globulins</strong>\x20are\x20of\x20three\x20types\x20-\x20&alpha;,&beta;,\x20and\x20&gamma;-globulins.\x20Globulins&nbsp;bind\x20<strong>glucocorticoids</strong>\x20and\x20<strong>progesterone</strong>\x20in\x20the\x20blood.</p>\x0a<p>Option\x20C-\x20<strong>Lipoproteins</strong>\x20like\x20VLDL,\x20LDL\x20can\x20bind\x20<strong>anti-cancer\x20drugs</strong>\x20like&nbsp;5-fluorouracil&nbsp;and\x20doxorubicin.&nbsp;</p>','Entry\x20inhibition','min','Hydrochlorothiazide','<p>Nivolumab\x20is\x20used\x20as\x20a\x20checkpoint\x20inhibitor\x20in\x20<strong>Hodgkin\x27s\x20lymphoma</strong>.</p>\x0a<p>FDA\x20approved\x20uses\x20of\x20nivolumab:</p>\x0a<ul>\x0a<li>Advanced\x20<strong>melanoma</strong></li>\x0a<li>Advanced\x20non-small\x20cell\x20lung\x20cancer(<strong>NSCLC</strong>)\x20that\x20are\x20previously\x20treated</li>\x0a<li>Renal\x20cell\x20carcinoma</li>\x0a<li>Advanced\x20head\x20and\x20neck\x20cancers</li>\x0a<li>Refractory/relapsed\x20classical\x20<strong>Hodgkin\x27s\x20lymphoma</strong></li>\x0a</ul>\x0a<p>Nivolumab\x20is\x20a\x20<strong>checkpoint\x20inhibitor</strong>\x20that\x20blocks\x20the\x20interaction\x20between\x20<strong>PD-1\x20and\x20its\x20ligand</strong>s.\x20It\x20is\x20a\x20fully\x20human\x20monoclonal\x20IgG4\x20antibody.\x20It\x20has\x20a\x20good\x20response\x20rate\x20in\x20patients\x20with\x20pretreated\x20solid\x20tumors\x20and\x20hematological\x20malignancies.\x20Similar\x20effectiveness\x20is\x20also\x20seen\x20with<strong>\x20pembrolizumab</strong>\x20which\x20is\x20also\x20an\x20anti-PD-1\x20monoclonal\x20antibody.</p>\x0a<p>Adverse\x20effects:</p>\x0a<ul>\x0a<li>In\x20melanoma\x20patients\x20<strong>rash</strong>\x20is\x20a\x20commonly\x20seen\x20side\x20effect&nbsp;</li>\x0a<li>fatigue,\x20dyspnea,\x20musculoskeletal\x20pain,\x20cough,&nbsp;\x20decreased\x20appetite,\x20and\x20constipation\x20can\x20be\x20seen\x20in\x20advanced\x20squamous\x20NSCLC\x20patients</li>\x0a<li>Pneumonitis,\x20colitis,\x20nephritis,\x20hepatitis,\x20and\x20renal\x20dysfunction\x20are\x20also\x20seen</li>\x0a</ul>\x0a<p>Important\x20note:</p>\x0a<p>The\x20FDA\x20on\x20<strong>May\x202021</strong>\x20has\x20approved\x20the\x20use\x20of\x20<strong>nivolumab</strong>\x20in\x20patients\x20having\x20c<strong>ompletely\x20resected\x20esophageal\x20or\x20gastroesophageal\x20junction\x20cancers</strong>\x20with\x20residual\x20pathologic\x20disease\x20who\x20have\x20received\x20neoadjuvant\x20chemoradiotherapy.</p>','MtpsJ','bookmarked','ETVva','Causes\x20endometrial\x20thinning','Which\x20of\x20the\x20following\x20is\x20incorrectly\x20matched?','length','getItem','tMFvx','loijE','wIVBE','Levopropoxyphene','The\x20table\x20below\x20gives\x20the\x20AUC\x20of\x20drug\x20B\x20alone\x20and\x20that\x20of\x20drug\x20B\x20when\x20combined\x20with\x20another\x20drug\x20A.\x20If\x20the\x20\x20value\x20is\x20<0.01,\x20then\x20which\x20of\x20the\x20following\x20statements\x20is\x20true?','quizSidebar','className','MPcXY','wHSoB','Metoprolol','incorrectAnswers','They\x20are\x20enzyme\x20specific\x20and\x20used\x20in\x20rational\x20drug\x20design','VOAEY','keydown','LTKQL','kUsPd','zDkWv','FwsiD','nav-btn-bookmarked','Piperacillin-Tazobactam','kDMhq','zHJXc','floor','Dose\x20adjustment\x20in\x20renal\x20failure','ZbCay','width','lQxDq','eHcJF','GLzdW','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','customQuizData','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','<p><strong>Vilazodone</strong>\x20is\x20the&nbsp;novel\x20antidepressant.</p>\x0a<p\x20id=\x22__p9\x22>The\x20antidepressant\x20effect\x20of\x20vilazodone\x20is\x20due\x20to\x20its\x20<strong>enhancement</strong>\x20of\x20<strong>serotonergic\x20activity</strong>\x20in\x20the\x20CNS\x20through\x20selective\x20inhibition\x20of\x20serotonin\x20reuptake.\x20It\x20binds\x20with\x20<strong>high\x20affinity</strong>\x20to\x20the\x20serotonin\x20reuptake\x20site\x20<strong>but\x20not</strong>\x20to\x20the\x20norepinephrine\x20or\x20dopamine\x20reuptake\x20site.\x20As\x20a\x20result,\x20vilazodone\x20<strong>potently</strong>\x20and\x20<strong>selectively\x20inhibits</strong>\x20the\x20reuptake\x20of\x20serotonin.</p>\x0a<p>Vilazodone\x20is\x20also\x20a\x20<strong>partial\x20agonist</strong>\x20at\x20serotonergic\x20<strong>5-HT<sub>1A</sub></strong>&nbsp;receptors;\x20the\x20result\x20of\x20this\x20activity\x20on\x20serotonergic\x20transmission\x20also\x20plays\x20a\x20role\x20in\x20its\x20antidepressant\x20effect.</p>\x0a<p>Thus\x20it\x20offers\x20a\x20<strong>novel</strong>\x20combination\x20of\x20<strong>selective\x20serotonin\x20reuptake\x20inhibition\x20(SSRI)</strong>\x20and\x20serotonergic\x20(<strong>5-HT<sub>1A</sub></strong>)\x20receptor\x20<strong>partial\x20agonist</strong>\x20activity.&nbsp;Because\x20of\x20these\x20characteristics,\x20vilazodone\x20has\x20been\x20termed\x20a\x20serotonin\x20partial\x20agonist&ndash;reuptake\x20inhibitor\x20(<strong>SPARI</strong>).</p>\x0a<p>Vilazodone\x20is\x20never\x20combined\x20with\x20a\x20<strong>monoamine\x20oxidase</strong>\x20(<strong>MAO</strong>)\x20inhibitor\x20or\x20given\x20within\x20<strong>14\x20days</strong>\x20of\x20discontinuing\x20or\x20initiating\x20MAO\x20inhibitor\x20therapy\x20due\x20to\x20the\x20serious\x20risk\x20of\x20<strong>serotonin\x20toxicity</strong>.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:<strong>\x20Lurasidone&nbsp;</strong>is\x20a\x20second-generation\x20antipsychotic\x20that\x20is\x20a&nbsp;<strong>5-HT<sub>2A&nbsp;</sub></strong>and\x20<strong>D</strong><sub><strong>2</strong>&nbsp;</sub>receptor\x20antagonist.\x20it\x20is\x20used\x20in\x20the\x20treatment\x20of\x20schizophrenia\x20and\x20bipolar\x20depression\x20(as\x20monotherapy\x20or\x20as\x20an\x20adjunct).</p>\x0a<p>Option\x20C:<strong>\x20Asenapine&nbsp;</strong>is\x20a\x20second-generation\x20antipsychotic\x20which\x20is\x20also\x20a&nbsp;<strong>5-HT<sub>2A&nbsp;</sub></strong>and\x20<strong>D</strong><sub><strong>2</strong>&nbsp;</sub>receptor\x20antagonist,\x20used\x20in\x20the\x20management\x20of\x20schizophrenia\x20and\x20acute\x20mania.</p>\x0a<p>Option\x20D:\x20<strong>Blonanserin</strong>\x20is\x20a\x20second-generation\x20antipsychotic,\x20which\x20acts\x20as\x20an\x20antagonist\x20at\x20<strong>D<sub>2</sub></strong>,\x20<strong>D<sub>3</sub></strong>,\x20and\x20<strong>5-HT<sub>2A</sub></strong>&nbsp;receptors.\x20Blonanserin\x20has\x20a\x20low\x20affinity\x20for\x205-HT<sub>2C</sub>,\x20adrenergic\x20&alpha;<sub>1</sub>,\x20histamine\x20H<sub>1</sub>,\x20and\x20muscarinic\x20M<sub>1</sub>&nbsp;receptors,\x20but\x20displays\x20a\x20relatively\x20high\x20affinity\x20for\x205-HT<sub>6</sub>&nbsp;receptors.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20schizophrenia.</p>','fDEOI','bookmarkBtn','gwuwQ','Hemophilus\x20alters\x20penicillin\x20binding\x20protein\x20sites,\x20hence\x20resistant\x20to\x20ampicillin','kRRVs','<p>The\x20false\x20statement\x20regarding\x20suicidal\x20inhibition\x20is\x20the\x20inhibitor\x20can\x20bind\x20with\x20any\x20site\x20resulting\x20in\x20suicidal\x20inhibition.</p>\x0a<p>In\x20suicidal\x20inhibition,\x20the\x20inhibitor\x20can\x20only\x20bind\x20with\x20the\x20<strong>active\x20site</strong>\x20of\x20an\x20enzyme\x20and\x20is\x20<strong>unreactive\x20outside</strong>\x20the\x20confines\x20of\x20the\x20enzyme\x27s\x20active\x20site.&nbsp;</p>\x0a<p>The\x20enzyme\x20inhibition\x20helps\x20to\x20modify\x20the\x20rate\x20of\x20reactions\x20it\x20catalyzes\x20and\x20this\x20inhibition\x20can\x20either\x20be\x20<strong>reversible</strong>\x20or\x20<strong>irreversible</strong>.\x20Reversible\x20inhibitors\x20bind\x20to\x20enzymes\x20through\x20non-covalent\x20bonds.\x20Irreversible\x20inhibitors\x20usually\x20bind\x20to\x20an\x20enzyme\x20through\x20covalent\x20bonds\x20and\x20do\x20so\x20strongly\x20so\x20that\x20it\x20can\x20no\x20longer\x20dissociate.</p>\x0a<p>Suicide\x20inhibitors\x20are\x20a\x20category\x20of\x20irreversible\x20inhibitors\x20also\x20called\x20<strong>mechanism-based\x20inhibitors</strong>.\x20They\x20are\x20specialized\x20substrate\x20analogs\x20that\x20contain\x20a\x20chemical\x20group\x20that\x20reacts\x20with\x20the\x20catalytic\x20machinery\x20of\x20the\x20target\x20enzyme.\x20In\x20these\x20types\x20of\x20inhibitors,\x20the\x20substrate\x20analog\x20<strong>irreversibly</strong>\x20ties\x20up\x20with\x20the\x20binding\x20site\x20of\x20an\x20enzyme,\x20deceiving\x20the\x20enzyme\x20by\x20concealing\x20its\x20functional\x20group\x20resulting\x20in\x20the\x20formation\x20of\x20a\x20<strong>highly\x20reactive\x20molecule</strong>,\x20which\x20brings\x20about\x20<strong>self-inactivation</strong>\x20of\x20the\x20enzyme.</p>\x0a<p>Suicide\x20inhibitors\x20bind\x20to\x20the\x20enzyme\x20by\x20means\x20of\x20<strong>covalent\x20bonds</strong>;\x20they\x20are\x20<strong>enzyme-specific</strong>\x20and\x20unreactive\x20outside\x20the\x20confines\x20of\x20the\x20enzyme&rsquo;s\x20active\x20site.</p>\x0a<p>An\x20example\x20of\x20this\x20would\x20be\x20the\x20binding\x20of\x20<strong>clavulanic\x20acid</strong>\x20to\x20the\x20active\x20site\x20of\x20<strong>beta-lactamases</strong>\x20in\x20bacteria.\x20Clavulanic\x20acid\x20mimics\x20the\x20structure\x20of\x20a\x20beta-lactam\x20antibiotic&nbsp;and\x20forms\x20a\x20covalent\x20adduct\x20with\x20the\x20&beta;-lactamase\x20active\x20site.\x20This\x20leads\x20to\x20a\x20rearrangement\x20that\x20creates\x20a\x20much\x20more\x20reactive\x20derivative,\x20which\x20is\x20subsequently\x20attacked\x20in\x20its\x20active\x20site\x20to\x20irreversibly\x20acylate\x20the\x20enzyme\x20and\x20inactivate\x20it.\x20Thus,\x20amoxicillin\x20and\x20clavulanic\x20acid\x20are\x20combined\x20to\x20overcome\x20bacterial\x20resistance\x20to\x20amoxicillin\x20alone.</p>\x0a<p>The\x20development\x20of\x20clavulanic\x20acid\x20to\x20target\x20beta-lactamase-producing\x20bacteria\x20is\x20also\x20an\x20example\x20of\x20the\x20<strong>rational\x20design</strong>\x20of\x20drugs.\x20Rational\x20design\x20of\x20drugs\x20refers\x20to\x20the\x20ability\x20to\x20predict\x20the\x20appropriate\x20molecular\x20structure\x20of\x20a\x20drug\x20on\x20the\x20basis\x20of\x20information\x20about\x20its\x20biological\x20receptor.</p>','SwvxE','Wqymn','quizHierarchy','markReviewText','Nivolumab\x20is\x20used\x20as\x20a\x20checkpoint\x20inhibitor\x20in','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','Blonanserin','uxxaC','duers','addEventListener','Benzalkonium\x20chloride','qwYhX','WdRsX','toLowerCase','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','Furosemide','https://cdn1.dailyrounds.org/uploads/e5f470b5d0ef4785a0a3eaba9c8dfafa.JPEG','053\x20Pharmacology\x20Ini-Cet\x202021','nav-btn-current','<p>The\x20<strong>minimum\x20duration</strong>&nbsp;of\x20time\x20between\x20the\x20consumption\x20of<strong>\x20phenytoin</strong>\x20and\x20<strong>sucralfate</strong>\x20should\x20be\x20<strong>120\x20minutes</strong>.</p>\x0a<p>Sucralfate,\x20in\x20an\x20<strong>acidic\x20environment</strong>\x20(<strong>pH\x20&lt;\x204</strong>)\x20acts\x20by\x20producing\x20a\x20<strong>viscous</strong>,<strong>\x20sticky\x20polymer</strong>\x20that\x20adheres\x20to\x20ulcer\x20craters\x20and\x20epithelial\x20cells\x20for\x20up\x20to<strong>&nbsp;6\x20hours</strong>\x20after\x20a\x20single\x20dose.\x20This\x20<strong>viscous\x20layer\x20produced</strong>\x20in\x20the\x20stomach\x20leads\x20to\x20<strong>inhibition\x20</strong>of<strong>\x20absorption</strong>\x20of\x20other\x20drugs,\x20like\x20<strong>phenytoin</strong>,\x20digoxin,\x20cimetidine,\x20ketoconazole,\x20and\x20fluoroquinolone\x20antibiotics.\x20Therefore,\x20sucralfate\x20should\x20be\x20taken\x20after\x20a\x20gap\x20of\x20at\x20least\x202\x20hours\x20/<strong>\x20120\x20minutes</strong>&nbsp;after\x20the\x20administration\x20of\x20phenytoin.&nbsp;</p>\x0a<p><strong>Constipation</strong>\x20is\x20the\x20most\x20common\x20side\x20effect\x20of\x20sucralfate.\x20It\x20should\x20be\x20<strong>avoided</strong>\x20in\x20patients\x20with\x20<strong>renal\x20failure</strong>\x20who\x20are\x20at\x20risk\x20of\x20<strong>aluminium\x20overload.</strong>&nbsp;Aluminum-containing\x20antacids\x20should\x20not\x20be\x20combined\x20with\x20sucralfate\x20in\x20these\x20patients.\x20&nbsp;As\x20the\x20viscous\x20gel\x20produced\x20by\x20sucralfate\x20is\x20sticky,\x20it\x20may\x20eventually\x20lead\x20to\x20<strong>bezoar</strong>\x20formation.</p>\x0a<p>It\x20is\x20generally\x20used\x20for\x20<strong>prophylaxis</strong>\x20of\x20peptic\x20ulcers,\x20but\x20<strong>rarely</strong>\x20so\x20because\x20of\x20its\x20side\x20effects\x20and\x20its\x20risks\x20outweigh\x20its\x20benefits.</p>','location','IMP\x20dehydrogenase\x20inhibition','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','navBtn_','vRYMG','seEIc','AyHvr','okWtl','nQsCH','UIXgG','return\x20(function()\x20','Rauoq','TTLKU','modeModal','6exIlDg','iyLQu','JkaYv','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','SQhoO','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','incorrect','OCD','UcEnH','red','AFgqk','wRCFb','EJWDP','Albumin','Medulloblastoma','status','data-option-index','zIRLJ','uMNwn','Ganciclovir','Drug\x20A\x20decreases\x20intestinal\x20absorption\x20of\x20Drug\x20B','3|1|2|5|4|0','gKFSv','endsWith','none','log','PFfUD','Herniated\x20disc','Cost\x20ratio\x20from\x20cheap\x20to\x20expensive','EoghP','Retinoblastoma','gBWkJ','hierarchy','selectedAnswer','solutionVideo','src','Which\x20of\x20the\x20following\x20is\x20false\x20about\x20the\x20selection\x20of\x20essential\x20drugs?','bxGaD','kzNbu','ATGQL','Sibutramine','hXWTh','DOMContentLoaded','statsBar','DeNUq','rQVsi','5474145JVpMkA','attachMedia','ssXDd','srgYf','Cefepime','Hodgkin\x27s\x20lymphoma','explanation_audio_eng','gYypG','QnykV','review-question\x20','ZZgdT','IHaMO','lxGdp','Prejunctional\x20M2\x20receptor\x20blockade','WrWUY','ssIPu','study','info','zlhYF','Marked','poxek','WUaEX','replace','NYKEs','RtTuF','Drug\x20A\x20reduces\x20first\x20pass\x20metabolism\x20of\x20Drug\x20B','Category\x20A,\x20B,\x20C,\x20D,\x20X\x20in\x20drug\x20classification\x20are\x20indicative\x20of\x20which\x20of\x20the\x20following?','32GvxyVv','padStart','3290740XfLxgS','Ciraparantag:\x20Fondaparinux','{}.constructor(\x22return\x20this\x22)(\x20)','style','URaaN','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','question_images','606591uXKMPA','MaOmx','bind','OGwfA','oXVjd','UIyZn','createElement','KERyA','nav-btn-marked-review','strokeDashoffset','lTosx','QHuTF','awCvk','PZbPo','tpcFY','A\x2014-month-old\x20boy\x20was\x20diagnosed\x20with\x20Hemophilus\x20influenza\x20meningitis.\x20The\x20initial\x20treatment\x20plan\x20was\x20to\x20start\x20on\x20ampicillin\x20but\x20later\x20was\x20shifted\x20to\x20ceftriaxone.\x20What\x20could\x20be\x20the\x20probable\x20reason?','TjxuX','GQUtO','XEYmF','PSiHH','isSupported','Meropenem','ofcGL','IzRYv','Which\x20of\x20the\x20following\x20is\x20the\x20most\x20effective\x20drug\x20in\x20smoking\x20cessation?','solutionImages','Xroso','Intra\x20abdominal\x20infections','Fixed\x20drug\x20combination\x20is\x20preferred\x20over\x20single\x20drugs','div','dwVJs','RIvRW','fLrJm','upRMd','optionsContainer','bPZGf','AtccE','cgDAS','apply','WuDvp','vJTBp','application/vnd.apple.mpegurl','VfdrU','SUFza','A\x20patient\x20is\x20on\x20phenytoin\x20for\x20a\x20seizure\x20disorder.\x20He\x20was\x20prescribed\x20sucralfate\x204\x20times\x20a\x20day\x20for\x20peptic\x20ulcers.\x20What\x20should\x20be\x20the\x20minimum\x20duration\x20of\x20time\x20between\x20consumption\x20of\x20these\x20drugs?','Vitamin\x20C','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','PbYfL','HkADl','<p>Administration\x20of\x20<strong>ritonavir</strong>\x20would\x20increase\x20the\x20bioavailability\x20of\x20<strong>saquinavir</strong>.</p>\x0a<p>Saquinavir\x20is\x20an\x20<strong>HIV\x20protease\x20inhibitor</strong>\x20that\x20inhibits\x20replication\x20of\x20both\x20HIV-1\x20and\x20HIV-2.\x20It\x20is\x20metabolized\x20predominantly\x20by\x20the\x20hepatic\x20enzyme\x20<strong>CYP3A4</strong>.\x20Inhibition\x20of\x20CYP3A4\x20results\x20in\x20an\x20increase\x20or\x20a\x20boost\x20in\x20the\x20concentration\x20of\x20saquinavir.&nbsp;\x20Ritonavir\x20is\x20one\x20such\x20drug\x20that\x20inhibits\x20CYP3A4.\x20Therefore\x20combining\x20it\x20with\x20a\x20protease\x20inhibitor\x20like\x20saquinavir\x20results\x20in:</p>\x0a<ul>\x0a<li>Enhanced\x20bioavailability</li>\x0a<li>Inhibition\x20of\x20systemic\x20clearance</li>\x0a<li>Inhibition\x20of\x20first-pass\x20metabolism,\x20and</li>\x0a<li>Longer\x20half-life\x20of\x20the\x20co-administered\x20HIV\x20protease\x20inhibitor.</li>\x0a</ul>\x0a<p>This\x20allows\x20for\x20a\x20<strong>reduction</strong>\x20of\x20drug\x20dose\x20and\x20dosing\x20frequency\x20of\x20saquinavir.</p>\x0a<p>All\x20protease\x20inhibitors\x20except\x20for\x20nelfinavir\x20are\x20predominantly\x20metabolized\x20by\x20CYP3A4.\x20Therefore,\x20the\x20administration\x20of\x20CYP3A4\x20inhibitors\x20like\x20ritonavir\x20or\x20<strong>cobicistat</strong>\x20can\x20increase\x20the\x20bioavailability\x20of\x20these\x20protease\x20inhibitors.\x20This\x20phenomenon\x20is\x20known\x20as\x20<strong>boosting</strong>&nbsp;protease\x20inhibitors\x20by\x20CYP\x20inhibitors.\x20The\x20dosage\x20of\x20ritonavir,\x20when\x20given\x20as\x20a\x20booster\x20drug,\x20is\x20100\x20to\x20200mg\x20once\x20or\x20twice\x20daily.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20B:<strong>&nbsp;Vitamin\x20C</strong>\x20/\x20<strong>Ascorbic\x20acid</strong>\x20is\x20a\x20water-soluble\x20vitamin\x20that\x20can\x20actually\x20reduce\x20the\x20steady-state\x20concentration\x20of\x20protease\x20inhibitors.\x20It\x20<strong>increases</strong>\x20the\x20absorption\x20of\x20dietary\x20<strong>iron</strong>.</p>\x0a<p>Option\x20C:&nbsp;<strong>Cimetidine</strong>\x20is\x20a\x20histamine\x202\x20receptor\x20antagonist\x20which\x20is\x20used\x20to\x20promote\x20gastric\x20and\x20duodenal\x20ulcer\x20healing.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20gastroesophageal\x20reflux\x20disease.\x20It\x20also\x20inhibits\x20CYPs,\x20but\x20only\x20ritonavir\x20and\x20<strong>cobicistat</strong>\x20are\x20used\x20for\x20boosting\x20protease\x20inhibitors.</p>\x0a<p>Option\x20D:<strong>&nbsp;Ganciclovir</strong>\x20is\x20a\x20guanine\x20nucleoside\x20analogue\x20which\x20has\x20inhibitory\x20activity\x20against\x20all\x20herpes\x20viruses,\x20especially\x20cytomegalovirus\x20(CMV).</p>','Adequate\x20safety\x20profile\x20needs\x20to\x20be\x20established','getElementById','xwOze','OnIvi','PzVHL','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','<p>The\x20clinical\x20features\x20and\x20the\x20CT\x20angiography\x20image\x20showing\x20diffuse\x20symmetrical\x20luminal\x20narrowing\x20of\x20the\x20lower\x20limb\x20vessels\x20are\x20suggestive\x20of<strong>\x20ergotism.</strong></p>\x0a<p>In\x20this\x20case,\x20a\x20patient\x20on\x20antiretroviral\x20therapy\x20is\x20given\x20ergotamine.\x20HIV\x20protease\x20inhibitors\x20used\x20in\x20ART\x20like\x20ritonavir,\x20lopinavir,\x20etc\x20are&nbsp;<strong>potent\x20inhibitors</strong>\x20of\x20the&nbsp;\x20<strong>CYP3A4\x20enzyme</strong>.\x20This\x20enzyme\x20is\x20responsible\x20for\x20the\x20<strong>metabolism\x20of\x20ergot</strong>\x20compounds.\x20Hence\x20inhibition\x20of\x20this\x20enzyme\x20leads\x20to\x20<strong>decreased\x20metabolism\x20of\x20ergotamine.</strong>\x20This\x20causes\x20the\x20accumulation\x20of\x20toxic\x20levels\x20of\x20ergotamine\x20in\x20the\x20patient\x20and\x20leads\x20to\x20ergotism.&nbsp;</p>\x0a<p>Ergotamine\x20is\x20a\x20partial\x20agonist\x20and\x20antagonist\x20at\x20<strong>alpha-adrenergic,\x205HT1;\x20and\x205HT2</strong>\x20receptors.\x20It\x20produces\x20sustained\x20vasoconstriction,\x20vasomotor\x20center\x20depression,\x20and\x20visceral\x20smooth\x20muscle\x20contraction.</p>\x0a<p>Adverse\x20effects:\x20Nausea,\x20vomiting,\x20and\x20abdominal\x20pain\x20may\x20be\x20seen.\x20Vasoconstriction\x20caused\x20by\x20the\x20drug\x20is\x20responsible\x20for\x20most\x20of\x20the\x20adverse\x20effects.\x20These\x20are\x20usually\x20seen\x20with\x20long-term\x20therapy\x20with\x20higher\x20doses.</p>\x0a<ul>\x0a<li>It\x20may\x20precipitate\x20or\x20aggravate\x20angina\x20pectoris\x20or\x20myocardial\x20infarction\x20due\x20to\x20coronary\x20insufficiency.</li>\x0a<li>Some\x20patients\x20develop\x20<strong>cold,\x20numb,\x20and\x20painful\x20extremities</strong>.</li>\x0a<li>Leg\x20claudication\x20may\x20be\x20seen</li>\x0a<li><strong>Gangrene</strong>\x20of\x20the\x20extremities</li>\x0a</ul>\x0a<p>&nbsp;Contraindications\x20for\x20ergotamine:&nbsp;</p>\x0a<ul>\x0a<li><strong>Peripheral\x20vascular\x20disease</strong></li>\x0a<li>Coronary\x20artery\x20disease</li>\x0a<li>Uncontrolled\x20hypertension</li>\x0a<li>Sepsis</li>\x0a<li>Pregnancy</li>\x0a<li>Liver\x20and\x20kidney\x20diseases</li>\x0a</ul>','What\x20would\x20happen\x20to\x20the\x20half-life\x20and\x20plasma\x20concentration\x20of\x20a\x20drug\x20which\x20follows\x20first-order\x20kinetics,\x20\x20if\x20the\x20dose\x20is\x20doubled?','VgqSs','lTZti','60\x20minutes','Globulin','cuRlI','EKYXR','mCZCS','performanceModal','cSnxv','YIqLb','2\x20and\x204\x20only','UxcJW','open','IhFWa','filter','What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20remdesivir?','Pleuropulmonary\x20blastoma','edkfa','BeRIr','video[data-src]','XrAbU','eXdUE','3340274SBCsfS','UtMhb','KrXCO','join','Antimicrobial\x20combinations\x20are\x20used\x20in\x20all\x20except','EtlJm','1,\x202\x20and\x203','A\x20patient\x20who\x20was\x20on\x20warfarin\x20therapy\x20for\x20atrial\x20fibrillation\x20is\x20prescribed\x20a\x20cephalosporin\x20antibiotic\x20for\x20the\x20treatment\x20of\x20a\x20lower\x20respiratory\x20tract\x20infection.\x20He\x20reports\x20back\x20to\x20the\x20hospital\x20after\x20having\x20developed\x20hemarthrosis.\x20Which\x20of\x20the\x20following\x20cephalosporins\x20is\x20likely\x20to\x20have\x20caused\x20this?','xyVcx','qFNKZ','bBPOF','__proto__','A\x2057-year-old\x20man\x20was\x20brought\x20to\x20the\x20hospital\x20with\x20complaints\x20of\x20dizziness\x20and\x20breathlessness.\x20During\x20his\x20physical\x20examination,\x20you\x20notice\x20the\x20following\x20discolouration\x20over\x20his\x20face.\x20He\x20is\x20presently\x20being\x20treated\x20with\x20amiodarone,\x20metoprolol,\x20verapamil,\x20lisinopril,\x20and\x20amlodipine.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20most\x20likely\x20responsible?','nav-btn-answered','jUCBi','4401102udeCfb','lfgVE','Polyradicular\x20neuropathy','nFVuY','ExyxV','Upregulation\x20of\x20CYP1A1','bFSph','<p>The\x20image\x20shows&nbsp;<strong>grey-blue\x20discoloration</strong>\x20over\x20this\x20patient\x27s\x20face\x20and\x20the\x20drug\x20responsible\x20for\x20this\x20is\x20<strong>amiodarone</strong>.</p>\x0a<p>Long-term\x20treatment\x20with\x20amiodarone&nbsp;is\x20responsible\x20for\x20skin\x20pigmentation.\x20<strong>Elderly\x20men</strong>\x20are\x20at\x20an\x20increased\x20risk\x20of\x20developing\x20this.&nbsp;</p>\x0a<p>Ultraviolet\x20light\x20reacts\x20with\x20amiodarone\x20and\x20its\x20metabolites\x20to\x20cause\x20local\x20vasodilatation.\x20This\x20increases\x20the\x20diffusion\x20of&nbsp;amiodarone\x20and\x20its\x20metabolites,\x20resulting\x20in\x20their\x20deposition\x20in\x20the\x20tissues,\x20causing\x20pigmentation.\x20Therefore,\x20it\x20is\x20usually\x20seen\x20in\x20<strong>sun-exposed\x20areas</strong>.</p>\x0a<p><strong>Cessation\x20</strong>of\x20amiodarone,\x20<strong>avoiding\x20</strong>exposure\x20to\x20<strong>sunlight</strong>&nbsp;using\x20<strong>sunscreen</strong>\x20cream\x20is\x20recommended.</p>\x0a<p>Amiodarone\x20is\x20an\x20iodine-containing\x20compound\x20that\x20is\x20structurally\x20related\x20to\x20thyroid\x20hormone.\x20It\x20is\x20a\x20<strong>class\x20III\x20antiarrhythmic\x20drug</strong>,\x20which\x20increases\x20the\x20duration\x20of\x20an\x20action\x20potential\x20by\x20<strong>blocking\x20potassium\x20channels.</strong>&nbsp;It\x20thereby\x20increases\x20the\x20time\x20taken\x20for\x20<strong>repolarization</strong>.\x20It\x20also\x20prolongs\x20the\x20refractory\x20period\x20and\x20suppresses\x20abnormal\x20automaticity.\x20It\x20also\x20has\x20weak\x20<strong>calcium\x20channel\x20</strong>blocking<strong>,\x20sodium\x20channel\x20</strong>blocking<strong>,</strong>\x20and\x20<strong>adrenergic\x20</strong>blocking\x20actions.</p>\x0a<p>It\x20is\x20used\x20to\x20maintain\x20normal\x20sinus\x20rhythm\x20during\x20<strong>atrial\x20fibrillation</strong>\x20and\x20prevent\x20<strong>recurrent\x20ventricular\x20tachycardia</strong>.&nbsp;</p>\x0a<p>Adverse\x20effects\x20of\x20amiodarone:</p>\x0a<ul>\x0a<li>Prolonged\x20usage\x20of\x20amiodarone\x20causes\x20interstitial\x20lung\x20disease.</li>\x0a<li>Heart\x20blocks,\x20bradycardia\x20and\x20QT\x20prolongation</li>\x0a<li>Hyperthyroidism\x20or\x20hypothyroidism</li>\x0a<li>Corneal\x20micro-deposits\x20and\x20vortex\x20keratopathy,\x20optic\x20neuropathy</li>\x0a</ul>\x0a<p>Drug\x20interactions\x20of\x20amiodarone</p>\x0a<ul>\x0a<li>Causes\x20<strong>digoxin\x20toxicity</strong>\x20by\x20decreasing\x20its\x20renal\x20clearance.</li>\x0a<li>Increases\x20concentration\x20of\x20quinidine\x20and\x20procainamide</li>\x0a<li>Potentiates\x20the\x20anticoagulant\x20effect\x20of\x20warfarin\x20when\x20given\x20simultaneously&nbsp;&nbsp;</li>\x0a</ul>','button','jYGDJ','IUfeZ','TmuPY','YNXQB','pgPti','UsuHE','dataset','Alpha-1\x20glycoprotein','XXDRi','zmynb','rufst','text','dePRg','totalAttempted','Eplerenone','Correct','gray','HyekX','testModeLegend','textContent','jFWqF','block','PUWFo','submitSection','removeItem','warn','What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20cyclosporine?','hniEI','Cost\x20to\x20benefit\x20has\x20to\x20be\x20considered','<div\x20class=\x22mt-4\x22><img\x20src=\x22','euWfM','The\x20dose\x20at\x20which\x20dopamine\x20acts\x20on\x20beta\x201\x20receptors\x20is\x20____.','Vilazodone','bookmarkText','jlJzl','rUYJm','No\x20solution\x20available.','stringify','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','<p>Category\x20A,\x20B,\x20C,\x20D,\x20X\x20in\x20drug\x20classification\x20are\x20indicative\x20of\x20their\x20safety\x20in\x20pregnancy.</p>\x0a<p>The\x20united\x20states\x20food\x20and\x20drug\x20administration\x20(FDA)\x20system\x20for\x20teratogenic\x20potential\x20attempts\x20to\x20quantify\x20teratogenic\x20risk\x20from\x20category\x20A\x20(safe)\x20to\x20category\x20X\x20(definite\x20human\x20teratogenic\x20risk).</p>\x0a<p><strong>Category\x20A</strong>:\x20The\x20possibility\x20of\x20fetal\x20<strong>harm</strong>\x20is\x20<strong>remote</strong>\x20and\x20studies\x20in\x20women\x20have\x20failed\x20to\x20demonstrate\x20any\x20evidence\x20of\x20risk\x20to\x20the\x20fetus.\x20Examples:\x20doxylamine,\x20folic\x20acid,\x20levothyroxine.</p>\x0a<p><strong>Category\x20B</strong>:&nbsp;Either\x20animal-reproduction\x20studies\x20have\x20not\x20demonstrated\x20a\x20fetal\x20risk,\x20but\x20there\x20are\x20no\x20controlled\x20studies\x20in\x20pregnant\x20women,\x20or\x20animal-reproduction\x20studies\x20have\x20shown\x20an\x20adverse\x20effect\x20that\x20was\x20not\x20confirmed\x20in\x20controlled\x20studies\x20in\x20pregnant\x20women.\x20Example:\x20Amoxicillin,\x20loratadine,\x20ondansetron.</p>\x0a<p><strong>Category\x20C</strong>:&nbsp;Either\x20studies\x20in\x20animals\x20have\x20revealed\x20adverse\x20effects\x20on\x20the\x20fetus,\x20that\x20is,\x20teratogenic\x20or\x20embryocidal\x20but\x20there\x20are\x20no\x20controlled\x20studies\x20in\x20women,\x20or\x20studies\x20in\x20women\x20and\x20animals\x20are\x20not\x20available.\x20These\x20drugs\x20should\x20be\x20given\x20only\x20if\x20the\x20potential\x20benefit\x20justifies\x20the\x20potential\x20risk\x20to\x20the\x20fetus.\x20Example:\x20fluconazole,\x20metoprolol,\x20sertraline.</p>\x0a<p><strong>Category\x20D</strong>:&nbsp;Though\x20there\x20is\x20evidence\x20of\x20human\x20fetal\x20risk,\x20the\x20benefits\x20from\x20use\x20in\x20pregnant\x20women\x20may\x20be\x20acceptable\x20despite\x20the\x20risk,\x20for\x20example,\x20if\x20the\x20drug\x20is\x20needed\x20in\x20a\x20life-threatening\x20situation\x20or\x20for\x20a\x20disease\x20for\x20which\x20safer\x20drugs\x20cannot\x20be\x20used\x20or\x20are\x20ineffective.\x20Example:\x20lisinopril,\x20lithium,\x20phenytoin.</p>\x0a<p><strong>Category\x20X</strong>:\x20There\x20is\x20evidence\x20of\x20fetal\x20risk\x20based\x20on\x20human\x20or\x20animal\x20experience\x20and\x20the\x20risk\x20of\x20the\x20use\x20of\x20the\x20drug\x20in\x20pregnant\x20women\x20clearly\x20outweighs\x20any\x20possible\x20benefit.\x20The\x20<strong>drug</strong>\x20is\x20<strong>contraindicated</strong>\x20in\x20women\x20who\x20are\x20or\x20may\x20become\x20pregnant.\x20Example:\x20methotrexate,\x20simvastatin,\x20warfarin.</p>\x0a<p>&nbsp;</p>','cvdgY','markedForReview','fill','solution','1,\x202\x20and\x204','Cimetidine','Chlorthalidone','QAZaT','hBWPI','Nicotine\x20gum','mHRKJ','jlFwq','A\x20patient\x20with\x20history\x20of\x20ischemic\x20stroke\x20was\x20started\x20on\x20clopidogrel.\x20However,\x20she\x20had\x20another\x20attack\x20of\x20stroke\x20after\x206\x20months.\x20Which\x20of\x20the\x20following\x20is\x20likely\x20to\x20be\x20responsible\x20for\x20the\x20failure\x20of\x20clopidogrel\x20in\x20this\x20patient?','The\x20anti-epileptic\x20drugs\x20which\x20can\x20also\x20be\x20used\x20for\x20the\x20treatment\x20of\x20neuropathic\x20pain\x20are','HiuUc','<p><strong>Linezolid</strong>\x20cannot\x20be\x20used\x20in\x20this\x20patient\x20as\x20<strong>bone\x20marrow\x20suppressio</strong>n\x20is\x20a\x20side\x20effect\x20of\x20this\x20drug\x20and\x20hence\x20it\x20can\x20worsen\x20the\x20post-chemotherapy\x20bone\x20marrow\x20suppression\x20in\x20this\x20patient.</p>\x0a<p>Linezolid\x20can\x20cause\x20<strong>myelosuppression</strong>\x20which\x20can\x20present\x20as\x20anemia,\x20thrombocytopenia,\x20leukopenia,\x20and\x20pancytopenia.\x20It\x20is\x20<strong>commonly</strong>\x20associated\x20with\x20<strong>thrombocytopenia</strong>\x20and\x20is\x20seen\x207-10\x20days\x20following\x20administration.\x20This\x20is\x20usually\x20reversed\x20on\x20discontinuation\x20of\x20the\x20drug.&nbsp;</p>\x0a<p>Other\x20adverse\x20effects\x20of\x20linezolid:</p>\x0a<ul>\x0a<li>It\x20inhibits\x20mitochondrial\x20protein\x20synthesis\x20and\x20may\x20lead\x20to\x20peripheral\x20neuropathy,\x20optic\x20neuritis,\x20and\x20lactic\x20acidosis\x20in\x20patients\x20receiving\x20the\x20drug\x20for\x20longer\x20durations.</li>\x0a<li>It\x20can\x20cause\x20<strong>serotonin\x20syndrome</strong>\x20when\x20coadministered\x20with\x20adrenergic\x20or\x20serotonergic\x20drugs\x20like\x20SSRIs\x20due\x20to\x20its\x20nonspecific\x20MAO\x20inhibition.</li>\x0a</ul>\x0a<p>It\x20is\x20a\x20protein\x20synthesis\x20inhibitor\x20of\x20the\x20class\x20<strong>oxazolidinone</strong>s.\x20It\x20mainly\x20acts\x20against\x20<strong>gram-positive</strong>\x20organisms.\x20It\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20the\x20following\x20conditions:</p>\x0a<ul>\x0a<li><strong>Skin</strong>\x20and\x20<strong>skin\x20structure\x20infection</strong>s\x20by\x20staphylococcus(Both\x20MRSA\x20and\x20MSSA)\x20and\x20streptococcus.</li>\x0a<li>Community-acquired\x20pneumonia\x20due\x20to\x20streptococcus\x20pneumoniae.</li>\x0a<li>Nosocomial\x20pneumonia\x20due\x20to\x20staphylococcus\x20aureus.&nbsp;</li>\x0a</ul>\x0a<p>Other\x20options:</p>\x0a<p><strong>Cefepime</strong>:\x20It\x20is\x20a\x20fourth-generation\x20antipseudomonal\x20cephalosporin.\x20It\x20is\x20useful\x20in\x20enterobacter\x20and\x20pseudomonas\x20infections\x20that\x20are\x20resistant\x20to\x20other\x20cephalosporins.</p>\x0a<p><strong>Piperacillin-Tazobactam</strong>-\x20It\x20is\x20a\x20combination\x20of\x20piperacillin\x20which\x20is\x20a\x20ureidopenicillin\x20and\x20tazobactam\x20which\x20is\x20a\x20beta-lactamase\x20inhibitor.\x20It\x20is\x20useful\x20in\x20various\x20infections\x20including\x20nosocomial\x20infections,\x20intraabdominal\x20infections,\x20pneumonia,\x20and\x20UTI.\x20It\x20is\x20highly\x20effective\x20against\x20<strong>E\x20Coli\x20and\x20Klebsiella</strong>.</p>\x0a<p><strong>Meropenem</strong>:\x20It\x20belongs\x20to\x20the\x20carbapenem\x20group\x20of\x20beta-lactam\x20antibiotics.\x20They\x20are\x20more\x20active\x20against\x20gram-negative\x20organisms.\x20Coadministration\x20of\x20<strong>cilastatin\x20is\x20not\x20required</strong>\x20with\x20this\x20drug.\x20(Cilastation\x20should\x20be\x20coadministered\x20with\x20imipenem\x20as\x20imipenem\x20is\x20sensitive\x20to\x20renal\x20peptidase\x20degradation)</p>','HKbnJ','Downregulation\x20of\x20CYP2E1','20.8\x20hours','questionMedia','ycvdk','muNGv','<p><strong>Gonorrhea</strong>\x20is\x20not\x20managed\x20by\x20antimicrobial\x20combinations.\x20According\x20to\x20the\x20latest\x20<strong>CDC\x20</strong>guidelines,\u00a0<strong>single-agent\x20therapy\x20with\x20ceftriaxone</strong>\x20is\x20the\x20preferred\x20treatment\x20for\x20gonococcal\x20infections.</p>\x0a<p>Single-dose\x20of\x20500mg\x20<strong>intramuscular(IM)\x20ceftriaxon</strong>e\x20is\x20given\x20for\x20gonorrhea.\x20It\x20is\x20important\x20to\x20note\x20that\x20the\x20previous\x20guidelines\x20that\x20recommended\x20<strong>dual\x20therapy</strong>\x20with\x20<strong>ceftriaxone\x20and\x20azithromycin\x20are\x20no\x20longer\x20preferred.</strong></p>\x0a<p>Monotherapy\x20with\x20ceftriaxone\x20is\x20given\x20when\x20<strong>concurrent\x20chlamydia\x20infection\x20is\x20ruled\x20ou</strong>t\x20by\x20molecular\x20testing.\x20If\x20this\x20is\x20not\x20done\x20then\x20presumptive\x20treatment\x20for\x20chlamydia\x20should\x20be\x20given\x20along\x20with\x20the\x20treatment\x20of\x20gonorrhea.\x20According\x20to\x20CDC\x20guidelines,\x20100mg\x20doxycycline\x20twice\x20daily\x20for\x207\x20days\x20is\x20given\x20as\x20presumptive\x20treatment\x20of\x20chlamydia\x20in\x20nonpregnant\x20individuals.</p>\x0a<p>Other\x20options:</p>\x0a<p><strong>Tuberculosis</strong>:\x20<strong>Multidrug\x20therapy</strong>\x20is\x20given\x20in\x20tuberculosis\x20for\x20proper\x20cure\x20and\x20to\x20prevent\x20the\x20selection\x20of\x20drug-resistant\x20mutants.\x20ATT\x20regimen\x20is\x20given\x20in\x20detail\x20in\x20the\x20pearl\x20attached.</p>\x0a<p><strong>Intraabdominal\x20infections</strong>:\x20It\x20is\x20usually<strong>\x20polymicrobial</strong>\x20and\x20can\x20result\x20in\x20an\x20intraabdominal\x20abscess\x20or\x20secondary\x20peritonitis.\x20These\x20are\x20managed\x20with\x20either\x20<strong>single-agent\x20or\x20combination\x20therapy</strong>.\x20Broad-spectrum\x20agents\x20with\x20gram-negative\x20cover\x20such\x20as\x20meropenem\x20or\x20piperacillin-tazobactam\x20can\x20be\x20used\x20alone.\x20Combination\x20therapy\x20with\x20metronidazole\x20and\x20other\x20agents\x20like\x20ciprofloxacin,\x20cefepime,\x20etc\x20are\x20used\x20as\x20empirical\x20agents\x20in\x20intraabdominal\x20infections.</p>\x0a<p><strong>Malaria</strong>:\x20It\x20is\x20also\x20treated\x20with\x20antimicrobial\x20combinations.\x20In\x20plasmodium\x20vivax\x20and\x20ovale\x20malaria,\u00a0schizontocides\x20like\x20chloroquine\x20are\x20combined\x20with\x20agents\x20that\x20attack\x20the\x20hypnozoites\x20like\x20primaquine\x20for\x20radical\x20cure.\x20Primaquine\x20is\x20also\x20given\x20in\x20combination\x20with\x20Artemisinin\x20combined\x20therapy(ACT)\x20for\x20plasmodium\x20falciparum\x20infections\x20as\x20a\x20gametocidal\x20agent.\x20Treatment\x20regimens\x20are\x20given\x20in\x20the\x20pearl\x20attached.</p>','Dementia','totalQuestionsResult','QUxrt','gSugN','The\x20elimination\x20rate\x20constant\x20of\x20a\x20drug\x20is\x200.05/hr.\x20What\x20is\x20its\x20half-life?','hettL','Hypertonic\x20saline','Stop\x20retigabine\x20and\x20start\x20on\x20carbamazepine','Ltjli','GUkTx','Lipoprotein','Topiramate\x20is\x20used\x20for','Metformin','Resistant\x20Parkinson\x27s\x20disease','KtTgz','OCUlQ','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','ArrowLeft','4lierUS','question_video','back','selected','<p>The\x20thiazide\x20diuretic\x20that\x20can\x20be\x20used\x20as\x20an\x20antihypertensive\x20in\x20this\x20patient\x20with\x20chronic\x20kidney\x20disease\x20is\x20<strong>metolazone.</strong></p>\x0a<p>In\x20patients\x20with\x20<strong>chronic\x20renal\x20failure,</strong>\x20<strong>thiazide</strong>\x20diuretics\x20are\x20<strong>ineffective</strong>.\x20But\x20metolazone,\x20despite\x20being\x20a\x20thiazide\x20diuretic,\x20is\x20effective\x20as\x20antihypertensives\x20in\x20patients\x20with\x20chronic\x20renal\x20failure.</p>\x0a<p><strong>Metolazone</strong>\x20is\x20useful\x20even\x20in\x20<strong>severe\x20renal\x20failure\x20(GFR\x20of\x20&sim;15\x20mL/min</strong>).\x20It\x20has\x20an\x20additive\x20action\x20when\x20combined\x20with\x20loop\x20diuretics\x20like\x20furosemide.\x20It\x20also\x20has\x20an\x20additional\x20proximal\x20tubular\x20action\x20(thiazides\x20mainly\x20act\x20on\x20DCT).\x20It\x20is\x20commonly\x20used\x20for\x20edema\x20and\x20is\x20occasionally\x20used\x20as\x20an\x20antihypertensive.</p>\x0a<p>Diuretics\x20in\x20hypertension:</p>\x0a<p><strong>Thiazides</strong>&nbsp;are\x20the\x20<strong>diuretics\x20of\x20choice</strong>\x20for\x20<strong>uncomplicated\x20hypertension</strong>.</p>\x0a<p>Mechanisms\x20of\x20antihypertensive\x20action:</p>\x0a<ul>\x0a<li>Decreases\x20plasma\x20and\x20ECF\x20volume\x20by\x20diuresis\x20thereby\x20decreasing\x20cardiac\x20output</li>\x0a<li>Even\x20when\x20the\x20compensatory\x20mechanisms\x20restore\x20the\x20Na+\x20levels\x20and\x20plasma\x20volume,\x20a\x20low\x20BP\x20is\x20maintained\x20by\x20a\x20reduction\x20in\x20total\x20peripheral\x20resistance.</li>\x0a<li>This\x20reduction\x20in\x20total\x20peripheral\x20resistance\x20is\x20due\x20to\x20the\x20persistence\x20of\x20a\x20small\x20sodium\x20and\x20volume\x20deficit\x20even\x20after\x20compensation.\x20The\x20decreased\x20intracellular\x20sodium\x20is\x20responsible\x20for\x20increased\x20compliance\x20of\x20the\x20vessel\x20wall\x20and\x20a&nbsp;\x20reduced\x20response\x20to\x20constrictor\x20stimulus.</li>\x0a</ul>\x0a<p>Advantages\x20of\x20thiazide\x20as\x20an\x20antihypertensive:</p>\x0a<ul>\x0a<li>It\x20can\x20be\x20given\x20as\x20once\x20a\x20day\x20dose\x20and\x20has\x20a\x20flat\x20dose-response\x20curve.</li>\x0a<li>Decreased\x20incidence\x20of\x20postural\x20hypotension\x20and\x20relative\x20freedom\x20from\x20CNS\x20side\x20effects</li>\x0a<li>No\x20tolerance</li>\x0a<li>No\x20fluid\x20retention</li>\x0a<li>Decreased\x20risk\x20of\x20<strong>osteoporotic\x20fractures</strong>\x20due\x20to\x20its\x20<strong>hypocalciuric</strong>\x20action</li>\x0a<li>Low\x20cost</li>\x0a<li>Effectiveness\x20in\x20<strong>isolated\x20systolic\x20hypertension</strong></li>\x0a</ul>\x0a<p>Thiazides\x20are\x20ineffective\x20both\x20as\x20antihypertensive\x20and\x20diuretic\x20in\x20patients\x20with\x20chronic\x20renal\x20failure.</p>\x0a<p><strong>High\x20ceiling\x20diuretics:</strong>&nbsp;Furosemide\x20is\x20the\x20prototype\x20drug\x20in\x20this\x20class\x20and\x20it\x20is\x20a\x20<strong>weaker\x20antihypertensive</strong>\x20agent\x20than\x20thiazides.\x20They\x20are\x20given\x20in\x20hypertension\x20only\x20in\x20the\x20presence\x20of\x20the\x20following\x20complications:</p>\x0a<ul>\x0a<li>Chronic\x20renal\x20failure\x20-\x20As\x20thiazides\x20are\x20ineffective</li>\x0a<li>Coexisting\x20refractory\x20congestive\x20heart\x20failure</li>\x0a<li>Resistance\x20to\x20combination\x20regimen\x20with\x20thiazides</li>\x0a<li>Marked\x20fluid\x20retention\x20with\x20the\x20use\x20of\x20potent\x20vasodilators.</li>\x0a</ul>\x0a<p>Potassium-sparing\x20diuretics\x20-\x20They\x20are\x20only\x20used\x20in\x20combination\x20with\x20thiazides\x20to\x20prevent\x20the\x20loss\x20of\x20potassium.</p>\x0a<p>Side\x20effects\x20of\x20diuretics\x20include\x20hypokalemia,\x20carbohydrate\x20intolerance,\x20dyslipidemia,\x20and\x20hyperuricemia.</p>\x0a<p>&nbsp;</p>','Easier\x20to\x20administer\x20IV\x20ceftriaxone\x20than\x20IV\x20ampicillin','VvrxG','AQNQx','toString','prevBtn','<p>Drug\x20A\x20reduces\x20the\x20<strong>first-pass\x20metabolism</strong>\x20of\x20Drug\x20B<strong>.</strong></p>\x0a<p>The\x20<strong>area\x20under</strong>\x20the\x20plot\x20of\x20<strong>plasma\x20concentration</strong>\x20of\x20a\x20drug\x20versus\x20<strong>time</strong>\x20after\x20dosage\x20is\x20called\x20the&nbsp;<strong>area\x20under\x20the\x20curve&nbsp;</strong>or\x20<strong>AUC</strong>.\x20It\x20can\x20be\x20used\x20as\x20a\x20measure\x20of\x20the\x20<strong>bioavailability</strong>\x20of\x20a\x20drug\x20and\x20to\x20calculate\x20its\x20<strong>clearance\x20rate</strong>\x20from\x20the\x20body.</p>\x0a<p>Bioavailability\x20refers\x20to\x20the\x20<strong>extent</strong>\x20to\x20which\x20an\x20administered\x20dose\x20of\x20the\x20drug\x20<strong>reaches</strong>\x20its\x20<strong>site\x20of\x20action</strong>;\x20if\x20the\x20metabolic\x20and\x20excretory\x20capacity\x20of\x20the\x20intestine\x20or\x20liver\x20for\x20the\x20drug\x20is\x20large,\x20bioavailability\x20is\x20<strong>reduced\x20substantially</strong>\x20and\x20this\x20is\x20called\x20the\x20<strong>first-pass\x20metabolism</strong>\x20whereas\x20bioavailability\x20is\x20<strong>increased</strong>\x20if\x20intestinal\x20absorption\x20of\x20the\x20drug\x20is\x20increased.</p>\x0a<p>The\x20greater\x20the\x20AUC,\x20the\x20greater\x20is\x20the\x20bioavailability\x20of\x20the\x20drug.</p>\x0a<p>In\x20the\x20question,\x20is\x20observed\x20that\x20when\x20drug\x20A\x20was\x20given\x20along\x20with\x20drug\x20B,\x20the\x20total\x20AUC\x20has\x20increased\x20(820\x20seconds\x20&plusmn;\x20124\x20seconds)\x20when\x20compared\x20to\x20the\x20AUC\x20when\x20drug\x20B\x20is\x20administered\x20alone\x20(570\x20seconds\x20&plusmn;\x20127\x20seconds).</p>\x0a<p>The\x20null\x20hypothesis\x20for\x20the\x20above\x20question\x20would\x20be\x20that\x20drug\x20A\x20doesn\x27t\x20increase\x20the\x20AUC\x20for\x20drug\x20B\x20and\x20for\x20this\x20to\x20be\x20true,&nbsp;\x20value\x20should\x20be\x20&gt;0.05.</p>\x0a<p>As\x20given\x20\x20value\x20is\x20<strong>&lt;0.01</strong>,\x20it\x20is\x20significant\x20and\x20the\x20<strong>null\x20hypothesis</strong>\x20is\x20<strong>rejected</strong>,\x20which\x20means\x20that\x20drug\x20A\x20has\x20indeed\x20increased\x20the\x20AUC\x20for\x20drug\x20B.</p>\x0a<p>This\x20indicates\x20increased\x20bioavailability\x20of\x20drug\x20B\x20when\x20administered\x20with\x20drug\x20A,\x20which\x20shows\x20that\x20drug\x20A\x20has\x20either\x20<strong>increased</strong>\x20the\x20<strong>intestinal\x20absorption</strong>\x20of\x20drug\x20B\x20or\x20has\x20<strong>reduced</strong>\x20its\x20<strong>first-pass\x20metabolism</strong>.</p>\x0a<p>Other\x20options:</p>\x0a<p><strong>Option\x20A</strong>:\x20If\x20drug\x20A\x20decreased\x20the\x20intestinal\x20absorption\x20of\x20drug\x20B,\x20this\x20would\x20mean\x20that\x20the\x20AUC\x20for\x20drug\x20B,\x20when\x20administered\x20with\x20drug\x20A,\x20would\x20be\x20reduced.\x20This\x20is\x20due\x20to\x20decreased\x20bioavailability\x20of\x20drug\x20B\x20when\x20given\x20with\x20drug\x20A.</p>\x0a<p><strong>Option\x20C</strong>:\x20If\x20drug\x20A\x20increases\x20the\x20metabolism\x20of\x20drug\x20B,\x20this\x20would\x20lead\x20to\x20a\x20shorter\x20t<sup>1/2&nbsp;</sup>and\x20duration\x20of\x20action\x20of\x20drug\x20B,\x20thereby\x20decreasing\x20the\x20AUC\x20for\x20when\x20drug\x20B\x20and\x20drug\x20A\x20are\x20given\x20together.</p>\x0a<p><strong>Option\x20D</strong>:\x20If\x20drug\x20A\x20increased\x20the\x20elimination\x20of\x20drug\x20B,\x20the\x20AUC\x20for\x20drug\x20B\x20when\x20given\x20with\x20drug\x20A\x20would\x20be\x20reduced\x20due\x20to\x20reduced\x20duration\x20of\x20action\x20of\x20drug\x20B.</p>','As\x20per\x20safety\x20or\x20therapeutic\x20index','totalTime','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','<p>The\x20probable\x20reason\x20why\x20the\x20drug\x20to\x20be\x20administered\x20was\x20changed\x20from\x20ampicillin\x20to\x20ceftriaxone\x20is\x20because&nbsp;Hemophilus\x20produces\x20<strong>beta-lactamase</strong>\x20and\x20hence,\x20is\x20resistant\x20to\x20ampicillin.</p>\x0a<p>A\x20considerable\x20percentage\x20of\x20isolates\x20of&nbsp;<em>Hemophilus\x20influenzae</em>\x20produce\x20beta-lactamase,\x20rendering\x20them\x20resistant\x20to\x20<strong>ampicillin</strong>,\x20a\x20beta-lactam\x20antibiotic.\x20However,\x20these\x20strains\x20are\x20still\x20sensitive\x20to\x20second\x20and\x20third-generation\x20cephalosporins.</p>\x0a<p>In&nbsp;<em>H.\x20influenzae</em>,\x20the\x20resistance\x20to\x20ampicillin\x20and\x20other\x20&beta;-lactam\x20antibiotics\x20is\x20generally\x20due\x20to\x20the\x20production\x20of\x20a\x20&beta;-lactamase.\x20In\x20the\x20case\x20of\x20&beta;-lactamase-negative\x20ampicillin-resistant\x20strains,\x20resistance\x20is\x20due\x20to\x20the\x20presence\x20of\x20altered\x20penicillin-binding\x20proteins.&nbsp;</p>\x0a<p><strong>Ceftriaxone</strong>\x20is\x20a\x20third-generation\x20cephalosporin\x20that\x20is\x20effective\x20against\x20<em>Hemophilus\x20Influenzae</em>&nbsp;and\x20considerably\x20resistant\x20to\x20beta-lactamase.\x20It\x20has\x20a\x20very\x20long\x20half-life\x20which\x20permits\x20once-daily\x20dosing\x20of\x20the\x20drug.\x20Because\x20of\x20the\x20efficacy\x20of&nbsp;third-generation\x20cephalosporins\x20in\x20the\x20therapy\x20of\x20meningitis\x20caused\x20by&nbsp;<em>Hemophilus\x20Influenzae&nbsp;</em>type\x20b,\x20ceftriaxone\x20administered\x20at\x20the\x20rate\x20of\x2050\x20mg/kg/dose\x20given\x2012th\x20hourly\x20should\x20be\x20a\x20part\x20of\x20the\x20initial\x20empirical\x20therapy.</p>\x0a<p>Vancomycin\x20combined\x20with\x20a&nbsp;third-generation\x20cephalosporin\x20like\x20ceftriaxone\x20is\x20the\x20recommended\x20empirical\x20antibiotic\x20regimen\x20in\x20a\x20suspected\x20case\x20of\x20meningitis,\x20beyond\x20the\x20neonatal\x20period.</p>','Causes\x20monofollicular\x20development','nav-btn-correct','dKxET','1,\x203\x20and\x204','Which\x20of\x20the\x20following\x20is\x20not\x20an\x20off-label\x20use\x20of\x20risperidone?','now','DrfuN','An\x20HIV-positive\x20woman\x20on\x20ART\x20was\x20prescribed\x20ergotamine\x20for\x20a\x20migraine\x20attack\x204\x20days\x20back.\x20She\x20presented\x20with\x20complaints\x20that\x20she\x20is\x20unable\x20to\x20feel\x20her\x20legs\x20from\x20the\x20mid-thigh\x20to\x20her\x20toes,\x20for\x20the\x20past\x20two\x20days.\x20The\x20angiography\x20image\x20is\x20given\x20below.\x20What\x20is\x20the\x20likely\x20diagnosis?','ZmLuq','A\x20patient\x20who\x20is\x20a\x20known\x20case\x20of\x20cirrhosis\x20of\x20the\x20liver\x20presents\x20with\x20abdominal\x20distension\x20and\x20swelling\x20of\x20the\x20lower\x20limbs.\x20The\x20preferred\x20diuretic\x20for\x20this\x20patient\x20would\x20be','Tuberculosis','vxObL','blgOA','jeXOc','explanation_video','setItem','Which\x20of\x20the\x20following\x20is\x20the\x20incorrect\x20statement\x20regarding\x20clomiphene\x20citrate?','1yODFDI','RLIfA'];_0x30a8=function(){return _0x1753eb;};return _0x30a8();}function toggleMarkForReview(){const _0x75be61=_0x1947e1,_0x323c37={'MASxm':function(_0x383e82){return _0x383e82();},'yJGYl':function(_0xdac849){return _0xdac849();}};questionStates[currentQuestionIndex][_0x75be61(0x26b)]=!questionStates[currentQuestionIndex][_0x75be61(0x26b)],_0x323c37[_0x75be61(0x2dd)](updateMarkReviewButton),_0x323c37[_0x75be61(0x340)](updateQuestionNav);}function updateMarkReviewButton(){const _0x4acfef=_0x1947e1,_0x27b736={'KgpTb':_0x4acfef(0x391),'EKYXR':_0x4acfef(0x1c9)},_0x415dff=document[_0x4acfef(0x20d)](_0x27b736['KgpTb']),_0xc8609e=document['getElementById'](_0x4acfef(0x40f)),_0x2c096e=questionStates[currentQuestionIndex][_0x4acfef(0x26b)];_0x415dff[_0x4acfef(0x3eb)]=_0x2c096e?_0x4acfef(0x291):'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center',_0xc8609e[_0x4acfef(0x255)]=_0x2c096e?_0x27b736[_0x4acfef(0x219)]:_0x4acfef(0x3b3);}function previousQuestion(){const _0x305b08=_0x1947e1,_0x421021={'UKrtI':function(_0x5b1e8b,_0x2d2fcc){return _0x5b1e8b>_0x2d2fcc;},'CeGeH':function(_0x3ed6e9){return _0x3ed6e9();}};_0x421021[_0x305b08(0x3b6)](currentQuestionIndex,0x0)&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x305b08(0x2f6)]+=Date[_0x305b08(0x2a7)]()-questionStartTime),currentQuestionIndex--,_0x421021['CeGeH'](displayQuestion));}function nextQuestion(){const _0x16425d=_0x1947e1,_0x367283={'AQNQx':'.m3u8','uecvh':function(_0x492f56){return _0x492f56();},'fLrJm':_0x16425d(0x306),'qrhdn':function(_0x1ece54,_0x42ac34){return _0x1ece54-_0x42ac34;},'PFfUD':function(_0x10fe99,_0x2d805e){return _0x10fe99-_0x2d805e;},'bHVfC':_0x16425d(0x2f3),'DeNUq':_0x16425d(0x308),'XXDRi':function(_0x191f3d,_0x4396c4){return _0x191f3d===_0x4396c4;},'zcJOY':'test','yagPH':function(_0x58a767,_0x259923){return _0x58a767===_0x259923;},'jSqnb':_0x16425d(0x2c8),'bWSmE':function(_0x2176e1,_0x8e1882){return _0x2176e1===_0x8e1882;},'grFEX':'xZnqS','TjxuX':_0x16425d(0x39a),'GpxrW':function(_0x518f15,_0x38bc1f){return _0x518f15===_0x38bc1f;},'bJKpN':_0x16425d(0x300),'xyVcx':'You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','OnIvi':function(_0x492402){return _0x492402();}};questionStartTime&&(questionStates[currentQuestionIndex][_0x16425d(0x2f6)]+=_0x367283[_0x16425d(0x34b)](Date[_0x16425d(0x2a7)](),questionStartTime));if(currentQuestionIndex<_0x367283[_0x16425d(0x448)](questionsData[_0x16425d(0x3e3)],0x1)){if(_0x367283[_0x16425d(0x311)]===_0x367283[_0x16425d(0x45a)]){const _0x2d2e71={'AtccE':_0x367283[_0x16425d(0x29a)]};_0x2b3ae[_0x16425d(0x3a6)]('video[data-src]')[_0x16425d(0x34e)](_0x86c67e=>{const _0x179469=_0x16425d,_0x321e60=_0x86c67e['dataset']['src'];if(_0x321e60&&_0x321e60[_0x179469(0x3c0)](_0x2d2e71[_0x179469(0x1fe)]))_0x2ff857(_0x86c67e,_0x321e60);else _0x321e60&&(_0x86c67e[_0x179469(0x451)]=_0x321e60);});}else currentQuestionIndex++,displayQuestion();}else{if(_0x367283[_0x16425d(0x24a)](currentMode,_0x367283[_0x16425d(0x2e7)])||_0x367283['yagPH'](currentMode,_0x367283['jSqnb']))_0x367283['bWSmE'](_0x16425d(0x2d9),_0x367283['grFEX'])?_0x367283['uecvh'](_0x1d5c53):confirm(_0x367283[_0x16425d(0x1ea)])&&submitQuiz();else{if(_0x367283[_0x16425d(0x3ae)]('YIlRm',_0x367283[_0x16425d(0x36a)]))confirm(_0x367283[_0x16425d(0x232)])&&(currentQuestionIndex=0x0,_0x367283[_0x16425d(0x20f)](displayQuestion));else return _0x2a63b4[_0x16425d(0x29b)]()['search'](czrwHK[_0x16425d(0x1fa)])[_0x16425d(0x29b)]()[_0x16425d(0x2c0)](_0x41ce37)['search'](czrwHK[_0x16425d(0x1fa)]);}}}function startTimer(){const _0x1b351f=_0x1947e1,_0x2760c7={'GUkTx':function(_0x5e5e47,_0xf4cb2f){return _0x5e5e47/_0xf4cb2f;},'TQZyc':_0x1b351f(0x2b7),'iHWWR':function(_0x28ddbc,_0x164842){return _0x28ddbc+_0x164842;},'lGsPS':function(_0xa51897,_0x5e1f69){return _0xa51897+_0x5e1f69;},'Ltjli':function(_0x172477,_0x449ff2){return _0x172477<=_0x449ff2;},'wnhYs':function(_0x8586ab,_0x148512){return _0x8586ab===_0x148512;},'veuNj':'timed_exam','rUYJm':_0x1b351f(0x2d8),'qVTDm':_0x1b351f(0x245),'YIqLb':function(_0x4c37f0){return _0x4c37f0();},'vmvXA':function(_0x42b941,_0x40c1c9){return _0x42b941!==_0x40c1c9;},'fEhmG':_0x1b351f(0x302),'jOgWV':function(_0x27a56c,_0x4d3178){return _0x27a56c(_0x4d3178);},'kRRVs':function(_0x14a17e){return _0x14a17e();},'YdHWY':function(_0x24dd70,_0x162a47,_0x5f0d3f){return _0x24dd70(_0x162a47,_0x5f0d3f);}};if(timer)_0x2760c7['jOgWV'](clearInterval,timer);timeRemaining=0x78,_0x2760c7[_0x1b351f(0x40a)](updateTimerDisplay),timer=_0x2760c7['YdHWY'](setInterval,()=>{const _0x1eb531=_0x1b351f;timeRemaining--,updateTimerDisplay();if(_0x2760c7[_0x1eb531(0x289)](timeRemaining,0x0)){clearInterval(timer);if(_0x2760c7[_0x1eb531(0x379)](currentMode,_0x2760c7['veuNj']))_0x2760c7[_0x1eb531(0x265)]!==_0x2760c7['qVTDm']?_0x2760c7[_0x1eb531(0x21d)](submitQuiz):_0x3834d9=_0x42d376[_0x1eb531(0x222)](_0x51bc8b=>!(_0x51bc8b[_0x1eb531(0x303)][_0x1eb531(0x3c0)](_0x206020[_0x1eb531(0x419)]()[_0x1eb531(0x1cc)](/ /g,'-'))&&_0x51bc8b['questionIndex']===_0x359e33));else{if(_0x2760c7['vmvXA'](_0x1eb531(0x3e0),_0x2760c7['fEhmG']))nextQuestion();else{const _0x344e6a=_0x4fe444[_0x1eb531(0x3fb)](_0x2760c7[_0x1eb531(0x28a)](_0x1e6328,0x3c)),_0x1f2f44=_0x1b9030%0x3c;_0xc09a7c[_0x1eb531(0x20d)](_0x2760c7[_0x1eb531(0x394)])['textContent']=_0x2760c7[_0x1eb531(0x3a3)](_0x2760c7['lGsPS'](_0x344e6a,':'),_0x1f2f44['toString']()[_0x1eb531(0x1d2)](0x2,'0'));}}}},0x3e8);}function updateTimerDisplay(){const _0x2d636b=_0x1947e1,_0x1613fb={'PwzVa':function(_0x5d011e,_0x3089e1){return _0x5d011e%_0x3089e1;},'FwsiD':function(_0x32e7f3,_0x107d17){return _0x32e7f3+_0x107d17;}},_0xfc3f47=Math[_0x2d636b(0x3fb)](timeRemaining/0x3c),_0x4581dd=_0x1613fb[_0x2d636b(0x2fd)](timeRemaining,0x3c);document[_0x2d636b(0x20d)](_0x2d636b(0x2b7))[_0x2d636b(0x255)]=_0x1613fb[_0x2d636b(0x3f6)](_0xfc3f47,':')+_0x4581dd[_0x2d636b(0x29b)]()[_0x2d636b(0x1d2)](0x2,'0');}function toggleSidebar(){const _0x4e9960=_0x1947e1,_0x519f35={'oImKV':'quizSidebar','RPOQQ':_0x4e9960(0x220)};document[_0x4e9960(0x20d)](_0x519f35[_0x4e9960(0x38a)])[_0x4e9960(0x3c4)][_0x4e9960(0x3d8)](_0x519f35['RPOQQ']);}document['addEventListener'](_0x1947e1(0x458),()=>{const _0x107092=_0x1947e1,_0x577d4b={'ofcGL':_0x107092(0x3ea),'DkkXo':_0x107092(0x34d),'qZwyb':_0x107092(0x1c5),'WHPPn':'flex','blgOA':function(_0x1ff7ad,_0x1871e8){return _0x1ff7ad!==_0x1871e8;},'HkADl':_0x107092(0x395),'DrfuN':function(_0x59ec70){return _0x59ec70();}};if(!window['location']['pathname'][_0x107092(0x445)](_0x577d4b[_0x107092(0x326)]))_0x577d4b['qZwyb']===_0x577d4b[_0x107092(0x355)]?document[_0x107092(0x20d)]('modeModal')[_0x107092(0x1d6)][_0x107092(0x3cb)]=_0x577d4b[_0x107092(0x31d)]:_0x5e8938['getElementById'](_0x577d4b[_0x107092(0x1f0)])[_0x107092(0x3c4)]['toggle']('open');else{if(_0x577d4b[_0x107092(0x2ae)](_0x577d4b[_0x107092(0x20a)],_0x577d4b[_0x107092(0x20a)])){if(_0x4e25bb['isSupported']()){const _0x24deec=new _0xece63f();_0x24deec[_0x107092(0x352)](_0xd8afb1),_0x24deec[_0x107092(0x45d)](_0x5a9b25);}else _0x20587e['canPlayType'](_0x107092(0x203))&&(_0x4cd1b4[_0x107092(0x451)]=_0x4db1b1);}else _0x577d4b[_0x107092(0x2a8)](initializeQuiz);}}),document[_0x1947e1(0x415)](_0x1947e1(0x3f2),function(_0x1c8457){const _0x4394f7=_0x1947e1,_0x68a2aa={'ZmyPB':function(_0x4279d4,_0x248ed7){return _0x4279d4!==_0x248ed7;},'zArOp':_0x4394f7(0x42d),'uMNwn':_0x4394f7(0x446),'gBWkJ':function(_0x1b7567,_0x7a3d79){return _0x1b7567===_0x7a3d79;},'awCvk':_0x4394f7(0x32a),'HpawQ':function(_0x331421,_0x491ebe){return _0x331421>=_0x491ebe;},'ZmLuq':function(_0x33be91,_0xe25f30){return _0x33be91<=_0xe25f30;},'IHaMO':function(_0x46e5a9,_0x4df638){return _0x46e5a9-_0x4df638;},'LJlui':function(_0x4efef7,_0x37a96c){return _0x4efef7(_0x37a96c);},'hXWTh':_0x4394f7(0x337),'RlNUd':function(_0x21ce6a,_0x375234){return _0x21ce6a<_0x375234;},'ZdGfm':function(_0x6a6e26,_0x5e802c){return _0x6a6e26===_0x5e802c;},'pvpSv':_0x4394f7(0x292),'jwpeh':function(_0x16cc21){return _0x16cc21();},'lTZti':'ArrowRight','cSnxv':function(_0x5b7859){return _0x5b7859();},'mLDpS':_0x4394f7(0x1c6),'qQMtn':_0x4394f7(0x2e5),'cvdgY':function(_0x1e5c1d,_0x28e8f7){return _0x1e5c1d===_0x28e8f7;},'upRMd':_0x4394f7(0x2c8),'wBIOi':'test','kUsPd':function(_0x59a24b,_0xe53bfe){return _0x59a24b===_0xe53bfe;},'okWtl':function(_0x5077cb){return _0x5077cb();}};if(_0x68a2aa[_0x4394f7(0x35b)](document[_0x4394f7(0x20d)](_0x68a2aa[_0x4394f7(0x2fa)])[_0x4394f7(0x1d6)][_0x4394f7(0x3cb)],_0x68a2aa[_0x4394f7(0x440)]))return;if(_0x68a2aa[_0x4394f7(0x44d)](document[_0x4394f7(0x20d)]('performanceModal')[_0x4394f7(0x3c4)][_0x4394f7(0x2cd)](_0x68a2aa[_0x4394f7(0x1e6)]),![]))return;if(_0x68a2aa['HpawQ'](_0x1c8457['key'],'1')&&_0x68a2aa[_0x4394f7(0x2aa)](_0x1c8457[_0x4394f7(0x38d)],'4')){const _0x18cdf5=_0x68a2aa[_0x4394f7(0x467)](_0x68a2aa[_0x4394f7(0x3be)](parseInt,_0x1c8457[_0x4394f7(0x38d)]),0x1),_0x1bdd50=document[_0x4394f7(0x3a6)](_0x68a2aa[_0x4394f7(0x457)]);if(_0x68a2aa[_0x4394f7(0x30a)](_0x18cdf5,_0x1bdd50[_0x4394f7(0x3e3)]))_0x68a2aa[_0x4394f7(0x3be)](selectOption,_0x18cdf5);}else{if(_0x68a2aa['ZdGfm'](_0x1c8457[_0x4394f7(0x38d)],_0x68a2aa['pvpSv']))_0x68a2aa[_0x4394f7(0x3ce)](previousQuestion);else{if(_0x68a2aa[_0x4394f7(0x44d)](_0x1c8457[_0x4394f7(0x38d)],_0x68a2aa[_0x4394f7(0x215)])||_0x68a2aa[_0x4394f7(0x44d)](_0x1c8457['key'],'\x20'))_0x1c8457[_0x4394f7(0x357)](),_0x68a2aa['cSnxv'](nextQuestion);else{if(_0x1c8457[_0x4394f7(0x38d)][_0x4394f7(0x419)]()==='b'&&(currentMode===_0x68a2aa[_0x4394f7(0x37f)]||currentMode===_0x68a2aa['qQMtn']))_0x68a2aa[_0x4394f7(0x21c)](toggleBookmark);else{if(_0x68a2aa[_0x4394f7(0x26a)](_0x1c8457[_0x4394f7(0x38d)][_0x4394f7(0x419)](),'m')&&(_0x68a2aa[_0x4394f7(0x44d)](currentMode,_0x4394f7(0x2fc))||currentMode===_0x68a2aa[_0x4394f7(0x1fb)]))_0x68a2aa[_0x4394f7(0x3ce)](toggleMarkForReview);else _0x68a2aa[_0x4394f7(0x26a)](_0x1c8457['key']['toLowerCase'](),'s')&&(_0x68a2aa[_0x4394f7(0x26a)](currentMode,_0x68a2aa['wBIOi'])||_0x68a2aa[_0x4394f7(0x3f4)](currentMode,_0x68a2aa['upRMd']))&&_0x68a2aa[_0x4394f7(0x427)](submitQuiz);}}}}});</script>

</body></html>